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ABSTRACT 
 
Metallo-β-lactamases (MBLs) are zinc ion dependent enzymes that responsible for the 
emergence and spread of β-lactam resistance. The increasing number of novel 
members of this family is threatening to global health care. MBLs are divided into 
three subclasses, i.e. B1, B2 and B3. The recent discovery of an unusual MBL from 
Serratia proteamaculans (SPR-1) suggests the presence of an additional subgroup, i.e. 
B4. A database search reveals that SPR-1 has several homologues including a MBL 
from Cronobacter sakazakii, CSA-1. These MBLs have a unique active site and my 
employ a mechanism distinct from other MBLs. 
 
Characterisation of a novel B3 MBL from Pseudomonas aeruginosa in Adelaide, 
Australia, Adelaide Imipenemase-1 (AIM-1) suggests the presence of a super enzyme 
that is biochemically broad spectrum and physically stable. In this study, X-ray 
crystal structure of AIM-1 was solved and site-saturation mutagenesis was used for 
probing several interesting residues. Moreover, directed evolution was introduced for 
finding the prospective variants that have better activity against antibiotics. Variants 
found in this study suggest AIM-1 has the potential to increase activity against β-
lactams antibiotics. Information gained from this study may also be useful in the 
design of inhibitors that could be used as anti-bacterial agents. 
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SSM   Site-saturation mutagenesis 
StEP   Staggered extension process 
StEP-ePCR (eStEP) Staggered Extension Process – Error Prone PCR 
TEMED  N,N,N’,N’ – Tetramethylethylenediamine 
Tm   Melting temperature 
TMP   Trimethoprim 
Tris   Tris(hydroxymethyl)methylamine 
SWISS-MODEL  A particular bioinformatics program  
U    Unit of enzyme activity 
Vmax    Maximum velocity of an enzyme reaction 
v/v   Volume per volume ratio 
w/v   Weight per volume ratio 
YENB   Yeast Extract Nutrient Broth medium 
Definitions: 
Mutants  Bacteria strains that carry mutations 
Mutations  Refer to changes in DNA 
Replacements  Refer to specific alternations in amino acid sequence 
Substitutions  Refer to specific alternations in DNA sequence 
Variant proteins Protein that have altered amino acid sequences 
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AGE-1  Acinetobacter gerneri, UniRef N8YDY5, uncharacterised MBL (B4 
MBL) 
AGE-2  Acinetobacter sp., UniRef L9M5Q0 (B4 MBL) 
AGE-3 Acinetobacter genomosp., UniRef N8S6D5, uncharacterised (B4 
MBL) 
AIM-1  Adelaide Imipenemase number 1 (B3 MBL) 
BcII   Bacillus cereus type II (B1 MBL) 
BJP-1  Bradyrhizobium japonicum MBL (B3 MBL) 
BlaB   β-Lactamase class B (B1 MBL) 
CcrA   Cefoxitin and carbapenem resistant (B1 MBL) 
CDA-1 Cedecea davisae, UniRef S3IYJ8, putative MBL (B4 MBL) 
CphA  Carbapenem hydrolysing and first (‘A’) from Aeromonas hydrophila 
(B2 MBL) 
CSA-1  Cronobacter sakazakiiI, UniRef A7MFY4, uncharacterised (B4 MBL) 
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ENTR-1 Enterobacter sp., UniRef J0MDG7, putative MBL (B4 MBL) 
FEZ-1   Legionella (Fluoribacter) gormanii endogenous MBL (B3 MBL) 
GIM-1  German Imipenemase (B1 MBL) 
Glyoxalase II Catalyses the hydrolysis of S-D-lactoylglutathione to form D-lactate 
and glutathione 
IMP-1   Imipenemase-1 (B1 MBL) 
ImiS   Imipenemase from Aeromonas veronii bv. Sobria (B2 MBL) 
L1  Labile enzyme from Stenotrophomonas (Pseudomonas, Xanthomonas) 
maltophilia (B3 MBL) 
LRA-3  Lactamase resistance from Alaskan soil number 3 (B3 MBL) 
LRA-17  Lactamase resistance from Alaskan soil number 17 (B3 MBL) 
MPH  Methyl Parathion Hydrolase 
NDM-1  New Dehli MBL number 1 (B1 MBL) 
Sfh-1  Serratia fonticola strain UTAD54 MBL (B2 MBL) 
SLI-1  Serratia liquefaciens, UniRef S5EJZ6, putative MBL (B4 MBL) 
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SSV-1  Salmonella sp., UniRef B4TZZ5, putative MBL (B4 MBL) 
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CHAPTER 1 - INTRODUCTION 
1.1 PREAMBLE  
 
This thesis is concerned with understanding the mode of action of the metallo-β-
lactamases (MBLs). These enzymes provide bacteria with a defense against β-lactam 
antibiotics such as penicillins. Although the structures of various MBLs are known, 
many aspects of their mode(s) of action are still poorly understood. Furthermore, the 
MBLs represent a significant medical problem since they can degrade most β-lactam 
classes and there are no clinical useful inhibitors at present. The object of this work 
was to determine critical residues that regulate substrate specificity and that are 
important for catalysis. The main tool used in the present study is molecular biology, 
in particular directed evolution. The information gained should be useful in 
developing MBL inhibitors.  
 
A brief introduction to various aspects of the work is required to place this study in 
context. Specifically, a brief description of antibiotics and antibiotic resistance will be 
given. This will be followed by a thumbnail sketch of the different classes of β-
lactams and the β-lactamases - enzymes that have evolved to counter the effects of the 
β-lactams. A more detailed account of MBL structures and what is known of how 
they function will be given as well as the work done on these molecules within our 
laboratory. Since some of the tools used in the present study are not widely known, a 
short introduction to the relevant techniques will be given. Finally the specific aims 
and outline of the work contained in this thesis will be given in this introduction. 
 
1.2 ANTIBIOTICS 
1.2.1 Brief History 
 
Bacterial diseases were a significant threat to human health for thousands of years. 
For example, history tells us that at times these diseases decimated a significant 
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fraction of the European population. It was not until a few hundred years ago that 
bacteria were identified as the causative agents for many of these diseases so that 
steps could be taken to mitigate their harmful effects. The introduction of hygienic 
practices greatly moderated the effects of bacterial diseases, but it was not until the 
early 1940s that a general weapon to attack bacteria was introduced. Howard Florey, 
an Australian scientist who was working in Oxford University, led a team that first 
isolated penicillin from a fungus that had been found by Flemming to have 
antibacterial activity (1). The Oxford team spent some time developing the 
technology to produce enough penicillin so that it could be tested for antibacterial 
activity and used as a drug. Penicillin was eventually thoroughly characterised by 
chemists and analogues made so that a range of highly effective antibacterial agents 
could be produced.  
 
1.2.2 Modes of Action - Brief Description 
 
Reviews of the various antibacterial agents have been published and the interested 
reader can consult these for detailed information (2-7). For our purposes it is useful to 
know that penicillins work by irreversibly inhibiting an enzyme that is involved in the 
synthesis of the bacterial cell wall, penicillin binding protein (PBP) (8). This protein 
is an ideal target for an antibacterial agent because the bacteria cell wall is quite 
different to the structure that encapsulates eukaryotic cells so that penicillins are not 
likely to adversely effect higher organisms. The bacterial ribosome also differs from 
that found in higher organisms and it also is a suitable target for antibacterial agents 
like streptomycin (2) and chloramphenicol (3) that were introduced shortly after the 
first penicillin in 1949.  Other antibacterial agents have been discovered over the 
years. However, the introduction of each new antibacterial agent was followed by the 
discovery of bacteria that had developed resistance. This resistance took time to 
spread allowing new anti-bacterial agents time to be developed. A timeline of the 
deployment of antibacterial agents and the evolution of resistance is shown in the 
figure 1.1 (9). This figure graphically illustrates that the close connection between the 
introduction of an antibacterial agent and resistance to it. It also shows that there was 
a long period of time in which no new type of antibacterial agent was introduced and 
  
 
3 
that in the last few years new agents have been introduced and resistance quickly 
encountered.  
 
Although Figure 1.1 has a great deal of useful information it does have some 
shortcomings. It does not give a detailed depiction of the progress made in developing 
new antibacterial agents; for example, the diagram would become unreadable if all the 
β-lactams that have been deployed over the years were included in it. Also, the 
development of inhibitors such as clavulanic acid, which counter the β-lactamase 
resistance that are currently used in antibacterial medication, is not shown in the 
figure.  
 
Clavulanic acid inhibits β-lactamases and is often included in penicillin/ amoxicillin 
preparations to stop degradation (10-12). In short, as antibiotics were developed, 
evolution gave rise to new agents to counter their effects. 
 
 
 
Figure 1.1. Timeline of antibiotic deployment and the evolution of antibiotic 
resistance 
Above the timeline illustrates the year each antibiotic was deployed. The year each 
antibiotic resistance was observed is illustrated below the time line. The appearance 
of antibiotic resistance does not necessarily imply that a given antibiotic has lost all 
clinical utility. (Adapted from a figure in reference (9).) 
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1.2.3 Modes of Resistance 
 
There are at least four ways by which bacteria can evade the effects of antibiotics 
(Figure 1.2). In some cases the antibiotic can be prevented from reaching its target 
through the action of efflux pumps that remove antibiotic from the organism or by 
inactivating host transporters that normally provide the antibiotic access to the cell. 
Alternatively, in a second mode of action the antibiotic target can be altered in such a 
way that it is no longer susceptible to the antibiotic. A third approach gives a similar 
effect; molecules with the same activity as the target can be used to bypass the effects 
of the antibiotic. Finally, the antibiotic can be inactivated by enzymatic chemical 
modification (13-16). There are several types of modification that can be used to 
inactivate antibiotics; the one relevant to the present study is hydrolysis by β-
lactamases. 
 
 
 
Figure 1.2. Antibiotic defense system in bacteria 
Big yellow dots represent antibiotic. The figure shows five ways of antibiotic defense: 
altered target sites, penetration, porin efflux, bypass pathways and enzymatic 
inactivation/ nodification. 
= Antibiotic 
Altered target site 
Bypass pathways 
Penetration 
Porin Efflux 
Enzymatic 
inactivation or 
modification 
efflux 
  
 
5 
 
The molecules responsible for resistance can be encoded on the chromosome of the 
organism or then can be found on mobile genetic elements, such as plasmids that 
provide a ready means of transmission to other organisms (17). We will not be 
concerned with the transmission of antibiotic resistance in bacteria.  
 
1.2.4 History, Structures and Mode of Action of β-Lactams 
 
Since their introduction in the 1940s β-lactam antibiotics such as penicillins have 
been the most effective and useful chemotherapeutics to fight bacterial infections. 
They are widely used to combat a multitude of bacterial infections (5) and still 
account for half of the total drug prescriptions worldwide (18, 19). 
 
Hou and Poole have published an extensive review of the β-lactams that covers their 
structures and activities (20) so that only a brief descriptions of these molecules need 
be given here. The central feature of the β-lactams is a strained, four-membered ring 
that can be modified in various ways to give a variety of molecules. These molecules 
can be classified into four major groups: (I) penicillins (21, 22), (II) cephalosporins 
(23), (III) carbapenems (24, 25) and (IV) monobactams (26).  Figure 1.3 shows the 
structures of the three common classes of β-lactams and Figure 1.4 shows the 
examples that are used in this study. Within each group the side chain modifications 
give antibiotics with different specificities and potencies (7) (Table 1.1). For instance, 
ampicillin is a more effective drug than penicillin due to the substitution of an amino 
group (27). Penicillins and cephalosporins contain a thiazolidine and dihydrothiazine 
rings, respectively while the carbapenems have a double-ring structure. Aztreonam is 
the only commercially available monobactams (28). These molecules have a β-lactam 
ring that is not fused to another ring. The monobactams only work against gram-
negative bacteria; since they are not common they have not been used in this study.  
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Compounds generic 
names 
Other names Mechanism of 
action 
Activity and properties Clinical uses 
Penicillins 
Penicillin G (23) 
Penicillin V (29) 
Ampicillin (27) 
Carbenicillin (4) 
Amoxicillin (6) 
Piperacillin (30) 
 
Benzylpenicillin 
Phenoxymethylpenicillin 
Penbritin 
Pyopen 
Amoxycillin 
Piper 
It inhibits the 
synthesis of cell 
wall by blocking 
the penicillin-
binding proteins, 
which caused the 
inhibition of the 
synthesis of cross-
linkage between 
the linear 
peptidoglycan 
polymer chains. 
Generally speaking, 
penicillins are broad 
spectrum against gram-
negative bacteria and 
gram-positive bacteria 
such as Staphylococcus 
strains.  
Penicillins are 
effective against 
many previously 
serious diseases, such 
as syphilis, and 
infections caused by 
staphylococci and 
streptococci. 
Ampicillin is also 
used to treat urinary 
tract infections, otitis 
media, Haemophilus 
influenzae, 
salmonellosis and 
Listeria meningitis. 
Cephalosporins 
First generation 
Cephalosporin C 
(31) 
Cephaloridine (31) 
Cephalexin (32) 
Cephalothin (33) 
Second generation 
Cefoxitin (34) 
Cefuroxime (35) 
Cefmetazole (36) 
Third generation 
Ceftazidime (37) 
Cefotaxime (37) 
Moxalactam (38) 
Fourth generation 
Cefepime (39) 
Fifth generation 
Ceftobiprole (40) 
 
 
(N/A) 
 
Cefaloridine 
Cefalexin 
Cefalotin 
 
Mefoxin 
Zinacef 
Zefazone 
 
Cefzim, Fortum, Fortaz 
Tolycar 
Latamoxef 
 
Maxcef 
 
BAL-9141 
It inhibits the 
synthesis of 
bacteria cell wall. 
Most of 
cephalosporins 
are preferred base 
on the low 
toxicity to human 
then penicillins. 
In 1945, a fungus, 
Ceplialosporium 
acwmonium, was isolated 
and was found to 
elaborate several 
antibacterial compounds. 
One of these compounds, 
was named cephalosporin 
C. 2nd generation has 
extended spectrum and a 
better treatment than the 
1st generation against 
Klebsiella spp, Pr 
mirabilis and E. coli. 3rd 
and the generations after 
are wider spectrum and 
more effective than the 1st 
and 2nd generations 
against aerobic gram-
negative bacteria. 
These antibiotics are 
broad spectrum and 
commonly used to 
treat serious post-
operative sepsis and 
in 
immunocompromised 
patients such as 
patients who 
underwent treatment 
for leukemia 
treatment and other 
malignancies. 
Carbapenems 
First generation 
Imipenem (24) 
Second generation 
Meropenem (41) 
Third generation 
Biapenem  (42) 
Ertapenem (43) 
Doripenem (44) 
 
 
 
Tienamycin 
 
Merrem, Meronem 
 
Talipexole  
Invanz 
Doripenem monohydrate 
 
By the inhibition 
of cell wall 
synthesis in gram-
positive and 
gram-negative 
bacteria. 
Generally, 
carbapenems have 
the broadest 
spectrum of 
activity compared 
to other beta-
lactams, and they 
are less likely to 
be degraded by 
beta-lactamases. 
These compounds have 
very broad spectrum of 
activity against most 
gram-negative and gram-
positive bacteria, aerobes 
and anaerobes. 
These carbapenem 
type antibiotics are 
effective in treating 
various infections 
including community 
acquired pneumonia, 
nosocomial 
pneumonia, 
meningitis, 
complicated urinary 
tract infections, intro-
abdominal infections, 
skin and skin structure 
infections and febrile 
neutropenia. 
 
Table 1.1. Different types of β-lactam antibiotics and their other names, 
mechanism of action, catalytic activity and clinical uses 
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Figure 1.3. Backbone structures of the three common classes of β-lactams 
 
(a) Ampicillin 
 
(b) Benzylpenicillin 
 
(c) Piperacillin 
 
(d) Cefmetazole 
 
(e) Cefotaxime 
  
(f) Cefoxitin 
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(g) Cefuroxime 
 
(h) CENTA (45)
 
(i) Cephalothin 
 
(j) Moxalactam 
  
(k) Imipenem 
 
(l) Biapenem 
  
(m) Meropenem 
 
(n) Clavulanic acid 
 
 
Figure 1.4. Chemical substrates involved in this study 
(a) - (c) Penicillins. (d) - (j) Cephalosporins. (k) - (m) Carbapenems. (n) A β-
lactamase inhibitor. 
  
M!1 cm!1). The kcat and Km values were derived from initial
rate measurements with the help of the Hanes linearization of
the Henri-Michaelis equation and direct fitting on the hyper-
bolic equation by nonlinear regression or from complete time
courses (3). The lowest Km values obtained with SHV-1, CfiA,
OXA-10, and OXA-2 were verified by using CENTA as a
competitive inhibitor versus 100 "M nitrocefin for the first
three enzymes and versus 300 "M cefaclor for the fourth one.
The other experimental conditions are detailed in Table 1.
Inactivation of the R61, R39, and K15 DD-peptidases was
monitored by incubating the enzymes with various concentra-
tions of CENTA and measuring the residual activity of an
aliquot after increasing periods of time. Activity was deter-
mined by measuring the production of D-alanine from N#,Nε-
diacetyl-L-lysyl-D-alanyl-D-alanine by the D-amino acid oxidase
method (6). In the case of the K15 enzyme, the assay mixture
also contained 10 mM glycylglycine. The buffers were as fol-
lows: for R39, 50 mM Tris (pH 8.0) plus 1 mMMgCl2; for R61
and K15, 50 mM Tris (pH 8.0).
Table 1 summarizes the kinetic constants obtained with
CENTA and the various $-lactamases and compares them with
those obtained with nitrocefin. CENTA was a relatively good
substrate of all the enzymes with the sole exception of the
CphA enzyme, which is very specific for carbapenems and
similarly exhibits very poor activity against nitrocefin. The ki-
netic parameters of OXA-10 and SHV-1 with nitrocefin were
determined in the present work. When compared to nitrocefin,
the initial rates recorded at the same 100 "M concentration
are of the same order of magnitude with the exceptions of
those for the OXA-10 and SHV enzymes. One should be
reminded, however, that the %ε value of CENTA (&6,400 M!1
cm!1) is significantly lower than that of nitrocefin (&17,500
M!1 cm!1). Nonetheless, CENTA can easily be used for mon-
itoring the presence of all the enzymes (excepted CphA) in
chromatographic fractions and as a reporter substrate for de-
tailed kinetic studies even with enzymes (M. tuberculosis and
OXA-10) which exhibit rather low levels of activity against this
compound. The maximum change of absorbance of the leaving
group is different from that for most $-lactam antibiotics. In-
terestingly, and in contrast to nitrocefin, hydrolysis of CENTA
FIG. 1. Structure of CENTA.
TABLE 1. Kinetic parameters for interaction between active-site serine and zinc $-lactamases and CENTA of nitrocefina
Enzyme group and
enzyme
CENTA Nitrocefin
(v0)N/(v0)Cc
Methods [CENTA](mM) [Enz] (nM)
kcat
(s!1)
Km
("M)
kcat/Km
("M!1 s!1) kcat (s
!1) Km ("M)
kcat/Km
("M!1 s!1) Reference
b
Class A $-lactamases
TEM-1 v0 0.025–0.3 11.5 110 70 1.6 930 52 18 17 9.4
NMCA v0 0.25–1.5 7 340 100 3.4 88 104 0.84 19 0.25
SHV-1 CTC & RS 0.25–1 1.4–170 11 27 0.4 88 104 0.84 1 32
TOHO 1 v0 0.25–1.5 1.8 2,000 180 11 520 60 9 10 0.45
M. tuberculosis v0 0.25–1.5 310 5 120 0.04 31 80 0.4 22 7.5
S. aureus v0 0.01–0.1 77 2 10 0.2 16 1.5 10 4 8.7
Class C $-lactamases
908R CTC 0.03 10 110 10 11 780 23 34 7 6.3
P. aeruginosa CTC 100–200 25–50 390 63 6.3 740 27 27 7 NDd
C. freundii CTC 100–200 50–90 75 25 3 330 12 28 7 ND
ACT-1 CTC 100–200 1–2 690 80 8.6 ND ND ND ND ND
Class D $-lactamases
OXA-10 CTC & RS 0.1–1 14–1,000 0.4 9 0.04 3,000 450 6.6 13 1,500
OXA-2 CTC & RS 0.025–0.5 4.8 95 13 7.3 Burst
complex
kinetic
Burst
complex
kinetic
Burst
complex
kinetic
13 ND
Class B $-lactamases
BcII v0 0.25–1.5 14 50 330 0.15 45 70 0.64 16 2.3
CphA v0 0.1 6,000 NH NH NH 0.31 100 0.0003 9 ND
IMP-1 v0 0.25–1.5 1 400 200 2 63 27 2.3 12 0.37
CfiA CTC & RS 0.025–0.5 2.5–10 40 7 5.7 200 16 12.5 23 4.7
BlaB v0 0.05–0.4 14 4.5 31 0.15 17 66 0.26 3 3
VIM-1 v0 0.05–2.2 1.8 430 600 0.7 95 17 5.6 5 ND
a Complete time courses (CTC) were recorded over 3- to 15 min periods; initial rate (v0) values were recorded over 1 min. With CphA, no hydrolysis (NH) of 100
"M CENTA could be detected after 30 min (initial rate, '5 "M h!1). The low Km values were measured as Kis with the help of a reporter substrate (RS) (usually
100 "M nitrocefin, with the exception of the OXA-2 enzyme, with which 300 "M cefaclor was used). Standard deviation values did not exceed 10%.
b Kinetic data for nitrocefin were found in the cited references.
c The ratio between the expected initial rates for the hydrolysis of 100 "M nitrocefin [(v0)N] and 100 "M CENTA [(v0)c] by the same amount of enzyme.
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β-Lactam antibiotics work by inhibiting enzymes involved in the synthesis of the 
bacterial cell wall - a structure that is essential for the survival of these bacteria. The 
rigidity of the cell wall is due to alternating N-acetylmuramic acid (NAM) and N-
acetylglucosamine (NAG) units that are linked with peptides. This crosslinking is 
achieved by first attaching a pentapeptide to each NAM unit. These pentapeptides 
contain a terminal D-alanine-D-alanine linkage that is one substrate of a 
transpeptidase that links the NAM pentapeptides from adjacent NAM-NAG polymers 
(46). This transpeptidase is known as the penicillin binding protein (PBP) as it was 
identified as the target for penicillin before its function was known (47). β-Lactams 
mimic the D-alanine-D-alanine unit and irreversibly inhibit the PBP and in so doing 
they compromise the integrity of the cell wall (Figure 1.5) (48). As already mentioned 
the bacterial cell wall is an ideal drug target as it differs significantly from that of 
higher organisms.  
 
 
 
Figure 1.5. Mode of action of β-lactams 
(a) Catalysis of transpeptidation. (b) N-Acyl-D-Alanyl-D-Alanine peptide. (c) 
Penicillins backbone. (d) Cephalosporins backbone. The arcs indicate regions of 
negative electrostatic potential.  
will be used throughout this review. The constants k2 and k3
describe the acylation and deacylation rates, respectively.
The second-order rate constant k2/Kd is the efficiency of
acylation, which allows calculation of the overall acylation
rate at a given antibiotic concentration. The inhibitory
potency of a b-lactam for a PBP is given by the c50, which is
the antibiotic concentration resulting in the inhibition of
half the PBP molecules at a steady state (when the acylation
and deacylation reactions proceed at the same rate). The
value of c50 is equal to the ratio k3/(k2/Kd). Here, as in the
literature in general, PBPs are said to be or to have high or
low affinity for b-lactams. This affinity implicitly refers to
the c50, and should not be confused with the strength of a
noncovalent interaction.
Despite detailed kinetic studies and several crystal struc-
tures of PBPs, the reaction mechanism is still a matter of
debate, and likely differs between various ASPRE enzymes,
and even for a single protein and different b-lactams (Oliva
et al., 2003).
PBP-based b-lactam resistance
Inhibition of PBPs produces an imbalance in cell wall
metabolism, resulting in growth inhibition or lysis. The link
between PBP inhibition and the biological outcome remains
poorly understood [e.g. Escherichia coli (de Pedro et al.,
2002), Staphylococcus aureus (Giesbrecht et al., 1998),
Enterococcus hirae (Pucci et al., 1986), Streptococcus pneu-
moniae (Mascher et al., 2006)]. Despite the ignorance of the
detailed consequences of b-lactam treatment, various means
of resistance have been uncovered and investigated, such as a
(a)
(b) (c) (d)
Fig. 1. (a) Catalysis of transpeptidation. Fragments of glycan strands are represented by chains of hexagones standing for the hexoses N-acetyl
glucosamine (G) and N-acetyl muramic acid (M). The ‘donor’ pentapeptide is depicted on the upper glycan strand, whereas the ‘acceptor’ is attached
here on the lower strand. The peptides shown are those from Streptococcus pneumoniae. The second and third amino acids may differ in various
species. Note that in many instances, including in Streptococcus pneumoniae, various intervening amino acids are attached to the third residue of the
acceptor peptide, and provide the free amine that attacks the acyl-enzyme intermediate. Such stem peptides are called ‘branched’. Structural similarity
between b-lactams and the natural substrate of the PBPs. (b) N-Acyl-D-Alanyl-D-Alanine peptide. (c) Penicillin backbone. (d) Cephalosporin backbone.
The regions of negative electrostatic potential are ndicated by arcs.
−1
−1
Fig. 2. Kinetic scheme of the reaction between a PBP (E) and a b-lactam
(I). EI represents a preacylation noncovalent complex. EI! represents the
covalent acyl-enzyme complex. P is the open inactivated product.
FEMS Microbiol Rev 32 (2008) 361–385c! 2008 Federation of European Microbiological Societies
Published by Blackwell Publishing Ltd. All rights reserved
362 A. Zapun et al.
D-Ala-D-Ala Penicillins Cephalosporins 
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In gram-negative bacteria, such as E. coli, the PBP is located in the cell membrane 
facing the periplasm space that separates the two membrane components of the cell 
wall as shown in Figure 1.6. The outer cell wall contains porins that make it easy for 
molecules such as β-lactams to gain entry into the periplasmic space. Molecules 
synthesised in the cytoplasm of the cell require a leader sequence that is usually 
cleaved during the transport into the periplasm. The present study only involves E. 
coli, a gram-negative organism - the cell wall structure of gram-positive bacteria has 
been described elsewhere (7). 
 
 
 
Figure 1.6. Section of periplasm of gram-negative bacteria including mode of 
action of β-lactamase 
There are two fates of β-lactams after entering gram-negative bacteria periplasm: one 
is binding to PBP and the other is hydrolysed by β-lactamase. 
 
1.2.5 Resistance to β-Lactams - β-Lactamases 
 
Bacteria can overcome the effects of β-lactams in a number of ways. In some cases 
resistance arises because the bacteria acquire a form of the PBP that no longer binds 
these molecules. Scientists have responded to this threat by producing numerous 
different β-lactams that target different forms of the PBP (49). In most cases, 
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however, bacteria can defeat β-lactams by acquiring enzymes that can degrade them, 
the β-lactamases (50). There are four different types of β-lactamases. Three of them, 
designated as Classes A, C and D, bear some structural and mechanistic similarity to 
PBP and can be inhibited by drugs such as clavulanic acid that is frequently co-
administered with the β-lactam antibiotics (6). The Class B enzymes require metal 
ions for activity and were first observed in the 1960s, but have only become common 
in recent years (51). These enzymes bear no structural or mechanistic similarity to the 
enzymes in classes A, C and D and unlike these latter enzymes, they act on most 
types of β-lactams (52, 53).  
 
A schematic representation of the mode of action of β-lactamases in gram-negative 
bacteria was given in Figure 1.6. From this diagram it can be seen that in gram-
negative bacteria the β-lactamases function in the periplasm - the genes for these 
proteins have a 5’ sequence that results in the protein being directed to that location 
(54).   
 
The structures of various PBPs have been determined, as have the structures of 
representative examples of the Class A, C and D β-lactamases.  These latter enzymes 
all belong to the same structural family and are known as the serine β-lactamases as 
an active site serine residue is necessary for hydrolysis (55). The class B enzymes (the 
MBLs) are quite different to the serine enzymes. At a practical biochemical level, 
MBL activity is metal ion dependent while that of the serine enzymes is not (56). 
However, the difference between the MBLs and other classes of β lactamases extend 
into more areas than just metal ion dependence (57). The serine β-lactamases and 
MBLs show no sequence homology or structural similarity and exhibit quite different 
activity profiles, as will be described later. This thesis focuses on the investigation of 
the catalytic mechanism of MBLs. 
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1.3 METALLO-β-LACTAMASES (MBLS)  
 
Numerous members of the MBL family of enzymes have been characterised and 
found to vary considerably in character. For convenience they have been divided into 
three sub-families: designated B1, B2 and B3. These enzymes have metals that are 
responsible for catalytic activity, but the specific metal ion requirements vary between 
the subclasses. In addition, even within the different subclasses the precise details of 
the catalytic mechanism are still subject to a degree of uncertainty (58).  
 
1.3.1 Classes of MBLs 
 
MBLs have been subdivided into three sub-classes as assigned by the Ambler system 
(59): B1, B2 and B3. B1 and B3 are di-zinc enzymes that possess broader substrate 
specificity as opposed to mono-zinc B2 for which the substrate spectrum is narrower. 
B1 shares sequence homology with B2, whereas B3 is structurally homologous to B1 
and B2 classes but with very little sequence similarity (60, 61). Samples of the 
sequences of the B class enzymes are shown in Figure 1.7, conserved residues and 
metal binding ligands have been marked in this Figure. The properties of a variety of 
MBL have been summarised in reviews. For example, Bebrone has provided a 
concise summary of the classification and kinetic properties of the different B class 
enzymes (62, 63). Only information relevant to the present study will be given below.  
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Figure 1.7. Sequence alignment of B1, B2 and B3 MBLs 
Metal binding ligands regions are configured in squares and conserved residues are in 
colours. Secondary structure marks are shown above the sequences. 
 
  
    ß1      ß2    ß3           ß4 
                     ==>                           ======>   =========>   ===========>  = 
B1_BCII       SQKVEKTVIKNETG......................TISISQLNK.NVWVHTELGSFNG.EAVPSNGLVLNTSKG   
B1_IMP-1      AESLP...............................DLKIEKLDEG.VYVHTSFEEVNGWGVVPKHGLVVLVNAE   
B1_NDM-1   28 SNAIRPTIGQQMETGDQRFG................DLVFRQLAP.NVWQHTSYLDMPGFGAVASNGLIVRDGGR   
B2_CPHA    41                                    AGMSLTQVSG.PVYVVEDNYY......VQENSMVYFGAKG   
B2_SFH-1                                      MSEKNLTLTHFKG.PLYIVEDKEY......VQENSMVYIGTDG   
B3_L1         AEVPLPQLRAYTVDAS.................WLQPMAPLQIAD.HTWQIGTE.........DLTALLVQTPDG   
B3_BJP-1      MRRLTAALCALTLLSTGAQAQTIKDFLAVAMKKWTAPFEPFQLID.NIYYVGTD.........GIAVYVIKTSQG   
B3_FEZ-1      AYPMPN..............................PFPPFRIAG.NLYYVGTD.........DLASYLIVTPRG   
B3_SMB-1      QDRDWS.............................SPQQPFTIYG.NTHYVGTG.........GISAVLLSSPQG   
B3_AIM-1   27 ASRGCADDAGWN.......................DPAMPLKVYG.NTWYVGTC.........GISALLVTSDAG   
      ß5      α1      ß6     α2   ß7   α3  
              ===>    \/\/\/\/\/\/\/\/\    ====>    \/\/\/\/\//\/\/   ==>/\/\/\/\/\ 
B1_BCII    80 LVLVDSSWDDKLTKELIEMVEKKFQK..RVTDVIITHAHADRIGGIKT.LKERGIKAHSTALTAELAKK......   
B1_IMP-1   44 AYLIDTPFTAKDTEKLVTWFVERGYK...IKGSISSHFHSDSTGGIEW.LNSRSIPTYASELTNELLKK......   
B1_NDM-1   86 VLVVDTAWTDDQTAQILNWIKQEINL..PVALAVVTHAHQDKMGGMDA.LHAAGIATYANALSNQLAPQ......   
B2_CPHA    80 VTVVGATWTPDTARELHKLIKRVSRK..PVLEVINTNYHTDRAGGNAYWKS.IGAKVVSTRQTRDLMKSDWAEIV   
B2_SFH-1   80 ITIIGATWTPETAETLYKEIRKVSPL..PINEVINTNYHTDRAGGNAYWKT.LGAKIVATQMTYDLQKSQWGSIV   
B3_L1      49 AVLLDGGMP.QMASHLLDNMKARGVTPRDLRLILLSHAHADHAGPVAELKRRTGAKVAANAESAVLLARGGSDDL   
B3_BJP-1   66 LILMDTAMP.QSTGMIKDNIAKLGFKVADIKLILNTHAHLDHTGGFAEIKKETGAQLVAGERDKPLLEGGYYPGD   
B3_FEZ-1   80 NILINSDLEA.NVPMIKASIKKLGFKFSDTKILLISHAHFDHAAGSELIKQQTKAKYMVMDEDVSVILSGGKSDF   
B3_SMB-1   37 HILVDGTTEK.GAQVVAANIRAMGFKLSDVKYILSTHSHEDHAGGISAMQKLTGATVLAGAANVDTLRTGVSPKS   
B3_AIM-1   69 HILVDAATP.QAGPQILANIRALGFRPEDVRAIVFSHEHFDHAGSLAELQKATGAPVYARAPAIDTLKRGLPDRT   
        ß8        ß9              ß10            ß11 
                          /               =====>    =====>           ==>           ====>/ 
B1_BCII   149 ............NGYEEPLGDLQT....VT..NLKFGNMKVETFYPGKGHTEDNIVVWLPQ......YNILVGGC   
B1_IMP-1  109 ............DGKVQATNSFSG...VNY..WLVK..NKIEVFYPGPGHTPDNVVVWLPE......RKILFGGC   
B1_NDM-1  152 ............EGMVAAQHSLTFAANGWVEPATAPNFGPLKVFYPGPGHTSDNITVGIDG......TDIAFGGC   
B2_CPHA   155 AFTRKGLPEYPDLPLVLPNVVHDG....DF..TLQE..GKVRAFYAGPAHTPDGIFVYFPD......EQVLYGNC   
B2_SFH-1  155 NFTRQGNNKYPNLEKSLPDTVFPG....DF..NLQN..GSIRAMYLGEAHTKDGIFVYFPA......ERVLYGNC   
B3_L1     123 HFGDG.....ITYPPANADRIVMD...GEV..ITVG..GIVFTAHFMAGHTPGSTAWTWTDTRNGKPVRIAYADS   
B3_BJP-1  140 EKNED.....LAFPAVKVDRAVKE...GDR..VTLG..DTTLTAHATPGHSPGCTSWEMTVKDGKEDREVLFFCS   
B3_FEZ-1  155 HYANDSS...TYFTQSTVDKVLHD...GER..VELG..GTVLTAHLTPGHTRGCTTWTMKLKDHGKQYQAVIIGS   
B3_SMB-1  111 DPQFGSLS...NFPGSAKVRAVAD...GEL..VKLG..PLAVKAHATPGHTEGGITWTWQSCEQGKCKDVVFADS   
B3_AIM-1  143 DPQFEVA...EPVAPVANIVTLAD...DGV..VSVG..PLALTAVASPGHTPGGTSWTWRSCEGDDCRQMVYADS   
      α4      α5                      ß12 
              \/                         /\/\/\/\/\/\/\/\        ===>     
B1_BCII   222 LVKSTSAKDLGNVAD...........AYVNEWSTSIENVLKRYR....NINAVVPGHGE................   
B1_IMP-1  159 FIKPYG...LGNLG...........DANIEAWPKSAKLLKSKYG....KAKLVVPSHSE................   
B1_NDM-1  209 LIKDSKAKSLGNLG...........DADTEHYAASARAFGAAFP....KASMIVMSHSAP...............   
B2_CPHA   222 ILKEK....LGNLS...........FADVKAYPQTLERLKAMK....LPIKTVIGGHDS................   
B2_SFH-1  222 ILKEN....LGNMS...........FANRTEYPKTLEKLKGLIEQGELKVDSIIAGHDT................   
B3_L1     186 L........SAPG...YQLQGNPRYPHLIEDYRRSFATVRA......LPCDVLLTPHPG...ASNWDYAAG....   
B3_BJP-1  203 G........TVALN...RLVGQPTYAGIVDDYRATFAKAKA......MKIDVLLGPHPE...VYGMQAKRA...E   
B3_FEZ-1  222 IG........VNPG..YKLVDNITYPKIAEDYKHSIKVLES......MRCDIFLGSHAG...MFDLKNKYVLLS.   
B3_SMB-1  176 L........TAVSADSYRFSDHP...EVVASLRGSFEAVEK......LSCDIAIAAHPEVNDMWTRQQRAAK...   
B3_AIM-1  208 L........TAISDDVFRYSDDAAHPGYLAAFRNTLARVAA......LDCDILVTPHPS...ASGLWNRIG....   
   α6 
                             \/\/\/\/\/\  
B1_BCII   277 ............VGDKGLLLHTLDLLK                 
B1_IMP-1  200 ............VGDASLLKLTLEQAVKGLNESKKPSKPSN   
B1_NDM-1  254 ...........DSR..AAITHTARMADKLR              
B2_CPHA   266 ...........PLHGPELIDHYEALIKAAPQS            
B2_SFH-1  266 ...........PIHDVGLIDHYLTLLEKAPK             
B3_L1     237 .....ARAGAKALTCKAYADAAEQKFDGQLAKETAGAR      
B3_BJP-1  255 MKDGAPNPFIKPGELVTYATSLSEDFDKQLAKQTAALEKK    
B3_FEZ-1  278 ..KGQNNPFVDPTGCKNYIEQKANDFYTELKKQETG        
B3_SMB-1  231 ...EGNSAYVDNGACRAIAAAGRKRLETRLASEKR         
B3_AIM-1  262 ..PRAAAPLMDTTACRRYAQGARQRLEKRLAEEAAA        
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1.3.2 Sequence and Structural Similarity Between MBLs 
 
X-ray structures of a number of MBLs have been determined - including examples 
from each of the different subclasses (64-66) and examples are shown in the figure 
1.8 below. In general, all the MBLs share a common topology, an α/β/β/α sandwich 
fold with two β-sheets in the centre and a-helices on the outer face flanking the 
protein core. The similarity between the individual β halves of the protein suggests 
that the enzyme may have evolved from a gene duplication event (Figure 1.9) (67). 
The active site is located in a wide shallow groove formed by loops that connect the β 
strands that form the sheets as shown in Figure 1.8. Most MBLs exist as monomers in 
solution, but L1 MBL from Stenotrophomonas maltophilia from the B3 class is 
tetrameric, as determined by sedimentation equilibrium (66).  
 
 
 
Figure 1.8. The overall folds of three different subclasses MBLs 
Each class shares a similar α/β/β/α fold. α-helices are coloured in red, β-sheets in 
yellow and loops in green. Zinc atoms are marked as grey spheres. (a) B1 - IMP-1. (b) 
B2 - Sfh-1. (c) B3 - L1 (monomer form). 
 
 
B1 – IMP-1 B2 – Sfh-1  B3 – L1 
α  /  ß   /    ß   / α  
(a)      (b)       (c) 
C 
N 
Flexible loops 
  
 
15 
 
 
Figure 1.9. The diagram of α/β/β/α sandwich folds in MBL superfamily 
Shown is the folding of a B1 enzyme: IMP-1. 
 
 
 
Figure 1.10. An overview of the super-positioned AIM-1 - a B3 MBL, and MPH 
Colours of AIM-1 are shown as red α-helixes, yellow β-sheets and green loops; and 
MPH are shown as blue α-helixes, purple β-sheets and pink loops. 
N-terminals 
C-terminals 
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It should be noted that the overall fold of the MBLs is similar to that found in a 
variety of other proteins - this fold is usually referred to say the metallo-β-lactamase 
fold (MBL fold). Other examples of the fold include methyl parathion hydrolase 
(MPH) from Pseudomonas sp. (68) and glyoxalase II from H. sapiens (69). MPH 
catalyses the degradation of the organophosphate pesticide methyl parathion. 
Glyoxalase II catalyses the conversion of toxic 2-oxoaldehydes to 2-
hydroxycarboxylic acids using glutathione as a coenzyme. Figure 1.10 shows the 
superposition of the structures of an MBL and MPH to give an idea of the folding 
similarity of the two folds. 
 
1.3.3 Active Site Structure - Metals and Metal Coordination 
 
Most MBLs have two zinc binding sites - Zn-1 and Zn-2.  As can be seen from Figure 
1.11 and Table 1.2, the amino acids responsible for metal binding differ between the 
classes. In dinuclear zinc MBLs such as B1 and B3 classes, Zn-1 is normally bound 
by three histidines, His116, His118 and His196 according to the BBL numbering 
scheme (70). His116 is replaced by an Asn in CphA and Sfh-1 from the B2 class and 
in GOB-1 from the B3 class. These three residues as well as a bridging hydroxide 
molecule coordinate Zn-1 tetrahedrally. On the other hand, Zn-2 is trigonal 
bipyramidally coordinated by D120, C221, H263, the bridging hydroxide and a 
terminally bound water molecule. Although B2 enzymes, such as CphA and Sfh-1, 
are capable of binding two metals, only one metal is necessary for activity and 
binding the second zinc is inhibitory (71). The ligands in the “Zn-1 site” are Asn116, 
His118 and His196 but the site is not occupied by metal, possibly owing to 
replacement of His116 by Asn116. The functional Zn-2 ion is tetrahedrally 
coordinated by D120, C221, H263 and a carbonate ion (72).  MBL from Bacillus 
cereus is a B1 class enzymes that possesses two zinc sites, However, the affinity of 
metal for each site differs significantly; the dissociation constant is 0.3 µM for the 
first and 3 µM for the second zinc ion (73, 74).  
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It should be noted that the metal coordination sites in other enzymes with the MBL 
fold differ from the MBL enzymes. For example, the MPH enzyme requires two 
metals for activity and its metal coordination site is similar to those found in the B1 
and B3 enzymes. However, it differs in that the side-chain of an amino acid (D221) 
forms a bridge between the two metals in addition to the bridging hydroxide found in 
the B1 and B3 MBLs (68). 
 
All the MBL classes have flexible loops that lie above the metals and that probably 
interact with the substrates. One such loop has been found in IMP-1 and CcrA (74) of 
the B1 class, CphA of the B2 class and L1 and FEZ-1 of the B3 class. This loop has 
several non-conserved residues including one or two hydrophobic amino acids and 
moves upon substrate binding and is thought to lock the substrate in the active site. 
The hydrophobic residues in this loop are thought to interact with the non-polar 
substituents of the phosphotriester substrates such as penicillins and cephalosporins 
(75). Mutating residues in the loop alters the catalytic properties of the MBL in 
question (76).  
 
It is not likely that the MBLs function via a common catalytic mechanism given the 
enormous variation in sequence, structure and metal coordination sites. Mechanisms 
have been published (77) although the experimental evidence supporting them is not 
strong. Reference to these mechanisms will be made when the results this work are 
presented in Chapters 4 and 5. 
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Table 1.2. Ligands for metal ions coordination in three B subclasses of MBL 
B1, B2 and B3 indicate the class of MBL. 
 
 
 
 
Figure 1.11. Active site ligands and metals of MBLs 
(a) B1-IMP-1. (b) B2-Sfh-1. (c) B3-AIM-1. Water molecules are shown as red 
spheres in AIM-1 active site. Molecules distances are shown as yellow lines. 
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1.4 TECHNIQUES USED IN THIS THESIS 
1.4.1 Structural Biology 
 
X-ray crystallography was used to determine the structure of the AIM-1 protein. This 
technique has been used for many years and the various steps necessary to obtain a 
structure have been reviewed (78); only those steps relevant to the present work will 
be presented in this thesis. In fact, the rate limiting step in structure determination is 
frequently the production of crystals suitable to structure analysis and it is this step 
that has occupied much of the time in this study. The techniques to express purify and 
crystallise proteins are described in chapter 2; the theory associated with these 
processes has been reviewed elsewhere and will not be covered here.  
 
1.4.2 Protein Engineering - Directed Evolution 
 
Directed evolution is one of the techniques that can be used to modify proteins for 
practical applications or as a means to gain a better understanding of how they 
function. There are other approaches that can be used to achieve these ends and the 
field can be referred to as “protein engineering”. A brief outline of the need for 
engineering proteins and a short history of the field is given below. The important 
point to note is that the field is relatively new and the techniques for the work are still 
being developed. Only the approach taken in this study will be referred to below and 
interested reader can consult a number of recent reviews (79, 80) for a broader 
description of the field.  
 
There is a real need to be able to engineer proteins. They have evolved over millions 
of years, a period of time in which one would expect that their properties would be 
optimised for their function. A particular protein may evolve to the point where it 
satisfies the needs of the organism and no more. An organism may only require low 
levels of a particular substance so that the enzyme responsible for its production may 
be expressed at low levels (81). So, being able to produce a protein does not mean 
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that it can be used in practical applications. Enzymes as they occur in nature often 
require modification so that they can be used in practical applications.  
 
Proteins can be modified by chemical means, but the results are usually focused on 
site-specific modification but quantitative conversions are not common, see the book 
by Means, Lundblad or their more recent review (82-84). Modified proteins can also 
be produced by direct synthesis, but again the process is expensive and yields are 
relatively poor. However, the idea that proteins could be modified for use in industrial 
application became a realistic proposition with the development of site directed 
mutagenesis by Smith in 1978 (85-87). One could improve an existing protein by 
mutating its gene.  
 
PCR has revolutionised molecular biology. Many of the existing techniques of 
molecular biology were greatly simplified and new techniques were developed. For 
example, it became possible to generate large mutant libraries of a gene (or portion of 
a gene) with a specified average error rate (88). This meant that it was realistic to 
consider improving protein properties in an analogous manner to that used in nature, 
evolving them. The field of protein evolution has developed rapidly in the last few 
years and is generally referred to as directed evolution or directed molecular 
evolution. In addition to the techniques noted above, other instrumental developments 
have also been essential in the development of directed evolution which implicate 
plate scanners to analyse large libraries of variant proteins (89).  
 
 
Figure 1.12. Directed evolution of enzymes - an overview 
•  Candidate 
Parent 
Genes 
1. Target 
Identification 
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Genetic Diversity 
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The word evolution usually implies Darwinian evolution that involves the repetition 
of two steps: the creation of genetic diversity followed by selection to produce a 
superior product (shown schematically in Figure 1.12) (90). Before expanding upon 
these steps it is useful to point out that the success of laboratory evolution will depend 
upon a number of factors; some of the more important factors are given here. The first 
is that the results of the experiment will depend on the size of the mutant library or the 
number of mutants that can be tested. The second point to note is that significant 
change may only become apparent after a number of rounds of evolution. The third is 
that most mutations have a negative or no effect on the enzyme; selection removes 
them from the population. 
 
1.4.2.1 Library Generation - Preparation of A Mutant Library 
 
In the past, mutations could be made to genes using chemical methods or mutator 
strains of E. coli (91). However, these processes were difficult to control and to carry 
out in a reproducible manner (92); one was never sure that observed changes were 
due to changes in the target gene and not elsewhere in the genome.  
 
PCR insured that mutations were concentrated in a specific gene or region of the 
gene. It has been reviewed extensively and only a brief outline is necessary here. The 
PCR experiment consists of three cycles (Figure 1.13). In the first, an increase in the 
temperature causes the strands of DNA to separate. Short oligonucleotides (primers) 
are present in excess of the DNA concentration and are designed (made to be 
complementary) to bind (hybridize) selectively to one of the two strands of the target 
DNA. The DNA strands re-anneal with the primers when the temperature is lowered. 
Also present in the PCR solution is a DNA polymerase that binds to the primer 
termini and extend them according to the sequence specified by the template strand. 
The DNA polymerase is usually from a thermophile and can withstand the high 
temperatures required to denature DNA during each round of replication. The activity 
of the polymerase is usually optimal at temperatures above that required for annealing 
that the temperature for the final step of each round is usually higher than for the 
annealing step. 
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It is probably worthwhile making a few comments about the PCR process. First the 
primers mark the ends of DNA to be amplified and can be used to add restriction sites 
to the ends of the fragment so that it can be cloned into a plasmid. The choice of 
primer sequences and its length are crucial for the success of the PCR experiment 
such as the temperatures and the timing of the actual experiment. There are three 
temperatures used in a typical PCR experiment: one to separate the strand, one to 
allow optimal binding of the primers and the third to allow optimal extension of the 
primer strands by the polymerase. It should be noted that the choice of the extension 
time is usually made long enough to allow the complete replication of the DNA 
fragment. A short extension time results in the fragment being “shuffled” genes, as 
noted in a subsequent paragraph. Each cycle increases the yield of amplified DNA by 
a factor of 2 (n cycles increase by a factor of 2n). 
 
 
 
Figure 1.13. The principles of PCR 
Three PCR cycles are shown. Black lines represent parental DNA strands and blue 
bars represent newly synthesised complementary DNA strands. Forward and reverse 
primers are shown as green and brown arrows respectively. Double stranded DNA 
template is denatured at 94-96 °C, followed by annealing of primers to template DNA 
as temperature is lowered below the melting point of the primers. Complementary 
strands are extended by DNA polymerase at 68-72 °C and numbers of synthesised 
strands increased exponentially. For simplicity, DNA polymerase is shown only in the 
first cycle. 
 
Parental Strands 
Denature Anneal Extend 
1st Cycle 
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1.4.2.2 Error-Prone PCR (ePCR) 
 
DNA polymerases usually have a domain that has 3’ to 5’ exonuclease activity (or 
“editing” activity) so that the DNA is faithfully replicated (93). However, not all 
polymerases possess such a domain and there can be used to introduce mutations into 
the DNA. Enzymes like Taq polymerase (from Thermus aquaticus) add the incorrect 
base about 1 to 2 times in 104 depending on the reaction conditions (94, 95). Given 
that a PCR experiment involves about 30 cycles the cumulative error rate should be 
about 1 in 103 nucleotides (96) which is not a high enough error rate for generating 
diversity. Higher error rates can be achieved with a number of protocols. These 
include methods that involve increasing the concentration of MgCl2, the addition of 
Mn2+, and the addition of triphosphate nucleoside analogues (97-99).  Using these 
methods libraries with a range of average numbers of mutations per gene can be 
generated. However, one should sequence a number of randomly selected genes to 
verify the error rate.  
 
So, what size library should be generated and what average error rate should be used? 
It has been shown in our own laboratory and a number of others that a protein with 
enhanced properties can be produced with a relatively small number of mutations, 
typically between 1 and 10 changes. An enormous library would be required to cover 
all the mutations required to give an average of 10 mutations per gene which would 
be too large to screen and the probability of finding a favourable change by screening 
a small subset of the library would be low. The relevant question to be asked is: what 
size library should be screened with the facilities and time available? The answer will 
give an indication of a reasonable level of genetic diversity for the mutant library. In 
the work described in this thesis, the error rate has been kept at around 2 to 3 per gene 
so that several rounds evolution are required to generate optimal activity. 
 
It should be noted that ePCR is similar to bacterial replication. Selected genes 
produced in one cycle are used to generate the library to be screened in the next cycle 
that is analogous to asexual replication. However, in nature genetic recombination is 
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probably the most important factor used to generate genetic diversity. Can we 
simulate recombination in a test tube? 
 
1.4.2.3 DNA Shuffling - Genetic Recombination. 
 
In the mid 90s Stemmer developed a PCR protocol that gave in vitro recombination of 
a collection of genes, DNA shuffling (100, 101). The technique requires a pool of 
homologous genes that are usually produced by ePCR. In these experiments the DNA 
is broken into small fragments (about 30 bases in length) using a nuclease. Primerless 
PCR is used to reassemble the fragments into a full-length gene. The shuffling 
process often introduced new mutations into gene to further increases genetic 
diversity. In practice, Stemmer’s protocol had a few limitations for example that large 
quantities of template DNA were required.  
 
 
 
Figure 1.14. Staggered Extension Process 
Gene recombination in StEP is introduced by the short extension time used during 
PCR, generating smaller gene fragments that serve as primers for random product 
extension in the next cycle. Repeated cycles of denaturation, annealing and extension 
will result in template switching and shuffling of the gene. 
 
Producing short fragments by PCR 
Parent genes with 
different mutations 
Short fragments randomly prime 
the templates 
Thermal cycles repeated until full-
length genes were produced  
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Fortunately, techniques to shuffle DNA in a single PCR step have been developed 
that the procedure is known as StEP (Staggered Extension Process) (102, 103). As can 
be seen in Figure 1.14, short extension times do not give insufficient time for the 
complete replication of the gene in a single cycle. In the next cycle, the partially 
extended fragments randomly anneal with templates and the extension continues, this 
results in template switching or gene shuffling. The procedures involved in StEP are 
easier to perform than Stemmer shuffling. 
 
Shuffling it takes DNA fragments from different genes and links them in different 
ways to generate new genes. Ideally, the fragments should be short enough so that the 
different mutations in the parental genes so that they can be fused together in a novel 
fashion. In nature this is referred to as recombination. Each new gene is likely to have 
sections from a number of parent genes. The most likely outcome will be the native 
gene, but importantly, the shuffling process allows the possibility that favourable 
mutations can accumulate in a single gene. To persist a mutation must confer a 
selective advantage on the gene. For this reason, neutral or detrimental mutations 
disappear from the sequences over a number of rounds of directed evolution. A full 
review of shuffling is beyond the scope of this thesis, but the interested reader can 
consult a number of useful reviews (104, 105).  
 
1.4.2.4 Site-Saturation Mutagenesis  
 
In a previous section it has been suggested that the error rate should be kept at low 
levels. This is a practical restriction that places significant limitations on what can be 
achieved with directed evolution. In addition, one would expect that active site 
residues will have the greatest affect on activity and the investigator may want to 
concentrate his mutagenesis on that area - this can be achieved with site saturation 
mutagenesis (SSM). It should be noted that the need for SSM could arise from an 
analysis of the results of ePCR. Often, the sequences of variant proteins may show an 
accumulation of mutations in a particular part of the protein, a “hot spot”, suggesting 
that this area may be important for enhanced activity. Ideally, many mutations can be 
made in these hot spots using site saturation mutagenesis (106).  
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Figure 1.15. General diagram of site-saturation mutagenesis - uses an NNK 
random codon for example 
NNK random codon is able to generate a full amino acid types in a specific position. 
Site-saturation mutagenesis library can be screened or picked randomly for the 
experiment needs. 
 
1.4.2.5 Selection/Screening Libraries.  
 
Finding a suitable method to screen or select mutants from a library is often a 
challenging process. In selection, the activity of the target enzyme must be essential 
for survival so that the mutant carrying the desired function can be easily 
distinguished from the background of reactions of all other mutants. The term 
“selection” has its origins in molecular genetics and assumes that a mutation will 
confer a growth or survival advantages to the host organism. These are in vivo 
techniques and the organism survives (or grows rapidly) only if it possesses an 
enzyme with appropriate activity for example, antibiotic resistance. Selection methods 
are generally less laborious and can involve large libraries. Selection techniques are 
generally applied to mutants grown on solid media (agar plates) and are typically used 
with libraries of the order of 105. They are relatively easy to use, but they may not 
give a good quantitative response, in which case a secondary screen will be required. 
*** 
NNK 
*** 
*** 
*** 
AGG 
N = A, T, G, 
C 
K = G, T 
GGG 
CTT 
Site-Saturation Mutagenesis 
SSM Mutants 
Library Screening/ 
Random Picking 
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However, not all enzymes can be linked to cell survival and the experimenter must 
resort to a screen.  
 
A screen involves a direct measurement of enzymatic activity. It is more laborious but 
more versatile than selection process. The throughput is usually lower for a screen 
than it is for a selection. Screening usually involves direct measurement of the 
enzymatic activity of a variant protein by a high-throughput assay that can be carried 
out using bacteria growing in the wells of microtiter plates or on agar plates. If the 
reaction involves the formation (or degradation) of a coloured or fluorescent 
substance then the assay can be carried out inside the cell and monitored by visual 
inspection. For example, bacteria can be transformed with the gene for an enzyme that 
can degrade organophosphate pesticides (OP) and grown on plates that contain an OP 
that forms a fluorescent hydrolysis product. Simply placing the plates over a UV lamp 
and noting which colonies produce the greatest fluorescence signal gives an indication 
of enzyme activity (107). 
 
Usually, screens are carried out with 96-well micro-titer plates mounted on a device 
that allows each well to be probed using spectrophotometers or fluorometers. A single 
colony (transformant) is grown in each well and the plate is replicated. The cells of 
the original plate are lysed and its contents used to measure the relevant activity. 
Useful clones can then be obtained from the copied plate. Plate readers usually 
operate at speeds that allow libraries of the order of 104 to be screened in a reasonable 
time where smaller libraries that can be screened using an agar plate screen or 
selection. However, plate readers are much more versatile instruments than agar 
plates in the sense that they produce a quantitative reading for enzyme activity and the 
coupled assays can be used to monitor enzyme activity.  
 
Screening and selection can be referred to collectively as “interrogating a mutant 
library”. They are quite different to the processes involved in generating a mutant 
library in a number of important ways. A great deal of effort has been put into the 
development of techniques to manipulate DNA and much of this effort has been made 
available to the scientific community in the form of commercial kits. The properties 
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of DNA are not highly sequence-dependent and procedures devised for one gene can 
generally be applied to most, if not all genes. By way of contrast, different enzymes 
usually possess quite different properties and the screen or selection process for one 
enzyme cannot be used for others.  
 
It should be noted that although a selection or screen may be carefully designed to 
identify mutants with a particular characteristic, nature might not respond 
accordingly. For example, a screen may be designed to identify mutants with 
enhanced enzymatic activity and might use cell lysate to monitor enzyme activity. 
However, the mutations may cause an increase in enzyme expression and not an 
increase in the catalytic rate. In other words, it may be easier for the cell to produce 
more enzyme rather than a better enzyme. The general principal is that “you get what 
you select for”, but what you select for may not be what you want.  
 
1.4.3 Approaches to Improve Protein Solubility 
  
Improving the solubility of a protein can be achieved in two major ways: external 
factors and gene modifications (108-112). External factors include choice of 
expression vectors, temperature, time and culture media as well as in vitro refolding 
inclusion bodies, an insoluble precipitant or aggregate of a protein. Although 
refolding is useful to obtain large quantities of soluble protein, the down side of this 
method is that it is difficult to optimize the conditions. Also the half-life of refolded 
protein due to the insolubility nature is usually short and the further characterisations 
such as kinetic assays are difficult to be carried out. 
 
The other approaches to solve the intrinsic insolubility property of the protein are 
gene modifications that protein residues could be mutated for enhancing the 
solubility. This method usually based on an accurate structure that requires 
information between the structure and the solubility, which is usually unavailable for 
an insoluble protein. Prediction of suitable mutations can be made by computational 
methods, for example, identification of hydrophobic surface residues for charged side 
chain mutagenesis. Also, predicted mutations can be incorporated into directed 
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evolution so that shuffled mutant libraries can be screened. Commonly a reporter that 
fuses the target protein was used for directed evolution such as green fluorescent 
protein (GFP) (113, 114) and dihydrofolate reductase (DHFR) (115, 116).  
 
1.4.3.1 DHFR Fusion Reporter System 
 
Our laboratory has developed a powerful directed evolution strategy to improve the 
solubility of an enzyme by fusing it into DHFR. DHFR is a highly soluble protein 
with 18 kDa mass found in tetrahydrofolate pathway. It is responsible for the survival 
of E. coli by reducing 7, 8-dihydrofolate (DHF) to 5, 6, 7, 8-tetra-hydrofolate (THF) 
in the presence of NADPH. This method is based on the insensitivity of E. coli to the 
antibiotic trimethoprim (TMP) if DHFR expressed at an appropriate level. Take SPR-
1, an insoluble recombinant protein, fused to DHFR for example. The decreased 
solubility of the fusion protein hampered the activity of DHFR thus the cells are 
unable to survive at certain level of TMP. Therefore, variant proteins with better 
solubility will be selected with directed evolution. 
 
1.5 PREVIOUS STUDIES WITH SPR-1 AND AIM-1 ENZYMES 
 
The work in this thesis has focused on two MBLs, specifically enzymes from Serratia 
proteamaculans (SPR-1) and Pseudomonas aeruginosa (AIM-1).  
 
1.5.1 Previous Studies of SPR-1 From Serratia proteamaculans 
 
Serratia proteamaculans is a gram-negative bacterium that has been observed in 
plants, soils and insects (117). This organism has caused infections in clinical 
settings; they were rare and resulted in pneumonia (118, 119). Resistance to β-lactams 
was reported in 2003, but the cause of the resistance was not identified.  
 
S. proteamaculans is one of the S. liquefaciens complex species. In 1982, based on 
DNA relatedness studies, Patrick Grimont and his coworkers divided the S. 
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liquefaciens complex into three species and two subspecies, namely S. liquefaciens 
sensustricto, S. proteamaculans subsp. proteamaculans, S. proteamaculans subsp. 
quinovora and S. grimesii (120). Strains of the S. liquefaciens complex predominantly 
cause sepsis and bloodstream infections via contaminated clinical equipment and 
blood components (119). In one case S. proteamaculans was shown to cause human 
disease (118). Most clinical data only refer to the S. liquefaciens group and do not 
differentiate the species therein and the clinical significance of these species is still 
unclear (121). 
 
Serratia proteamaculans strain 568 was sequenced in 2007 and the gene for blaSPR-1 
was identified as a putative MBL (122). The signal peptide of SPR-1 was predicted by 
SignalP 3.0 HMM to cut at residue 22 (123). E. W. W. Leung studied SPR-1 in 2009 
(124) and A. M. Hashim in 2011 (125). In the latter study the β-lactam hydrolysis 
activity of SPR-1 was dramatically improved. Unfortunately, the best mutant of SPR-
1 could not been fully characterised due to the their poor solubility. We have tried 
changing various conditions for the expression of SPR-1. The conditions including 
the incubation temperature, the culture medium, the IPTG concentration, the growth 
phase and the expression time In addition detox strains have been used for expression. 
None of these experiments gave improvements in the solubility of SPR-1. Leung and 
Hashim tried to use directed evolution to evolve a soluble variant of SPR-1 but were 
plagued by technical difficulties; the present study attempts to over come some of 
these difficulties. 
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1.5.2 AIM-1 from Pseudomonas aeruginosa 
 
AIM-1 is a novel and poorly characterised MBL that was found in Women’s and 
Children’s Hospital, Adelaide, Australia (126). In a preliminary study of AIM-1 by Dr. 
Peter Vella (University of Queensland) it was shown that the recombinant AIM-1 
expressed in the periplasm of E. coli was soluble. Furthermore, the tertiary structure 
predicted by SWISS-MODEL (127-129) indicates that it is a B3 type MBL. 
Genetically, AIM-1 is most similar to an identified B3 MBL, SMB-1, with only 55% 
identity. AIM-1 was found in the chromosome and was flanked by two copies of 
ISCR elements that are implicated in the mobilisation of three MBL genes - blaSPM-1 
(130), blaNDM-1 (131) and blaAIM-1 (132). These mobile elements will accelerate the 
spread of these resistance genes among clinically opportunistic pathogens. 
 
The aim of my work was to express, purify and crystallise AIM-1 for structure 
determination.  This work was completed and being prepared for publication when a 
similar study was published (132). The worked completed as part of the present study 
is described in Chapter 4 while additional work that probed the mode of action of 
AIM-1 is covered in subsequent chapters. Specifically, site-saturation mutagenesis 
was made to probe the wall of active site residues while directed evolution was used 
to find alternative variant proteins by selection and screening. 
 
1.5.3 AIM-1 Universal Sequence Numbering 
 
The numbering of AIM-1 amino acids was rearranged that is consistent with other 
MBLs for the convenience of readers. Table 1.3 shows the origin and the universal 
numbering of AIM-1 amino acid sequence. This universal numbering of AIM-1 was 
based on the alignment to the other members of the MBL superfamily (73, 133-135). 
There were no matches of the first 39 amino acids therefore the universal number was 
started from the original number 40. According to the universal numbering of MBLs, 
number 40 from the original number was the universal number 51. Few universal 
numbers were omitted in AIM-1 such as 110, 179 and 180. Also the universal number 
was not assigned to the original residue 247. 
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Figure 1.16. Universal sequence numbering of AIM-1 
Original AIM-1 sequence is presented as bold numbers. And the universal numbering 
is underneath the origin numbers. Asteroid mark is the termination codon indicates 
the end of the amino acid sequence. Universal sequence matches most conserved 
sequence within MBL superfamily and it is for reader to review other MBLs when 
comes to residue recognitions. 
  
Origin     1          11         21         31 
Universal  1          11         21         31 
 MKRRFTLLGS VVALALSSTA LASDAPASRG CADDAGWND  
 
40         50         60         70         80 
51         61         71         81         91 
PAMPLKVYGN TWYVGTCGIS ALLVTSDAGH ILVDAATPQA GPQILANIRA  
 
90         99         109        119        129 
101        111        121        131        141 
LGFRPEDVR  AIVFSHEHFD HAGSLAELQK ATGAPVYARA PAIDTLKRGL  
 
139        149        159        167        177 
151        161        171        181        191 
PDRTDPQFEV AEPVAPVANI VTLADDGV   VSVGPLALTA VASPGHTPGG  
 
187        197        207        217        227 
201        211        221        231        241 
TSWTWRSCEG DDCRQMVYAD SLTAISDDVF RYSDDAAHPG YLAAFRNTLA  
 
237          248        258        268        278 
251          261        271        281        291 
RVAALDCDIL V TPHPSASGLW NRIGPRAAAP LMDTTACRRY AQGARQRLEK  
 
288        298 
301        311 
RLAEEAATSP SSGARP* 
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1.6 OUTLINE OF THESIS  
 
The general aims of this thesis were to gain a better understanding of how MBLs 
function with the long term idea of aiding in the design of inhibitors that could used 
as lead compounds in the development of antibiotics. A major priority was to gain 
insight into the catalytic mechanism of the MBLs and to determine the residues 
important for binding substrates.   
 
1.6.1 Aims 
 
As noted earlier, there are many different MBLs and only few of them can be studied 
in a limited time. The initial intention was to focus on the SPR-1 enzyme. This 
enzyme was from a bacterium found in a soil sample taken in Alaska; it was not from 
a clinical isolate. It was a putative MBL based on its sequence derived from genome 
of the host organism. Amalia Hashim isolated, purified and evolved the enzyme as 
part of her thesis work. However, the solubility of this enzyme was low and this made 
it very difficult to characterise. My role in this work was to find a way to improve 
solubility of the enzyme such as manipulating external factors of expression and 
protein engineering that it could be thoroughly characterised. Although some progress 
was made toward this end, physical studies were hampered by the limited solubility 
and the instability of this enzyme. Therefore, a search was made for a more suitable 
enzyme. 
 
AIM-1 was identified in a clinical isolate and it was belonged to the B3 class from its 
sequence. At the time this study was initiated there was little else known about the 
enzyme. However, during the course of this study it became apparent that another 
group had an interest in characterizing it. Our initial intention was to determine the 
structure of the enzyme and to then use molecule techniques to probe the role of 
active site residues in catalysis and to change the substrate specificity of the enzyme 
using directed evolution. The structure work was completed, but another group 
reported the structure. Nevertheless, we proceeded with other aspects of the project as 
summarised below.  
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1.6.2 Brief Outline 
 
Following is a brief summary of the subsequent chapters: Chapter 2 contains a 
description of the generic methods used throughout the research; Chapter 3 describes 
the work with SPR-1 MBL including methods of solubility improvement, directed 
evolution for increasing solubility, study of ampicillin evolved mutants and the 
identification of the new subgroup of class B MBLs; Chapter 4 involves fundamental 
characterisation and site saturation mutagenesis studies of the B3 MBL AIM-1; 
Chapter 5 contains the study of directed evolution of AIM-1 against a cephalosporin 
substrate; and Chapter 6 has the concluding remarks. 
 
  
  
 
35 
CHAPTER 2 - BIOCHEMICAL TECHNIQUES 
 
This chapter will introduce detailed material and methods that used through the 
projects. All chemicals and reagents used were of analytical grade and given in 
Appendix A.1 and A.4 along with recipes for buffers, solutions and growth media. 
DNA oligo sequences are given in Appendix A.2 and the equipment are in Appendix 
A.3. A MilliQ Reagent Water System was used to produce all the MilliQ water in this 
thesis. An autoclave machine, model ASB170BT from Astell Scientific, was used to 
sterilise all glasswares, micropipette tips, growth media and buffers. 
 
2.1 CELL STRAINS AND VECTORS 
2.1.1 Escherichia coli Strains 
 
This section listed E. coli cell strains. Generally speaking, DH5α was for expression 
of constitutive vector and to produce plasmid for further purposes. E. coli BL21(DE3) 
was for larger protein expression, and was also used for generating as well as 
screening mutant libraries. DetoxET7 was a special strain that ought to control the 
expression if target protein was detrimental to the cell itself. 
 
2.1.1.1 E. coli DH5α 
 
Detailed genotype of DH5α strain - supE44 Δlac169 80 lacZΔM15 hsdR17 recA1 
gyrA96 thi-1 relA1. This strain was widely used for constitutive expression and 
library generation because of the high transformation efficiency, simple preparation 
and stable storage. Also, it was a K12 wild type strain that lacks recA, a protein 
responsible for recombination between homologous DNA sequences, so there was 
minimum chance of recombination between homologous sequences of plasmid gene 
and bacteria genome. The endA1 implies the deletion of the normally present non-
specific endonucleases that could possibly digests the foreign DNA, thus avoids 
difficulties when preparing plasmid. The designation hsdR17 indicates that a native 
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restriction enzyme that is normally present in E. coli has been eliminated, preventing 
degradation of target plasmid transformed into the cell. 
 
2.1.1.2 E. coli BL21(DE3) recA- 
 
The genotype of this strain was E. coli B F dcm ompT hsdS(rs- ms-) gal λ(DE3). 
BL21(DE3) recA- was used for high-level protein expression with T7 regulation 
vectors. T7 RNA polymerase was encoded by the DE3 gene and bind to T7 promoter 
after IPTG induction. This strain lacks both the lon protease and the ompT outer 
membrane protease for preventing target protein degradation during purification. Also, 
this strain lacks recA protein that necessary for homologous recombination. 
 
2.1.1.3 E. coli BL21 STARTM(DE3) 
 
BL12 STARTM(DE3): F- ompT hsdSB (rB-mB-) gal dcm rne131 (DE3) was ordered 
from Invitrogen (California, USA). A mutated ren gene (ren131), which encodes a 
truncated RNase E enzyme, that lacks the ability to degrade mRNA, resulting in an 
increase in mRNA stability. The lon and ompT proteases also absent in this strain. 
The transformation efficiency of this strain was more than 108 CFU/ µg DNA which 
was higher than the normal BL21(DE3) strain. 
 
2.1.1.4 E. coli DetoxET7 
 
Detox strain over-expresses lacI repressor was used for expressing toxic protein. The 
genotype of this strain was F- hsdS gal ompT (λ cI857 ind-1 nin-5 Sam-7 lacUV5-T7 
gene-1) Lon- and with an E. coli B strain with a pACYC117-derived 
chloramphenicol-resistant plasmid expressing medium level of lacI repressor. This 
strain was IPTG inducible for T7-based vectors and also included lon and ompT 
proteases. 
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2.1.2 Vectors 
 
This section listed vectors that carried target gene either for controlled expression or 
constitutive expression. Vectors pJWL1030 and pJWL1030folA were improved from 
pCY76 that developed by JWL. Vectors pET26b(+) and pJexpress411 is for 
controlled expression. 
 
2.1.2.1 pET26b(+) 
 
Vector pET26b(+) was a T7-based expression vector that purchased from Novagen. It 
has a general leading peptide gene called pelB that directs protein into periplasm of E. 
coli. Target protein could be chosen to express with or without pelB leader by insert 
between NcoI and EcoRI or NdeI and EcoRI sites respectively. It was an IPTG-
inducible vector and uses Kanamycin as a selectable marker. 
 
2.1.2.2 pHUE 
 
pHUE was a T7-based expression vector that can be induced with IPTG and an 
ampicillin resistance gene was used as a selection marker. Target protein that 
removed the stop codon was insert between SacII and EcoRI restriction sites to form a 
fusion protein with the ubiquitin, which was a small soluble protein that could help 
increasing the solubility of its fusion partner. The fusion protein was expressed with a 
His-tag attached at the C-terminal of the ubiquitin that was suitable for Ni2+ column 
purification (Section 2.8.4.3). The Ubiquitin was cut off from a protease cleavage site 
between target protein and the ubiquitin. One extra step of Ni2+ column purification 
was performed to separate target protein and the ubiquitin (136). 
 
2.1.2.3 pJWL1030 
 
Vector pJWL1030 was derived from a high-copy number vector pCY76 (par+, bla+, 
lacZpro, T7o10tir+), which was originally designed by Cy Jeffries. Jian Wei Liu 
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modified the vector by pasting a 414 base pairs PvuII fragment from pCY76 vector 
into pJJKmf after removal of a 381 base pairs PvuII fragment.(137) A leaky lac 
promoter constitutively expressing the gene controlled target gene that inserted 
between NdeI and EcoRI. To improve target protein expression, pJWL1030 was 
replaced with PvuII gene fragment that contained strong ribosome binding site (RBS) 
and translation initiation region from T7 phage as employed in Studier's and T7-based 
pET vector. 
 
2.1.2.4 pJWL1030folA 
 
This vector was for target protein fusing with DHFR protein to improve solubility and 
further applied for evolution. The 480 base pairs DHFR gene (folA) was amplified 
from E. coli genomic DNA and inserted between HindIII and SphI sites of pJWL1030 
vector. A fully insoluble protein, C11 (HocA), was cloned between NdeI and PstI 
sites to reduce the false-positive colonies during library preparation. Target gene 
fragment was inserted between NdeI and PstI (or HindIII) sites that replaced HocA 
gene (115). 
 
 
 
Figure 2.1. The E. coli DHFR fusion vector pJWL1030folA 
Target gene was inserted between restriction sites NdeI and PstI or HindIII. 
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sites of pJJKmf [20] after a 381-bp PvuII fragment was
removed, to produce an expression vector pJWL1030. A
480-bp folA gene encoding DHFR was ampliWed by PCR
from E. coli genomic DNA using a forward primer (5!-
CGC GCA TGC AAG CTT ATC AGT CTG ATT GCG
GCG-3!) and a reverse primer (5!-CCA GGC CTG CAT
GCT TAC CGC CGC TCC AGA ATC TC-3!) and then
cloned between HindIII and SphI sites of pJWL1030 to
produce the DHFR fusion vector, pJWL1030folA (Fig. 1).
Correlating DHFR overexpression with TMP resistance
The pJWL1030folA vector constitutively produced
DHFR at very high levels. Other expression vectors were also
tested for DHFR production. The folA was ampliWed by
PCR cloned between the NcoI and PstI sites of pTrcHisB
(Novagen) and the NdeI and StuI sites of pCL476 [21]. The
pCL476 vector required a temperature jump for induction
while pTrcHisB required IPTG for induction. Our experi-
ments were conducted at 30 °C with no IPTG so that low lev-
els of expression were expected for these two expression
systems. Overnight cultures were grown with cells expressing
each of the three plasmids. The cultures were diluted so that
their densities were the same. Equal volumes were removed
from each growth, spun down, and resuspended in cracking
buVer. The level of DHFR expression was assessed by a
visual inspection of a 20% SDS–PAGE. In addition, cells
with each of the three diVerent plasmids were plated out on
media with diVerent levels of TMP so that the eVects of
DHFR expression on TMP resistance could be assessed.
Solubility of pr teins fused to DHFR
The ge es of a number of prot ins were f s d to that of
DHFR so that the solubilities of the corresponding fusion
proteins could be examined. The proteins in question were:
dienelactone hydrolase (DLH), phosphotriesterase (hocA),
putative ACE, and sunXower seed albumin (SSA). The cod-
ing sequences of DLH, hocA, ACE, and SSA were ampli-
Wed by PCR, and then cloned between the NdeI and PstI
sit s of pJWL1030folA so th t the proteins ould be
expressed fused to DHFR.
TMP resistance assay
Cells expressing DHFR or proteins fused to DHFR
were assayed for TMP resistance using the same method.
The cell lines were streaked on Mueller Hinton Agar
(MHA; Difco) plates supplemented with diVerent concen-
trations of TMP and grown overnight at 37 °C. The level of
resistance was taken as the highest level of TMP with which
colonies grew.
Protein solubility assay
The solubilities of the various proteins (or the proteins
fused to DHFR) were assessed by visual inspection of
crude lysates run on SDS–PAGE gels. All cultures were
grown overnight at 37 °C in LB containing 50!g/mL kana-
mycin. Cells were harvested, resuspended in 0.5 mL of
10 mM Tris, pH 8.0. Lysis was achieved by adding Bug
Buster reagent (Novagen) and incubating at room tempera-
ture for 15 min. The lysates were centrifuged at 16,000g for
10 min at 4 °C. The supernatant and pellet were separated
and the pellet resuspended in buVer (0.5 mL of 10 mM Tris,
pH 8.0) by vortexing. Equal volumes of the solutions con-
taining the supernatant and pellet were run on a 20% SDS–
PAGE. The solubilities of the proteins could be determined
by comparison of band intensities for the proteins as found
in the supernatant (soluble) and the pellet (insoluble).
Directed evolution by DNA shuZing
Random mutations were introduced into the ACE gene
using DNA shuZing as described by Stemmer [22]. The
shuZed ACE gene was ligated between the NdeI and PstI
sites of pJWL1030folA. The plasmid was then transformed
into cells by electroporation. The transformed cells were
plated on MHA plates supplemented with 50!g/mL kana-
mycin and 5!g/mL TMP and incubated at 37 °C for 3–
5 days. A library of 150,000 clones was screened. Fifteen
TMP-resistant clones were selected and used for the next
round of directed evolution. Increasing concentrations of
TMP (10, 20, and 100!g/mL) were used for subsequent
rounds of DNA shuZing. At each round, a library of
150,000 colonies was screened. TMP-resistant clones (12–18
clones) were used for each of the next rounds of directed
evolution.
Results and discussion
The ACE gene used in this study
A search of databases revealed that the ACE gene cas-
sette was a very close, but not identical, match to a cassette
from an integron array in the sequenced genome of V. Wsc-
herii strain ES114 [23] (Fig. 2). Both cassettes were 613
bases in length and were diVerent at 29 positions (95.3%
identity). The two genes were even more highly conserved,
showing only 12 diVerences over a total gene length of 453
bases (97.3% identity). Of these 12 substitutions, 11 were
silent giving rise to a single amino acid diVerence between
the two predicted proteins. This single diVerence is at posi-
tion 101 in the protein and comprises a threonine residue in
Fig. 1. The Escherichia coli DHFR fusion vector pJWL1030folA. The
important elements in the cloning region are shown.
  g10 RBS      ATG
Plac
Gene of Interest
DHFR gene TAA
PvuII                       NdeI  PstI   HindIII                                    SphI PvuII
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2.1.2.5 pJexpress411 
 
Vector pJexpress411 was purchased from DNA2.0 alone with AIM-1 gene. This 
vector had high levels of copy numbers and protein expression. T7 promoter was 
applied on this vector but lacked T7 terminal sequence. This vector contained a 
kanamycin resistance marker and was able to be inducted by IPTG. 
 
2.2 TRANSFORMATION 
 
Electroporation was chosen over chemical transformation because of its higher 
efficiency in transforming bacterial cells with plasmid DNA, given an advantage of 
generating larger library. Cells were electric shocked in a very short time that caused 
the formation of small pores in the cell wall. Permeability of the lipid bilayer to small 
charged molecules was increased during electroporation. Charge DNA was passed 
through the temporary pores into the cells. 
 
Generally, 1 ng DNA (5 µL for cloned DNA library) was gently added to 50 µL of 
thawed electro-competent cells and pipetted several times. The mixture was then 
transferred into 0.2 mm electroporation cuvettes and a MicroPulserTM (Bio-Rad) was 
used to generate an electric potential of 2.5 kV within 5 ms for the cells. 1 mL YENB 
media (Appendix A.1.13) were added into the cuvette within 1 minutes and the 
recovered cells were incubated at 37 °C for 1 hour. During recovering, cells expressed 
the antibiotic resistance gene. 50 µL of each drop was then streaked onto agar plates 
containing antibiotics and grown overnight in a 37 °C incubator. 
 
2.2.1 Preparation of Competent Cells for Electrophoresis 
 
Single colonies or a scratch of frozen competent cells stock were inoculated in 20 mL 
YENB medium and grown overnight at 37 °C. 800 ml of YENB medium was seeded 
with 8 mL of the overnight culture and grown until the OD reached 0.8 to 1.0. The 
culture was then cooled to 4 °C and centrifuged at 4,000 rpm for 10 minutes. The 
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supernatant was discarded and the pellet was resuspended in 200 ml of 10% glycerol 
as a wash step. The resuspended cells were centrifuged again in the same condition 
and the supernatant was discarded. The washed pellet was then resuspended in 1 mL 
of 10% glycerol. The washed and resuspended cells were aliquotted into 50 µL 
aliquots and frozen at -70 °C. Cells were gradually thawed on ice prior to use. 
 
2.3 CULTURE GROWTH AND STORAGE 
 
E. coli cultures for the purposes of plasmid or protein preparation were seeded with 
single colonies isolated from LB agar plates. Cultures larger than 100 ml were grown 
in glass flasks and seeded with a starter culture of 1% of the large culture's volume, 
grown to at least OD595 0.6 to 0.8. Cultures smaller than 10 ml were grown in 15 ml 
plastic tubes. In addition to any other antibiotics added, each medium contained 50 
mg/L of kanamycin. 
 
2.3.1 Growth Media 
 
Various growth media were used according to different situations. The most used 
medium was Luria-Bertani (LB) and unless stated otherwise, a culture is LB medium 
or agar. Mueller Hinton Agar and Broth (MHA, MHB) were utilised when resistance 
to TMP and β-lactams were being assayed. In particular, MH media lack thymidine 
that limits bacterial growth when TMP presents in the media. TMP inhibits the 
synthesis of thymidine and the E. coli cell must depends on its in vivo synthesis to 
survive. LB medium contain excess thymidine therefore it is not suitable for TMP 
selections and assays. YenB media were used in salt free situations such as competent 
cell preparation and some expression conditions for further purification. Protocols of 
each type of medium are given in Appendix A.1. 
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2.3.2 Culture Storage and Disposal 
 
All types of the grown culture were stored in the 4 °C cold room for further uses. 
Agar culture wastes that existed over a month were collected in a plastic bag in the 
cold room waiting for autoclave. Liquid culture wastes were autoclaved immediately 
or added bleach and left overnight. 
 
2.4 DNA METHODS 
2.4.1 DNA Visualisation 
 
DNA samples were run in 0.8% to 1% agarose gels that made of 0.8 to 1 gram of 
agarose melted in 100 ml SB Buffer (Appendix A.1.12). The warm liquid gel was 
poured onto 125 mm x 80 mm-long flat glass plate to gain a 5 mm-thick layer of 
Agarose gel that was cast by surface tension. 
 
DNA samples were prepared with DNA loading dye (Appendix A.1.7) at the ratio of 
4:1. DNA samples were run in SB buffer. Comb of 20-lanes was used to create wells 
that the capacity of each was approximately 15 µL. Cooled agarose gels were then put 
into electrophoresis tank and fill up with SB Buffer. Electrophoresis was run under 
condition of 150 voltages and 300 mA for 20 minutes to 30 minutes until DNA dye 
was migrate near the bottom edge of the gel. 
 
Red SafeTM (iNtRON, Korea) was used to visualise DNA under UV or LED light. 
There were two ways to stain the gel with Red Safe, one was added Red Safe into the 
agarose gel before casting, the other way was immersed the gel in the SB Buffer with 
Red Safe for at least 30 minutes and then was immersed in SB Buffer for distaining 
another 30 minutes. Images of gel were taken using an UVI Pro electronic system. 
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2.4.2 DNA Ladders 
 
One kilobase DNA Ladder (NEB) were used together with DNA samples in the same 
gel to indicate the size of wanted DNA. Bands of molecular weight standards were 
digested from a number of proprietary plasmids that completed with appropriate 
restriction enzymes. The digested DNA includes fragments ranging from 0.5 to 10.0 
kilobases. The 3.0 kilobases fragment has increased intensity to serve as a reference 
band. If a 0.5 µg of DNA marker was loaded, the approximate mass of DNA in each 
of the bands is shown below(138). 
 
Fragment Mass (ng) 
Base 
Pairs 
1 42 10,002 
2 42 8,001 
3 50 6,001 
4 42 5,001 
5 33 4,001 
6 125 3,001 
7 48 2,000 
8 36 1,500 
9 42 1,000 
10a 21 517 
10b 21 500 
 
Table 2.1. A typical 1 Kb DNA ladders 
 
2.4.3 Plasmid Preparation – QIAprep Spin Miniprep Kit 
 
The QIAprep Spin Miniprep Kit was used for plasmid extraction and the protocol of 
manufacturer was applied. The procedure is based on alkaline lysis of bacterial cells 
followed by adsorption of DNA onto silica in the presence of high salt. For cell 
lysates, P1 is the resuspend buffer, P2 is the lyse buffer contains NaOH/SDS in the 
presence of RNaseA and N3 is the neutralising buffer contains high salt. In wash steps, 
PB buffer removes endonuclease and PE buffer removes salts. A brief method is 
described below. 
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Up to 5 mL of overnight E. coli culture was pelleted and the supernatant was 
discarded before being resuspended in P1 buffer. P2 buffer was added to lyse the cells, 
followed by Buffer N3 to neutralise the solution. The mixture was then centrifuged at 
top speed for 10 minutes. The supernatant was added onto the column for DNA 
binding. The column was then washed with PB buffer and PE buffer containing 
ethanol. Finally the purified DNA was eluted in EB buffer (10 mM Tris-HCl, pH 8.5) 
or MilliQ water. 
 
2.4.4 Agarose Gel DNA Extraction – Promega Gel Extraction Kit 
 
Agarose gel extraction is needed especially for recovering DNA samples after agarose 
gel electrophoresis; the purify method includes identification of target DNA fragment, 
isolation and removal of salt and stain. The Promega kit was applied for dissolving 
pieces of excised agarose gel that containing DNA. Membrane binding solution, a 
chaotropic agent, with a weigh (g) to volume (ml) ratio of 1:1 was added to agarose 
gel and incubated at 65 °C for 10 minutes. The dissolved solution was applied to 
DNA-binding-columns and washed two times with the wash buffer, a 70% ethanol 
wash. The DNA was then eluted in nuclease-free water or EB buffer. This kit was 
used for cleaning up ligated samples and PCR product as well. 
 
2.4.5 Restriction Digestion 
 
Restriction enzymes used in this study were all purchased from New England Biolabs 
(NEB). DNA samples for digestion were mixed with 10 U of restriction enzymes to a 
final volume of 50 µL in manufacturer's recommended buffers and BSA. The mixture 
was incubated at 37 °C for 3 hours or overnight. All enzymes in the reaction mixes 
were inactivated at 65 °C for 10 minutes. 
 
Methylated DNA that produced by E. coli such as plasmid was digested by DpnI. 
This enzyme was used after PCR for directed mutagenesis or directed evolution to 
reduce wild type gene in the insert pools. DpnI is usually added together with 
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restriction digestion and followed a gel extraction of DNA sample to remove 
unwanted fragments. 
 
2.4.6 Ligation 
 
Digested plasmid vectors were then treated with calf intestinal alkaline phosphatase 
(CIP) for 1 hour at 37 °C to avoid plasmid recircularisation as well as to decrease 
false positive colonies after transformation. Restriction enzymes-treated DNA was 
purified using a Gel Purification kit (Promega) as described in Section 2.4.4. 
 
T4 Ligation enzymes used in this study were purchased from Thermo, Fermentas and 
Roche. Molar ratio 1 : 3 of vector : insert was performed and 0.5 U of T4 DNA 
Ligase was used in the final volume of 20 µL for sticky-end samples. Ligation 
mixture was incubated overnight at 12 to 16 °C. Ligated sample were then purified 
and ready to transform. 
 
2.5 POLYMERASE CHAIN REACTION 
2.5.1 Gene Amplification 
 
According to different conditions, various DNA polymerases were applied according 
to manufacturer's protocols. High-Fidelity DNA Polymerases such as Phusion (139) 
(NEB) and Pfu (Thermo) was used for the DNA sequence needs to be correct after 
amplification. Taq DNA polymerase was for error-prone PCR or general uses that do 
not need self-correction. 
 
Thermo-cyclers GeneAmp® PCR System 9700 and iCycler® were supplied by 
Applied Bioststem and Bio-Rad respectively. The reaction mixture contained 50 ng to 
100 ng template DNA, 1 µM each of forward and reverse primer, 1.5 mM MgCl2, 0.2 
mM dNTP and 0.15 to 0.25 U DNA polymerase. The general PCR conditions were 25 
to 35 cycles of 94 °C for 30 seconds, 45 °C to 60 °C (according to the Tm of primers) 
for 30 seconds and 72 °C for 2 minutes (140). 
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2.5.2 Colony PCR 
 
Colony PCR was a quick method to check the existence of target gene. In addition, 
the amplified fragment could further processed for DNA sequencing. A master 
mixture containing 1 µM forward primer, 1 µM reverse primer, 0.2 mM dNTP, 1.5 
mM MgCl2 and 2.5 U Tag polymerase (Bioline or Roche) to a total volume of 20 µL 
was prepared. An initial denaturation step was carried out at 95 °C for 5 minutes to 
ensure cells were completely lysed, plasmid DNA were released and all cellular 
DNases were denatured. Single colonies were picked and resuspended into aliquotted 
PCR mixtures. PCCR was performed in 25 cycles at 94 °C for 30 seconds, 50 °C for 
30 seconds and 72 °C for 1 minute. 
 
2.5.3 Primer Design for Mutagenesis Experiments 
 
Primer pairs were designed complementary to each other and carried the substitutions 
of interest. Generally speaking, except for the codons to be substituted, at least 12 
bases on both side of the mutation were extended and that gave a length of 27 to 33 
base pairs. Site-saturation mutagenesis primers were designed using NNK that 
covering 20 different amino acids. SSM diagram was mentioned in Figure 1.15 in 
Chapter 1. All primers were ordered from Geneworks (Hindmarsh, SA, Australia) or 
IDT DNA (Coralville, Iowa, USA) and given in Appendix A.2. 
 
2.5.4 DNA Sequencing 
 
DNA samples were prepared for sequencing as described by the ACRF Bimolecular 
Resource Facility (BRF), The John Curtin School of Medical Research (JCSMR), The 
Australian National University. Each PCR reaction contains 100 to 300 ng DNA, 3.2 
pmol primer, 1 µL of Big Dye (Appendix A.1.2), 4 µL of 5X dilution buffer (400 mM 
Tris, pH 9 wiht 10 mM MgCl2) and MilliQ water fill up to a final volume of 20 µL. 
The PCR protocol was 5 minutes at 96 °C, followed by 30 cycles of 96 °C for 10 
seconds, 50 °C for 5 seconds and 60 °C for 4 minutes. DNA clean-up step was carried 
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out by preparing a EtOH/EDTA/NaOAc mixture, by combining 2.0 mL of 3 M 
NaOAc, pH 4.6, 2 mL of 125 mM EDTA, 62.5 mL of 95% EtOH and 14.5 mL of 
MilliQ water. Each PCR product were added 80 µL of the sequencing mix solution 
and left at room temperature for 15 minutes. The sample was subsequently 
centrifuged for 20 minutes at 13,200 rpm, the supernatant was discarded, the pellet 
was washed with 300 µL of 70% EtOH and centrifuged at the same speed for 5 
minutes again.  Sequencing samples were further washed once with 70% EtOH and 
then air-dried in a laminar hood or under reduced pressure. Genes cloned to 
pET26b(+), pHUE and pJexpress411 were sequenced by the T7 sequencing primer. 
Genes cloned to pJWL1030 were sequenced by the reverse primer M13, while that of 
pJWL1030folA by the reverse primer 1030folA. The samples were sent to the BRF, 
JCSMR, ANU for DNA sequencing. 
 
2.6 PRIMER BASED MUTANT GENERATIONS 
 
The following methods were suitable for both Site-Directed Mutagenesis (SDM) and 
Site Saturation Mutagenesis (SSM). However, Universal T7 Tail Amplification was 
only applied on SSM for higher probability of picking mutants. SDM was carried out 
using two established protocols, one was adapted from Stratagene and the other was 
an overlap extension PCR devised by Saiki et al. (141). 
 
2.6.1 Method for Mutagenesis Adapted from Stratagene 
 
Whole plasmid was amplified by Stratagene method without the necessity of routine 
cloning. The PCR program was performed 18 to 20 cycles of 95 °C for 20 seconds, 58 
to 65 °C for 20 seconds and 68 °C for 7 to 10 minutes. High-fidelity DNA polymerase 
was used and the extension and incorporation of the mutagenic primers were resulted 
in nicked circular strands. The PCR product was then applied with DpnI to digest 
methylated template DNA and cleaned with DNA purification kit. The plasmid that 
contained mutations was transformed into DH5α and streaked on LB agar plates that 
contained suitable antibiotic. The nicks resulting from PCR were repaired in vivo. 
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Single colonies were grown in LB medium for plasmid preparation and then the 
purified plasmid was sequenced to verify the mutations. The drawback of the method 
is that the success rate is about 10% that average one mutant can be found in ten 
random single colonies (data not shown). 
 
 
 
Figure 2.2. Site-directed mutagenesis method adapted from Stratagene 
There are four steps of this method. First a pair of primers designed for target site is 
required. Second, a PCR is carried out to amplify the whole plasmid. Followed DpnI 
digestion to remove the methylated template. Finally the nicked plasmid is 
transformed into E. coli that the nick can be repaired. 
 
2.6.2 Overlap Extension PCR 
 
This method involves two pairs of primers that a pair of flanking primers (denoted as 
primer A and D) and the other pair of mutagenic primers (denoted as primer B and C) 
is shown in Figure 2.3. PCR was performed in three steps that included two standard 
PCR steps (described in Section 2.5.1). 
 
* 
* 
* 
* 
* 
* 
* 
* 
Step 1 
Plasmid Preparation 
Step 2 
Temperature Cycling 
Step 3 
Digestion with DpnI 
Step 4 
Transformation 
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mutation 
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for mutation 
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The first PCR includes paring primers AC and primers BD to generate two mega 
primers. PCR products of correct molecular weight were purified by gel extraction. 
The two pairs of mega primers were then carried on to the second PCR that 
denaturation and annealing caused hybridisation of the complementary sequences. 
That generates a full-length PCR product AD with the intended mutations 
incorporated. The full-length PCR product was then digested with restriction enzymes 
and ligated into the desired vector. The construct was then transformed into DH5α 
and single colonies were picked for miniprep. Finally purified plasmid was sequenced 
to confirm the mutations. 
 
 
 
 
 
 
 
Figure 2.3. Overlap extension PCR 
Two sets of primers are needed for 
this method. The first PCR includes 
the flanking primer A and D and 
mutagenic primer B and C. The PCR 
products AC and BD are mixed and 
used as template in the second PCR 
using flanking primer A and D to 
create the full length PCR product 
with intended mutations introduced. 
The full-length gene is then digested 
with appropriate restriction enzymes 
and ligated into plasmid vector. 
Mutations are marked as “ | ”. 
 
 
 
 
2.6.3 Universal T7 Tail Amplification 
 
This novel method was suggested by Jian-wei Liu (CSIRO) and was used for site-
saturation mutagenesis products generation. It was performed with two steps of PCR 
and two specific primers: the T7 Terminal Tail (a designed sequence exclude from the 
A B 
C 
D 
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A+C and B+D 
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D 
Full length gene 
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vector that attached to the 3' end of T7 terminal sequence) and the Tail (the exclude 
sequence only); details of these primers sequences can be found in Appendix A.2. The 
first PCR includes a forward primer that contains target substitution codons and the 
T7 Terminal Tail primer (Figure 2.4(a)). Mega primers were generated from the first 
step with regular PCR condition and to be purified afterwards (Figure 2.4(b)). This 
method greatly increased the mutation rate because the Tail primer will only amplify 
the mega primer made by the T7 Terminal Tail primer. 
 
 
 
Figure 2.4. Universal T7 tail amplification  
(a) Mega primer is amplified with the T7 terminal tail reverse primer and the designed 
substitution forward primer, for example W37X indicates a SSM primer with NNK 
substitutions at amino acid position 37. (b) Full length products with desired 
substitution were amplified form the mega primer by using the tail primer and the T7 
forward primer. Blue lines are the templates and red lines are the PCR products. 
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W37X 
T7 Term Tail Reverse Primer 
Mega Primer W37X 
NdeI 
EcoRI * 
* 
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Target DNA 5’ 3’ 
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Ready for 
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50 
Detailed second PCR step was performed in 25 µL reaction as below: 
100 ng of wild type template 
1 µM 5' forward primer of the gene 
1 µM mega primer 
1 µM Tail primer 
0.2 mM dNTP 
1x PCR buffer 
2.5 U Taq polymerase 
 
Thermocycling conditions were conducted in 35 cycles of 94 °C for 30 s, 50 °C for 30 
s and 72 °C for 2 mins. 
 
Full-length products were purified and digested with restriction enzymes that were 
appropriated for the desired vector. The construct was then transformed into DH5α or 
BL21(DE3) and single colonies were picked for colony PCR. The products of colony 
PCR were further sequenced to confirm the mutations. The success rate of the method 
is about 60-80%, detailed result can be found in chapter 4. 
 
2.7 DIRECTED EVOLUTION 
 
There were two primary steps in directed evolution - library generation and screening 
or selection. The first step was library generation, which the gene of target protein 
was subjected to mutagenesis either via StEP, ePCR or StEP-ePCR as described in the 
sections below. The PCR product was digested with appropriate restriction enzymes 
and cloned into desired plasmid vector. The ligated products were then transformed 
into DH5α or BL21(DE3) competent cells according to the type of vector. 
Transformed cells were then grown on agar plates supplemented with the appropriate 
antibiotics or compounds for genetic selection. The antibiotics that were used during 
mutant selection are given in each chapter. Secondary or tertiary selection/screening 
was performed to find the best-performing mutants and the genes were pooled for 
subsequent rounds of directed evolution. 
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2.7.1 Error-Prone PCR (ePCR) 
 
The most common method to introduce random mutagenesis into a target gene was by 
using error-prone PCR (ePCR). This method differs from standard PCR reaction due 
to unbalanced concentration of MnCl2 and MgCl2. Generally speaking, a higher 
concentration of MgCl2 is used (5 to 7 mM) compared to standard PRC (1.5 mM). 
This was to stabilise non-complementary pairs as a result of mutations (142, 143). 
MnCl2 was added to reduce template specificity of the DNA polymerase. In this thesis, 
0.1 and 0.2 mM of MnCl2 sufficient to introduce 1-5 amino acid changes in a 800 to 
1000 base pairs gene. This mutation rate was found to be consistent to mutation rates 
determined in previous studies (144, 145). Taq polymerase that lacks 3' to 5' 
exonuclease proofreading abilities was used instead of high-fidelity DNA polymerase 
to facilitate mutations. An increased number of cycles was used to raise the overall 
number of genes containing mutations (146). 
 
In this thesis, ePCR was performed in 50 µL reaction as below: 
 
50 to 100 ng template 
1 µM forward primer 
1 µM reverse primer 
5 mM MgCl2 
0.2 mM dNTP 
1x PCR buffer (without Mg2+) 
0.1 or 0.2 mM MnCl2 
2.5 U Taq polymerase 
 
Thermocycling conditions were conducted in 30 to 40 cycles of 94 °C for 30 s, 50 to 
58 °C for 30 s and 72 °C for 2 mins. 
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2.7.2 Staggered Extension Process (StEP) 
 
StEP is a DNA shuffling approach that is simpler than the classical DNA shuffling 
method. It uses a shorter extension time during PCR to create smaller gene fragments 
that will anneal randomly to any complementary sequences. This strategy allows 
template switching randomly during cycles of denaturation and annealing proceed. In 
this thesis, StEP was introduced after the second round in which the gene was 
subjected to mutagenesis. Several steps were undertaken for optimizing the protocol 
such as the annealing and extension times were manipulated to give a maximum yield. 
Taq polymerase was introduced to increase the mutagenesis rate rather than the 
original StEP protocol in which high fidelity polymerase was used. The protocol was 
used to generate gene library of SPR-1 and AIM-1 as described in Chapters 3 and 5. 
 
The PCR was performed in 50 µl reaction as below: 
 
50 to 100 ng template 
1 µM forward primer 
1 µM reverse primer 
0.2 mM dNTP 
1x PCR buffer (contains 1.5 mM MgCl2) 
2.5 U Taq polymerase 
 
Thermocycling conditions were conducted with 30 to 40 cycles of 94 °C for 10 s and 
58 °C for 5 s. The extension rates of Taq DNA polymerase are over 60 nucleotides 
per sec at 70 °C and about 24 nucleotides per sec at 55 °C(102, 103). Although an 
extension time was not included in the PCR, the high extension rate of Taq DNA 
polymerase was sufficient to extend the gene and form a full length PCR product. 
(Scheme mentioned in Chapter 1 - Figure 1.14) 
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2.7.3 eStEP 
 
This protocol was the combination of error-prone PCR and StEP shuffling in a single 
PCR reaction. StEP-ePCR was prompted by an observation that ePCR can also result 
in template switching but at very low efficiency(144). The protocol is very similar to 
standard ePCR, but with minimum extension time. 
 
The PCR recipes are as below: 
 
50 to 100 ng template 
1 µM forward primer 
1 µM reverse primer 
5 mM MgCl2 
0.2 mM dNTP 
1x PCR buffer (without Mg2+) 
0.1 or 0.2 mM MnCl2 
2.5 U Taq polymerase 
 
Thermocycling conditions were conducted with 80 to 90 cycles of 94 °C for 10 s and 
50 °C for 10 s. 
 
2.8 PROTEIN METHODS 
2.8.1 Protein Visualisation 
 
SDS-PAGE (Laemmli) was used to visualise proteins. The method separates proteins 
according to their molecular weight. In most situations, 15% (w/v) of separating gel 
and 4.5% (w/v) of stacking gel were prepared in final concentration of 0.38 M Tris 
pH 8.8 and pH 6.8 respectively. Detailed conditions are listed below. 
 
Low molecular weight marker (Bio-Rad) was used throughout all the chapters. This 
standard contains six proteins that are Lysozyme, Soybean trypsin inhibitor, Carbonic 
  
 
54 
anhydrase, Ovalbumin, Bovine serum albumin and Phosphorylase b ranging from 
14.4 kDa to 97.4 kDa respectively. Each protein of the 20X stock was diluted with 
cracking buffer (Appendix A.1.5) to be 100 ng/ml and a final concentration of 1% 
(w/v) BME was added. After incubation at 100 °C for 2 minutes, the aliquots were 
stored at -20 °C for further usage. 
 
Two Minigels of Short 
Plate 
Separating Gel Stacking 
Gel 
Percentage 15% 4.5% 
Volume (µL) 8000 3333 
40% Acr-Bis (µL) 3000 377 
1.5M Tris pH8.8 (µL) 2000 0 
0.5M Tris pH6.8 (µL) 0 833 
10% SDS (µL) 80 33.3 
MilliQ water (µL) 2840 2070 
10% APS (µL) 60 20 
TEMED (µL) 10 3 
 
Table 2.2. SDS-PAGE ingredients 
 
The protein samples were prepared at the ratio of 1:1 with premixed cracking buffer 
that contained 1% (w/v) BME. The protein samples were then denatured at 100 °C 
incubator for 2 minutes before loading onto the SDS gel. The widths of the wells were 
5 mm for 10 lanes set and 3.5 mm for 15 lanes set. Maximum 20 µL of sample 
solution could be loaded into each well. 
 
The polyacrylamide gels were run in running buffer (Appendix A.1.11) at 300 V and 
a constant current of 30 mA for each gel. 40 to 50 minutes was sufficient for the 
protein dye to migrate off the end of the gel. 
 
2.8.2 Protein Expression 
 
General protein expression method is described below unless specific method is 
indicated. There are two ways of protein expression in this thesis - constitutive 
expression and IPTG induction expression, depending on the plasmid vectors as 
described in Section 2.1. The BL21(DE3) strain was used for expressing gene in pET-
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based vectors, and DH5α was used for lac promoter-based vectors. Single colonies 
were inoculated into 20 mL LB medium with antibiotic marker according to vectors 
as pre-culture seeds and incubated at 37 °C overnight, in specific, 50 µg/L Kanamycin 
was used throughout this thesis. 10 mL of pre-culture seed was then added into 1L 
culture in a flask and incubated at 37 °C. Cells were induced with a final 
concentration of 0.1 to 0.5 mM IPTG when an OD600 of 0.6 to 0.8 was reached. The 
culture was further incubated aerobically by orbital shaking for 3 hours or overnight 
until a sufficient level of protein was achieved. 
 
Cells were harvested by centrifugation at 4,000 or 5,000 rpm in a Sorvall SLA 3000 
or 46 rotors for 15 minutes respectively. The supernatant was removed and the cells 
were used immediately for lysis or stored at -80 °C for later use.  
 
2.8.2.1 Lower Temperature Expression - SPR-1 
 
SPR-1 gene was cloned into pET26b(+) vector and intend to express without any 
signal peptide. SPR-1-pET26b(+) construct was transformed into BL21(DE3) 
competent cells and streaked on a LB-Kanamycin agar plate, leaved at 37 °C 
overnight. Single colonies were inoculated into 10 mL LB medium as the starter seed. 
0.4 to 1 L of the BL21(DE3) culture that expresses SPR-1 was then placed in a shaker 
at 37 °C for approximately 3.5 hours until the OD600 reached 0.4 to 0.6. After reached 
the exponential phase, the culture flask was moved from the shaker to a cold room for 
cooling down to 4 °C. The culture was then induced with a final concentration of 0.1 
mM IPTG and keep shaking in the 18 °C room for at least 24 hours and the cell was 
ready for lysis. This step intends to let the cells express SPR-1 slowly in a lower 
temperature while keeping the SPR-1 from denaturation. 
2.8.3 Cell Lysis 
 
Three major methods for cell lysis were used in this thesis - French press, air operated 
homogenizer and rLysozymeTM. French press was the most efficient method for 
lysing bacteria cells and it was widely used in this thesis. A benchtop high-pressure 
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homogenizer was an alternative method when French press was not available. The 
third method - rLysozymeTM is described detailed below. 
 
2.8.3.1 rLysozymeTM 
 
rLysozymeTM (Novagen) involves two steps: freeze-thaw and lysozyme lysis. 
Centrifuged cell pellet was frozen immediately at -80 °C for 10 mins and was fully 
thawed at room temperature - this step was repeated three times. 7 mL of Buffer A 
(for column of choice of FPLC system) and 4.5 kU of rLysozymeTM were added per 
gram of cell pellet. The mixture was then shacked 200 rpm for 20 min at room 
temperature and was centrifuged 14,000 g for 20 min at 4 °C. The supernatant of the 
lysed cell was collected for further purification. 
 
It is worth to mention that the matured AIM-1 and its variants (30 kDa monomer) are 
expressed in the periplasm are perfect for freeze-thaw (without rLysozymeTM) 
extraction with better purity but at lower concentration. On the other hand, SPR-1 was 
expressed in the cytoplasm in this study that were not suitable for freeze-thaw method. 
 
2.8.4 Protein Purification - FPLC 
 
The method for purifying proteins is to express them with a ploy-histidine tail (His-
tag) and to use an affinity resin (immobilised metal affinity chromatography, IMAC) 
to separate them from other proteins. However, poly-histidine tail may bind to metals 
such as zinc ions that are necessary for the activity of the metallo-β-lactamase. For 
this reason ion exchange and size exclusion columns were used to purify proteins. 
Also, pHUE expression system that expressed Ubiquitin fused target protein with His-
tag was used in Chapter 3. The His-tag together with Ubiquitin will eventually be 
removed by USP-1 protease. Proteins were purified by an ÄKTATM FPLC system 
throughout this thesis. 
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2.8.4.1 Ion-Exchange Columns 
 
Two types of ion-exchange columns were used in this thesis - Q Sepharose and SP 
Sepharose (GE Healthcare). Q Sepharose is a strong anion exchanger and two 
different sizes, 5 mL and 50 mL, were used that depends on the volume of the cell 
lysate. The pH of binding buffer (Buffer A) for Q Sepharose was adjust according to 
the pI of the target protein for instance, pH 7.6 was used for pI 5.32 and 5.94 of AIM-
1 and SPR-1 respectively and pH 6.5 was used for the variant S221E (pI = 5.20). A 
gradient from 0% to 100% of eluting buffer (Buffer B) was used to separate target 
protein from others. Optimised elution program of gradient ranges, fraction volumes, 
flow rates and other parameters were varied. SP Sepharose is a strong cation 
exchanger and it was also used in the study in some situations. Detailed purification 
steps for AIM-1 and the variant S221E will be given below. 
 
Q Sepharose ion exchange column was used as the first step in FPLC purification of 
AIM-1. The supernatant from lysed cells was loaded into a 5 mL fast flow Q 
Sepharose. If the supernatant was lysed from cell culture that was more than 1 L, a 
100 mL high performance Q Sepharose was used. A fixed concentration of 40 mM 
NaCl in 10 column volume (CV) of Buffer B (Appendix A.1.4.1) was used for AIM-1 
protein elution. A flow rate of 2 mL per minute was used and 5 mL fractions were 
collected. Eluted fractions were tested for MBL activity with ampicillin in MBL assay 
buffer (Appendix A1.1) and analysed by SDS-PAGE. 
 
S211E lysate supernatant was pumped 2 mL/min into the 5 mL Q Sepharose Fast 
Flow column. A program of elution at 3% buffer B (Appendix A1.4.2) for 20 column 
volume was applied. From the second fraction, 60 mL of S221E eluted solution was 
collected. 
 
2.8.4.2 Size-Exclusion Columns 
 
Size-exclusion chromatography (SEC) is also known as gel-filtration chromatography 
that separates proteins by their native molecular size. Larger molecules elute earlier 
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than smaller ones. This is because the latter ones have more mobile phase that 
available for them to go through the interior of the beads. Two columns were used in 
this thesis - Sephadex G75 and Superdex 200. Fractions of target protein from ion-
exchange column were checked by SDS-PAGE and the wanted fractions were 
concentrated to 1 - 2 mL. The concentrated solution was then loaded into one of the 
size-exclusion columns and flow rate was set to 0.2 - 0.5 mL/min. Fractions from 
size-exclusion column were checked again by SDS-PAGE that determined the quality 
and the purity of the protein. Gel-filtration standards (Bio-Rad) can be applied to 
equilibrate the columns for determining the actual molecular weight of a protein in the 
solution (see section 2.8.5 below). 
 
2.8.4.3 Nickel-Charged Affinity Column 
 
Six histidines cloned onto the C-terminus of target protein was purified using a pre-
packed His-tag affinity column system, HiTrap Chelating HP (GE Healthcare). The 
column was charged with Ni2+ by injecting 4 to 5 mL of 0.1 M NiSO4 into the column 
and washed with 3 to 4 CV of filtered MilliQ water. The HiTrap Chelating HP 
column charged with NiSO4A was referred to the Ni2+ column throughout this thesis. 
In order to reduce protein degradation, all steps were performed at 4 °C. 10 mL of 
Buffer A for Ni2+ column (Appendix A1.3.2) per gram of wet cell pellet was added 
and completely resuspended. The resuspended cell solution was homogenised by 
French Press and centrifuged at 16,000 rpm for 45 minutes. The supernatant was 
loaded into Ni2+ column and collected flow through for checking unbound sample. 
The Ni2+ column was equilibrated with 5 CV of Buffer A, then by an increased linear 
gradient of Buffer B (Appendix A1.4.2) over 10 CV for target protein elution. A flow 
rate of 2 mL/min was used and 5 mL fractions were collected. The column was then 
washed with 100% of Buffer B for 2 CV to wash all tightly bound His tagged proteins. 
The column was then equilibrated with 2 CV Buffer A and ready for reuse. 
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2.8.5 Mass Spectrometry 
 
Mass spectrometry (MS) is an accurate measurement that produces spectra of the 
masses of the molecules. Ionised chemical compounds generate charged molecules 
and the mass-to-charge ratios were measured. MS was only used to determine the 
mass of the protein in this study. Protein samples were isolated, purified and dialysed 
in MilliQ water in the final step. Then total 200 µL of 20 µM of the dialysed protein 
was prepared. Dr. Thomas Huber carried out the MS measurements and 
computational calculations of SPR-1 and AIM-1 in RSC, ANU. This technique gives 
accurate mass of protein subunits - not the mass of protein oligomers. The theory of 
MS was reviewed elsewhere and it will not be given here.  
 
 
 
Figure 2.5. Molecular weight markers applied Superdex-200 column 
Ve/ Vo, ratio of the void volume/the elution volume. 
 
2.8.6 Molecular Size Determination 
 
One of the most popular methods for measuring the molecular mass of proteins is 
size-exclusion chromatography (SEC) (147). SEC is widely used for separation and 
characterisation of polymers, including biological macromolecules, in particular, 
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proteins. The size of the cellular protein can be measured in its native state. In this 
study, the gel filtration molecular weight markers kit for molecular weights 12,000 - 
200,000 Daltons (Sigma-Aldrich) was used and the technical bulletin followed will 
not be given detailed here. Superdex-200 size-exclusion column was calibrated with 4 
protein markers and the approximate size of target protein such as SPR-1 and AIM-1 
can then be determined. As a result, the calibration was finished as sorted in Figure 
2.5. 
 
2.8.7 Protein Solubility Assay 
 
Solubility was estimated using an SDS gel. This involved comparing the target 
protein present in total, soluble and insoluble fractions. 1.5 mL of culture that 
expressed target protein was centrifuged using a bench-top centrifuge at 13,200 rpm 
for 1 minute. The supernatant was removed and the cells were used immediately or 
frozen at -20 °C for future use. 
 
The pellet of cells were then resuspended in EB buffer (Appendix A.1.6) or MBL 
assay buffer. The final volume of buffer was given according to the OD600 reading, 
which was 100 µL for 1 OD600. Cell lysis was carried out by BugBusterTM (Novagen) 
or by freeze-thaw-lysozyme method. BugBusterTM is formulated for the gentle 
disruption of the cell wall of E. coli, resulting in the liberation of soluble protein. The 
10 times concentrated reagent was added to cells and resuspended to give a 1X 
concentration. The mixture was kept at RT for 15 minutes prior to centrifugation. 
While using freeze-thaw-lysozyme method, a stock solution of 10 mg/mL of 
lysozyme in 10 mM Tris pH 8.0 was prepared and added to the resuspended cells, to 
give a final concentration of 1 mg/mL of lysozyme. The cells and lysozyme mixture 
was incubated at 30 °C for 30 minutes. Three cycles of freeze and thaw were then 
performed for 10 minutes in -80 °C and until the cells were completely thawed 
respectively. 
 
After cell lysis, 10 µL of sample was taken and referred to as the total fraction (T). 
The remaining mixture was centrifuged again at 13,200 rpm for 10 minutes to 
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separate soluble (S) and insoluble (P) fractions. The supernatant or soluble fraction 
was transferred into an EppendorfTM tube and the pellet was resuspended in an equal 
volume of buffer. The soluble and insoluble fractions were mixed with an equal 
volume of cracking buffer plus BME as described in Section 2.8.1 to visualise the 
proteins in SDS-PAGE gels. 
 
      (a)                      (b) 
  
 
Figure 2.6. A scheme of disc diffusion assay 
(a) A schematic view of disc diffusion of AIM-1. The yellow lines are represents of 
cell colonies lines. The blue double-arrows are the distances (mm) from the edge of 
the drop to the top of cell lines. (b) A disc diffusion result of AIM-1 mutants against 
Imipenem. 
 
2.9 DISC DIFFUSION ASSAY 
 
Each mutant pET26b(+) construct was transformed into 50 µL electroporation-ready 
BL21(DE3) E. coli competent cells. After recovering the transformed mutants cells at 
37 °C, single colonies were made by streaking on LB kanamycin agar plate and 
incubated at 37 °C overnight. Ampicillin, Cefoxitin, Cephalothin and Imipenem 
antibiotic substrates were used in this assay (Chapter 4). A gradient of antibiotic 
concentration that gradually decreased from the centre to the edge of a peri dish agar 
plate was built.  10 µL of 100 mg/mL antibiotic substrate were added onto the center 
of the MH Kanamycin agar plate plus 50 µM IPTG. Single colonies were then 
streaked a line from the edge of the plate to the center, but avoid contacting the 
antibiotic drop. Cells were induced at a very low concentration of IPTG that helps 
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expressing target protein at a low amount without causing metabolic burden. Eight 
lines of mutant samples including a positive control of AIM-1 wild-type and a 
negative control of BL21(DE3) cells with C11-1030folA plasmid were made to be a 
plate of disc diffusion assay. The gap distance between the cell colonies line and the 
edge of the drop only depends on how efficient the AIM-1 mutants perform. 
Distances were recorded in millimeters and smaller numbers indicate better 
performance of the mutants as shown in Figure 2.6. 
 
 
 
Figure 2.7. A typical MICs assay of Cefoxitin for AIM-1 SSM variant proteins 
Each raw indicates which specific enzyme is expressed by E. coli. A ladder of 
Cefoxitin gradient from 0 to 1024 µg/mL was set up from column 1 to 12. Yellow 
colour represents the growth of bacteria cells. 
 
2.10 MINIMUM INHIBITION CONCENTRATIONS (MICS) ASSAY 
 
Rather than disc diffusion methods that gave qualitative conclusion of resistance, 
MICs were used to give a definitive answer for determining the susceptibility of 
organisms to antibiotic concentrations. This method was applied throughout this study 
that determined the lowest concentration of an antibiotic that will inhibit the visible 
growth of E. coli cells expressing target enzyme after overnight incubation. The range 
of antibiotic concentrations for determining MICs was diluted from 1 mg/L as 
required. LB or MH medium plus 50 µg/L kanamycin was used as the base medium, 
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and 96-well plate was used for setting up the target antibiotic concentration gradient. 
Each plate carried 8 samples including a positive control and a negative control, and 
the first column of the plate was left without the target antibiotic as positive controls. 
Each sample was in a row with 12 concentration gradients (up to 1024 µg/ml) of an 
antibiotic (148).  Samples for MICs Assay were pre-cultured overnight then 1 µL of 
each sample was added into each well. A typical result of a MICs plate is shown in 
Figure 2.7. 
 
2.11 SPECTROSCOPY 
2.11.1 UV/Vis Absorbance, Single Cell 
 
Single cell UV/Vis absorbance measurements were made with a Varian Cary UV/Vis 
Spectrophotometer. 10 mm path length was used in all measurements against 
appropriate reference cells. Absorption measurements at wavelengths greater than 340 
were made using disposable plastic semi-micro cuvettes, otherwise quartz cuvettes 
were used. AbsX was used as a shorthand notation to designate the absorption at a 
wavelength of X nm. 
 
2.11.2 UV/Vis Absorbance, 96-Well Plate 
 
A Labsystem Multiskan Ascent plate reader of 96-Well Plate UV/Vis Absorbance 
was used for secondary mutant library screening during the evolution experiments. It 
also used for activity assays that all measurements taken relied only on comparative 
rates or absorbencies. Due to path length varied with the volume of sample scanned, 
the ability to calculate absolute rate was unnecessary. Disposable plastic 96-well 
plates (Greiner UV-Star®, Sigma-Aldrich) were used in this thesis. 
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2.11.3 DNA and Protein Quantitation 
 
DNA and protein concentration were determined by NanoDrop® or Cary 1E 
spectrophotometer by monitoring absorption at 260 or 280 nm respectively. The Cary 
machine was equipped with temperature-controlled cell changer with 14 slots for 
cuvettes. Quartz cuvettes were used for analysis in the UV region or disposable 
plastic cuvettes were used otherwise. 50-100 µl of protein was mixed with 950 µl of 
6.0 M guanidium hydrochloride with 20 mM sodium phosphate at pH 6.5 and the 
absorbance was measured in quartz cuvette at 280 nm. The absorbance was then 
multiplied by the and dilution factor to give actual concentration of protein sample 
(149). Protein extinction coefficient was estimated by the ProtParam tool (150).  
 
2.12 CRYSTALLISATION OF AIM-1 
2.12.1 General Crystal Screening 
 
Hampton crystal screens including HR crystal screen HT, HR Index, HR PEG Ion HT, 
HR PEG Rx HT and HR SaltRx HT were used to identify crystallisation conditions. 
AIM-1 (purity > 99%) was concentrated to 20 mg/mL in 20 mM Tris-HCL, 150 µM 
ZnCl2, 10% Glycerol and pH 7.6 buffer. Hanging drop method was used for 
crystallisation and 0.5 µL of protein sample was mixed with 0.5 µL of each screen 
buffer. Total 495 conditions were tested using a robot dispensing system that was 
operated at room temperature. 96-well crystal plates were then placed in the 4 °C cold 
room. Crystal screening plates were examined every day of the first week and then 
every week after. 
 
2.12.2 Manual Crystal Screening 
 
Two sets of larger quantities crystal screens were made with 24-well plate of varied 
conditions from the HR crystal screen HT, D9. A set of Polyethylene glycol 8000 
ranged from 11% to 25% w/v and pH ranged from 6.0 to 5.0 was made. And a set of 
zinc acetate and sodium cacodylate ranged from 0.05 M to 0.5 M with fixed 
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polyethylene glycol (PEG) 8000 18% w/v and pH 5.0 was made. 2 µL of 20 mg/ml 
protein samples were mixed with 2 µL buffer of different conditions. The best AIM-1 
wild type crystals were obtained after 2 weeks at 4 °C with 0.2 M zinc acetate, 0.1 M 
sodium cacodylate pH 5.0, 16-18% w/v PEG 8000. 
 
2.13 ENZYME KINETICS 
 
All enzymes for kinetics assays were purified and the purities were checked with 
SDS-PAGE. MBL Assay Buffer (A.1.1) was filtrated for reducing background noises 
in this assy. HEPES buffer was used for all MBL kinetics assay instead of Tris-HCL 
buffer. Tris-HCl buffer contained zinc metals that would cause β-lactams self-
degradation in a detectable level that interferes the accuracy of kinetics assay. This 
phenomenon also indicated in the literature (21). 
 
2.13.1 Experimental Methods 
 
Concentrated enzymes, AIM-1 and its variants, were diluted in MBL Assay Buffer to 
be 100 ng/µL. Substrates were weighted and dissolved in MBL Assay Buffer to be a 
concentration of 100 µg/µL. A Carry spectroscopy machine was used to measure a 
UV length from 235 to 405 nm depends on substrates that were given detailed in 
Table 2.3. Enzyme kinetics were measured at 30 °C. 1 cm quartz cuvettes were used 
and a total volume of 1 mL was given for measurement. A Varian Cary UV/Vis 
Spectrophotometer that could be converted to concentration by co-efficient constant 
gave an absorbance reading of substrate. 1 µL of diluted pure AIM-1 was added into 1 
mL substrate solution. The initial velocity was judged and calculated in a period of 
time no less than 6 seconds. No less than 6 readings were calculated for kcat and KM, 
and the errors were calculated by repeating 3 times - gave a minimum of 18 readings 
for each substrate. 
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Class Compound λ (nm) Extinction Coefficient (M-1 cm-1) 
Penams 
Ampicillin 235 - 820 
Benzylpenicillin 235 - 775 
Piperacillin 235 - 820 
Cephalosporins 
Cefmetazole 265 - 7050 
Cefotaxime 260 - 7500 
Cefoxitin 260 - 7700 
Cefuroxime 260 -7600 
CENTA 405 6400 
Cephalothin 260 -6500 
Moxalactam 260 - 4000 
Carbapenems 
Imipenem 300 - 9000 
Biapenem 293 - 7600 
Meropenem 300 - 6500 
Inhibitors Clavulanic acid 215 - 5120 
 
Table 2.3. Substrates used in this study 
Products of lactams were the hydrolysed compounds that can only be measured as 
decreasing values. Therefore the extinction coefficients of lactams were negative 
values. Except the products of CENTA were measured by the cleaved group. 
 
2.13.2 Analysis of Data 
 
Kinetics data of AIM-1 was fitted to the classic Michaelis-Menten equation: 
 
 
(Equation 2.1) 
 
Where ν is initial velocity, KM is the Michaelis constant and [S] is the substrate 
concentration. The value of kcat is derived from the following equation: 
 
 
(Equation 2.2) 
 
The constant kcat is a first-order rate constant also called the turnover number. [E] is 
the enzyme concentration. 
ν = V!"#[S]K! + [S]!
k!"# = V!"#[E] !
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2.14 COMPUTER SOFTWARE PROGRAMS 
2.14.1 Sequence Analysis 
 
DNA sequencing data was displayed by Sequencher. Also Sequencher was used to 
analyse mutations of multiple samples. Serial Cloner was used to view plasmid 
construct and for primer design. Restriction sites were identified automatically by 
Serial Cloner and the program was suitable for cloning simulation. Protein sequences 
were analysed by Consurf (http://consurf.tau.ac.il/), which gave an overview of the 
conserved and non-conserved region of a protein. Interactive Structure based 
Sequences Alignment Program (STRAP http://www.bioinformatics.org/strap/) was 
used for multiple protein alignment, methodology by ClustalW 2.1 (151, 152), and 
secondary structure visualisation. Phylogenetic tree generation was based on the 
protein alignment and visualised by PHYLIP V3.6 (153-155). 
2.14.2 Structure Visualisation and Docking Software 
 
Protein three-dimensional structures were downloaded from Protein Data Base 
(http://www.rcsb.org/pdb) and viewed in Pymol. Pymol can do simple amino acids 
replacement simulation and protein structure alignment. Swiss Dock system 
(http://swissdock.vital-it.ch/docking) was used for docking simulation and substrates 
were displayed in Chimera (127-129, 156, 157). Structures of Substrates were down-
loaded from Zinc12 database (http://zinc.docking.org/). 
 
2.14.3 Other Software 
 
TopLib (http://stat.haifa.ac.il/~yuval/toplib/) was used for site saturation mutagenesis 
library size estimation (158). 
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CHAPTER 3 - PROPOSITION OF THE NEW B4 
SUBCLASS MBL - STUDIES OF AN UNDER 
CHARACTERISED MBL SPR-1 
 
3.1 INTRODUCTION 
 
Associate Professor Gary Schenk (University of Queensland) identified SPR-1 as a 
putative MBL during a search of sequence databases in 2010. This gene was called 
blaSPR-1 and was from Serratia proteamaculans - opportunistic pathogen usually 
found in soil and environment that was thought to be responsible for infecting hospital 
instruments (56). In order to study the protein, a gene coding for SPR-1 was made 
such that its sequence was optimal for expressing in E. coli. Although the protein 
expressed well, most of the resulting protein formed inclusion bodies - it was 
insoluble. Studies of SPR-1 were impeded because of the difficulty of producing 
soluble protein. A number of approaches were taken to improve the yield of this 
protein, including changing the expression conditions, cloning to various vectors and 
even evolving protein to be more soluble. E. W. W. Leung and A.M. Hashim carried 
out these experiments and despite considerable effort on their part, they failed to get 
significant improvement in the yield of soluble protein (124, 125). This study was an 
extension of the works of A.M. Hashim and this included solubility enhancement of 
SPR-1 using directed evolution.  
 
Several different approaches to improving the yield of SPR-1 are described below. 
Finally the low temperature expression was successful. A variant of SPR-1 that 
conferred enhanced resistance to ampicillin was studied in an attempt to identify the 
minimal set of changes required to confer increased resistance.  
 
The difficulties encountered in working with SPR-1 prompted a database search for 
related enzymes. Initially, SPR-1 was categorised as an unusual B3 MBL according to 
the overall sequence homology. The metal binding site of SPR-1 was significantly 
different from all other MBLs. Only three of the commonly observed Zn2+ ligands are 
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conserved; in particular the presence of an arginine instead of a histidine in position 
118 is unusual. A study of SPR-1 by P. Vella indicated that there was only one zinc 
ion in the active site when this protein is in the resting state as is the case for the B2 
MBLs. Kinetic measurements led to the hypothesis that SPR-1 may bind a second 
metal ion when a substrate is added as is similar to B1 and B3 MBLs (159). During 
data mining of blaSPR-1, a gene from Cronobacter sakazakii (called blaCSA-1) was 
found. CSA-1 gave the best match to SPR-1; these proteins appear to have identical 
active site ligand residues including a distinct metal co-ordination that differs from 
those found in other MBLs. The observations led to the proposal that SPR-1 and 
CSA-1 were a new class of MBLs, as described later in this chapter. 
 
3.2 CHARACTERISATION OF SPR-1 
3.2.1 Ubiquitin Fusion Expression 
 
One approach to obtaining soluble SPR-1 was to fuse it to the C-terminus of a stable 
and highly expressed protein. This approach was used to express NDM-1, a B1 MBL 
(160). The ubiquitin fusion system was used for the proposed work. The necessary 
plasmid (pHUE) for this work was obtained from the Board lab in the John Curtin 
School of Medical Research. The pHUE vector was a modified form of the pET15b 
vector with the T7 promoter, his-tag and ubiquitin gene followed by a cloning site to 
allow the insertion of a target gene (136). A forward 5’ PCR primer with SacII 
restriction site was designed (Appendix A.2) for of SPR-1 so that the gene could be 
cloned into pHUE. The construct of the Ubi-SPR-1 fusion protein was expressed with 
an N-terminal his-tag and a USP-2 cleavage site linked between ubiquitin and SPR-1.  
 
The Ubi-SPR-1 fusion protein was insoluble so that the majority of the protein formed 
inclusion bodies (Figure 3.1). Purification of supernatant part of the fusion protein 
was still carried out in a 5 mL nickel column followed by a digestion that separated 
ubiquitin and SPR-1. However, no soluble SPR-1 protein found after the FPLC step 
(figure not shown). 
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Figure 3.1. Ubi-SPR-1 fusion protein expression with pHUE vector in E. coli 
Molecular weight of the fusion protein is approximately 38,500 Da. M, Low range 
protein marker in Dalton. (a) Pellet part of cell lysate. (b) Supernatant part of cell 
lysate. 
 
3.2.2 Refolding of the Ubiquitin fusion protein 
 
The Ubi-SPR-1 inclusion bodies were denatured and solubilised in urea buffer then 
refolded in a chromatographic column. All these experiments were carried out at 4 °C 
to minimize the precipitation of the target protein.  
 
First, the pellet was washed in 2 M urea buffer (2 M urea, 20 mM Tris-HCl, Triton 2 
% and 0.1 M NaCl pH7.6) and then denatured at 8 M urea buffer (8 M urea, 20 mM 
Tris-HCl, 0.1 M NaCl and 20 mM imidazole pH 7.6). The 8 M urea buffer with Ubi-
SPR-1 was loaded into 5 mL nickel column and the flow through was examined to 
make sure the protein was bound to the column. A gradient that started from 0% and 
went to 100% of the refolding buffer (20 mM Tris-HCl, 150 µM ZnCl2, 0.1 M NaCl 
and 20 mM imidazole pH 7.6) in 150 mL with a flow rate of 0.2 mL/min was applied 
to the column. The protein was then eluted with a gradient from 0% to 100% of 
elution buffer (20 mM Tris-HCl, 150 µM ZnCl2, 0.1 M NaCl and 0.5 M imidazole pH 
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7.6) with 25 fractions of 5 mL each. Refolded fusion protein was then dialysed for 24 
hours in refolding buffer and digested with the USP-2 protease in the ratio of 100:1 
for 48 hours.  Unfortunately, protein precipitation was observed during dialysis and 
digestion. The digested protein solution was then filtrated and loaded onto nickel 
column so that the SPR-1 could be collected in the flow through and the ubiquitin 
with his-tag would remain on the column. The final purification of refolded SPR-1 
was unsuccessful as almost all the SPR-1 protein was precipitated during the 
refolding process as shown in figure 3.2. 
 
 
 
Figure 3.2. In-column refolding results of SPR-1 
M, Low range protein marker in Dalton. (a) Elution of refolded Ubi-SPR-1. (b) 
Digested SPR-1 at 30,000 Da. (c) Separated Ubiquitin of 8,500 Da. (d) Final step of 
purified SPR-1. 
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3.2.3 Detox Expression 
 
It was thought that SPR-1 could be toxic to E. coli so that the protein that was formed 
was deposited as inclusion bodies. In order to overcome this problem, a detox strain 
of E. coli (DetoxET7TM competent cell, Expression Technologies Inc., San Diego, 
USA) was used. This detox strain contains an extra pACYC177-derived 
chloramphenicol-resistant plasmid that constitutively over-expresses lacI inhibitor to 
minimize the leaky expression of the target protein. Expression of SPR-1 in 
DetoxET7 followed the manufactures’ protocol. The result of detox expression shows 
that SPR-1 was expressed at a significantly higher level than with BL21 strain under 
the same condition. However, SPR-1 was still insoluble and this result did not support 
the proposition that SPR-1 was toxic. 
 
 
 
Figure 3.3. SPR-1 expression by DetoxET7 and BL21 
Molecular weight of SPR-1 is 30,000 Da and the lacI protein is about 24,000 Da. M, 
Low range protein marker in Dalton. 
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3.2.4 Lower Temperature Expression 
 
During the previous two trails, SPR-1 was found to precipitate more easily at higher 
temperatures. Therefore, SPR-1 was expressed at lower temperature to avoid rapid 
precipitation. These experiments gave a remarkable amount of soluble SPR-1. Details 
method can be found in Chapter 2.8. Also, 10 % glycerol was included in buffers to 
enhance the stability of the protein. Unfortunately, although this method worked for 
SPR-1 the variant #2-76 did not express at lower temperature. 
 
 
 
Figure 3.4. Lower temperature expression of SPR-1  
M, low range protein marker in Dalton. (a) Pellet part of crude lysate. (b) Supernatant 
part of crude lysate. 
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3.2.5 Purification of SPR-1 
 
Soluble SPR-1 protein was expressed and ready for FPLC purification. All the 
purification steps were carried out at 4 °C or on ice. Cell pellets were centrifuged and 
suspended in Buffer A (Appendix A1.3.1). The cells were then homogenised with a 
French Press. Lysed cells were centrifuged again and the supernatant with SPR-1 was 
loaded into 5 mL Q Sepharose Fast Flow column. SPR-1 was eluted with a gradient 
from 1% to 3% Buffer B (Appendix A1.4.1) in 50 mL. Fractions of SPR-1 from the Q 
Sepharose Fast Flow column were concentrated to 1 mL and loaded into Superdex 
200 column.  SPR-1 pure protein was then eluted at the peak of 73± 1.5 mL from the 
Superdex 200 column (with a void volume of 45.5 mL). The SDS-PAGE of the 
fractions and the purity of SPR-1 are shown in figure 3.5. Approximately 2.75 mg of 
purified SPR-1 can be collected from 1 L culture. Also, a gel filtration column, 
Sephadex G75 was used for a better separation (Figure 3.5). 
 
 
 
Figure 3.5. SPR-1 purification 
This figure shows the result from FPLC second column, Sephadex G75. M, low 
molecular weight marker of protein in Dalton; Lane 1 to 7, sequential fractions from 
Sephadex G75 column.  
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3.2.6 Molecular Weight and Oligomeric Conformation 
 
SPR-1 was proposed to be an oligomer in Hashim’s study and some support for this 
contention was obtained with the Superdex 200 column. The calculated molecular 
weight of SPR-1 from amino acids sequence was 30414.57 Da (signal peptide 
excluded). However, Figure 3.6 shows the molecular weight of matured SPR-1 
measured by mass spectrometry was 28947.9 Da (data not shown) so that almost 1.5 
kDa was missing. This might be caused by protease hydrolysis in the cytoplasm of E. 
coli.  
 
Superdex 200, a size-exclusion column, was used to measure the molecular weight of 
the protein. The column preparation and calibration can be found in Chapter 2.8. 
SPR-1 was calculated to be 43.48 ± 7.8 kDa according to the elution volume from the 
column. In addition, Figure 3.7 shows that the size of SPR-1 is larger than the 
subsequent fraction 5 and 6 in which the two bands at 44 kDa. This indicates that the 
native SPR-1 is clearly larger than 44 kDa so that it is likely to be a dimer. But the 
possibility that it is a monomer cannot be excluded at the stage. 
 
 
 
Figure 3.6. SPR-1 Fractions from Superdex 200 
M, low molecular weight marker of protein in Dalton; Lane 1 to 6, sequential 
fractions. 
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3.2.7 Crystallisation Attempts with SPR-1 
 
Purified SPR-1 was then concentrated to 11 mg/mL in Buffer A for crystallisation. 
Hampton Research Crystallisation kits including IndexTM, Crystal ScreenTM, 
PEGRxTM, PEG/IonTM and SaltRxTM were used with a robotic dispensing system in 
RSC, ANU for 96 well plates. Also, various conditions of 0.05 - 0.5 M zinc acetate, 
0.05 - 0.5 M sodium cacodylate, 15 - 25 % PEG 8000 and pH 5.0 - 6.0 were applied. 
Unfortunately, precipitation occurred in most conditions of the crystal screens of 
SPR-1 and no crystals of SPR-1 were observed. 
 
3.3 DIRECTED EVOLUTION OF SPR-1 - IMPROVE SOLUBILITY BY DHFR 
FUSION SYSTEM 
 
Hashim had previously attempted to use directed evolution to improve the solubility 
of SPR-1. Four rounds of evolution based on DHFR fusion method (Chapter 2) and 
TMP selection had been established, but no significant mutant had been found. In the 
5th round evolution an alternative ribosome-binding site (RBS) at the C-terminal 
evolved in SPR-1 so that DHFR was expressed without SPR-1. A large number of 
false positive colonies were observed in the 5th round of evolution. To avoid this 
problem a mutant of SPR-1 in which a few C-terminal residues were deleted 
(including the RBS at position 274) was used in the experiments described below.  
 
If DHFR is over-expressed in E. coli the cell can grow with more than 200 µg/mL of 
TMP. Cells can grow with 100 µg/mL or more of TMP if soluble proteins were fused 
to DHFR then. Cells expressing native SPR-1 fused to DHFR could only survive on 
15 µg/mL TMP.   
 
TMP directed evolution in this study was started from the 6th generation. A library of 
3.1 × 105 cells was plated onto agar plate with 25 µg/mL TMP. Secondary selection 
that eliminates false positive colonies was applied on 96-well plate for nearly 300 
colonies. However, only 3 colonies were successfully sequenced and one of them was 
the new unique mutant, named #6-1. 4th and 6th mutants were then randomised and 
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shuffled to be the pool of 7th round library. There were about 2.8 × 105 colonies 
selected at 30 µg/mL TMP. And approximately 600 colonies were entered secondary 
selection. There were total 18 samples sequenced and 7 new unique mutants were 
identified. 
 
 9 89 105 117 130 159 174 208 251 256 
TMP 
µg/mL 
SPR-1 L A G Q D L T Q V L 15 
#4-4 V T    Q     25 
#6-1 V T    Q   G  40 
#7-10 V T V   Q   G  40 
#7-6 V T  R  Q   G   
#7-13 V T   G Q   G   
#7-8 V T    Q I  G   
#7-4 V T    Q  R G   
#7-3 V T    Q   G P  
 
Table 3.1. Directed evolution of truncated SPR-1 on TMP selection 
First lane indicates the amino acid sequence number and the second lane is the wild 
type sequence. The following lanes are the mutants. #4-4 was one of the 4th round 
mutants that were the base line of this directed evolution. #6-1 is the 6th round mutant 
and it was found through the 6th round to the 8th round of directed evolution. #7 
indicates the 7th round mutants and they were able to survive up to 40 µg/mL TMP. 
 
Unfortunately, directed evolution of TMP selection of SPR-1 was converged at the 8th 
round (it means the mutants could not be evolved further and no more variants were 
generated). The 8th round library was generated by eStEP of all the 4th, 6th and 7th 
round samples with the size of 105 colonies. The 8th round library was selected at 40 
µg/mL TMP. However, there were only 5 mutants identified in the 8th round and all of 
them were the same mutant as #6-1. At this point it was thought that the solubility of 
the variant protein should be assessed; it was expected to be about three times more 
soluble than the native protein.  
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3.3.1 Solubility of TMP Selected Variant #6-1 
 
Detailed method of solubility assay can be found in Chapter 2.8. It was difficult to tell 
the difference in solubility between variant #6-1 and the native on the SDS-PAGE 
(figure 3.8). It did not appear that the evolution was giving improved solubility; it was 
thought that perhaps variants might confer improved solubility to the fusion protein 
and that this might account for the increased TMP resistance.  
 
 
 
Figure 3.7. Solubility assay of #6-1 and SPR-1 wild type 
M, low range protein marker in Dalton. (a) #6-1 pellet part and (b) supernatant part. 
(c) SPR-1 wild type pellet part and (d) supernatant part. 
 
3.4 IDENTIFICATION OF CRUCIAL AMINO ACID REPLACEMENTS FOR 
AMPICILLIN RESISTANCE 
 
During the course of her studies with SPR-1, A. M. Hashim found a mutant that gave 
enhanced levels of resistance to ampicillin. The wild type SPR-1 allowed E. coli to 
survive on an agar plate with 2 µg/mL ampicillin.  Several variant proteins could 
survive on 100 µg/mL ampicillin and #2-76 would allow growth on 3,000 µg/mL 
ampicillin. The object of the work in this section of the thesis was to elucidate the role 
of individual amino acid changes that would result in increased resistance. Variant 
   (a)        (b)      M        (c)        (d)           M 
97,400 
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31,000 
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proteins with specific substitutions were made by site-directed mutagenesis and were 
assayed with MIC method. 
 
Mutating and then selecting for the ability to survive on increased ampicillin resulted 
in a number of mutants of SPR-1 that had greatly enhanced ability to confer resistance 
to ampicillin. The selection did not improve the solubility or expression properties but 
its kinetics parameters of the enzyme were enhanced. In this study, mutants were 
made by site directed mutagenesis. The starting point for these studies was the #2-76 
mutant. The mutants were characterised with a MICs assay. However, all the mutants 
made in this study (shown below in table 3.2) were unable to confer resistance to 
higher than 4 µg/mL ampicillin. The implication of this result was that all the changes 
found in #2-76 were all essential for its ability to confer elevated level of resistance. 
 
 
 
Table 3.2. MICs results of variants of #2-76  
PelB-SPR, is SPR-1 expressed with an artificial signal peptide. #1-13 and #2-88 are 
other mutants from the directed evolution. 
 
9 72 93 133 143 159 160 197 214 239 246 267 AmpR(ug/mL) 
SPR-1 L E Q S V L M L F M D F 2 
PelB-SPR 2 
#2-76∆14 R A P K Q V 2 
#2-76 D R A P K Q V 32000 
L9D+P+K D P K 4 
L9D D 4 
L159P P 4 
M160K K 2 
P+K P K 4 
9 72 93 133 143 159 160 197 214 239 246 267 
#2-88 V V R G A S 2 
#2-88+Q V V R G A Q S 2 
#2-88+P+K V V R G A P K S 2 
#2-88+PK
Q 
V V R G A P K Q S 2 
#2-88+D D V R G A S 2 
#1-13 V V R A P Q L V 2 
#1-13+D D V R A P Q L V 4 
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Replacements of Leu9 appeared both in TMP and AMP directed evolutions. This 
position was to valine and aspartate, two quite different amino acids. Also, deletion of 
14 N-terminal residues of #2-76 resulted in activity reduction back to the same level 
as the native protein. In this study, the L9D change resulted in doubled MICs 
compared to the wild-type enzyme, indicating the importance of the residue on 
catalysis.  
3.5 PROTEIN DATABASE SEARCH AND SEQUENCE COMPARISON 
 
Given the problems associated with the SPR-1 protein, it was decided to look for 
similar proteins to SPR-1 that might have physical properties more amenable to 
biophysical and biochemical studies. A search of sequence databases in the year of 
2011 revealed that the most similar protein was the CSA-1 from Cronobacter 
sakazakii that had 61 % identity and 74 % similarity to SPR-1. Later in 2013, eight 
more SPR-1-like proteins in addition to CSA-1 were found in the database and named 
(most according to the species): SLI-1, SMA-1, ENTR-1, CDA-1, SSV-1, AGE-1, 
AGE-2 and AGE-3. These SPR-1-like proteins appeared to have identical active site 
residues including those residues responsible for metal coordination. Furthermore the 
residues involved in metal coordination were different to other MBL superfamily 
members. Here, these SPR-1-like proteins are proposed as the new MBL subclass, B4. 
 
ClustalW 2.1 (151, 152) was used for sequence alignment of MBL superfamily in this 
study. Table 3.3 shows the level of sequence conservation and similarity between 
SPR-1 and other members of the MBL superfamily: the B4 proteins; the B1 proteins 
BCII, IMP-1 and NDM-1; the B2 proteins CphA and Sfh-1; the B3 proteins FEZ-1, 
BJP-1, L1, SMB-1 and AIM-1; and the functionally distinct Methyl Parathion 
Hydrolase (MPH) and human Glyoxalase II. Initially SPR-1 was categorised as 
subclass of the B3 MBLs based on sequence similarity to the L1 MBL. As shown in 
Table 3.3 the overall identities of SPR-1 to other B3 members are 40 - 46 % and with 
similarities at the level of 50 - 56 %. As for B1 and B2 MBLs, SPR-1 has only about 
26 % identities and 35% similarities to these proteins. SPR-1 has low identities to 
MPH and Glyoxalase II at 19 % and 24 % respectively. The level of sequence 
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conservation between SPR-1 and B4 proteins (51 - 86 % identity and 69 - 91 % 
similarity) was significantly higher than to any other sub-family. 
 
Table 3.4 shows the sections of aligned sequences that coordinate metals in the MBL 
superfamily members. The metal coordinating residues for the B1 MBLs are His116, 
His118 and His196 for Zinc-1 and D120, C221 and H263 for Zinc-2. Studies indicate 
that B1 enzymes have one metal in the active site when in the resting state and they 
are functional either with single or double zincs in the active site (73). The B2 MBLs 
metal binding ligands are similar to the B1 MBLs but B2 enzymes only use the 
ligands for Zn-2 metal with His116 is replaced by Asn116 (52). Other research 
indicates that B2 enzymes will lose activity when introducing a second metal in the 
active site (71). B3 MBLs are less similar to B1 and B2 enzymes. B3 enzymes use 
His116, His118 and His196 for Zn-1 and D120, His121 and H263 for Zn-2 and they 
do not use position 221 as the metal binding ligand (53). Instead, S221 appears to 
have a role in catalysis that will be discussed later in Chapter 4. MPH and Glyoxalase 
II have similar metal binding ligands to B3 except the D221 bridging ligand and the 
overall sequence similarities are more close to B1 and B2 enzymes.  
 
Some of the metal coordinating residues found in other MBL family members are not 
conserved in B4 proteins, indicating that their metal coordinating residues are 
different. The assignment of metal coordinating residues for SPR-1 was based on a 
number of assumptions. The overall fold of the MBLs was conserved and only a few 
loops made a close approach to the metals to allow coordination. Furthermore, not all 
amino acids are appropriate for metal coordination. So, if the metal coordinating 
residues were found close to metal binding ligands in the B1, B2 and B3 enzymes 
only His116, D120 and His196 are conserved in the active site. The metal binding 
residues for Zn-1 were thought to be His116, His196 and an unusual Arg118 - shown 
in Table 3.4. Kinetics and metal studies results from P. Vella indicate that SPR-1 is 
very likely to have one metal in the resting state like B1 enzymes and it could have 
the second metal when substrate is added. However, the likely ligands for the second 
metal, D120 and Asp220 and Asn262, require conformation with structure analysis. 
Figure 3.9 shows the metal coordinates sites for the B1 - B4 enzymes.  
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 IDENTITY SIMILARITY 
B1_BCII 27.45% 36.70% 
B1_IMP-1 27.16% 34.97% 
B1_NDM-1 25.43% 34.68% 
B2_CphA 26.87% 35.54% 
B2_Sfh-1 27.16% 35.83% 
B3_L1 
B3_FEZ-1 
46.24% 
45.08% 
56.64% 
54.62% 
B3_BJP-1 40.75% 50.57% 
B3_SMB-1 42.77% 52.60% 
B3_AIM-1 41.90% 52.89% 
B4_SLI-1 
B4_SMA-1 
B4_ENTR-1 
B4_CDA-1 
B4_CSA-1* 
B4_SSV-1 
B4_AGE-1 
B4_AGE-2 
B4_AGE-3 
86.69% 
73.99% 
62.84% 
62.62% 
61.61% 
59.32% 
56.94% 
51.90% 
53.19% 
91.81% 
87.16% 
76.35% 
78.79% 
74.74% 
72.20% 
74.73% 
68.86% 
69.50% 
MPH 19.36% 28.61% 
GLYOXALASE II 24.56% 34.10% 
 
Table 3.3. Sequence identity and similarity of SPR-1 to other MBL superfamily 
members 
CSA-1* and the rest of B4 proteins were found in the year of 2011 and 2013 database 
searches respectively. The universal reference number and the species (or only the 
genus) of these B4 proteins can be found in the cover pages - “List of Enzyme 
Abbreviations”. 
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  116   196   221    263 
B1_BCII THAHADR KGHTEDN GGCLVKS VPGHGEV 
B1_IMP-1 SHFHSDS PGHTPDN GGCFIKP VPSHSEV 
B1_NDM-1 THAHQDK PGHTSDN GGCLIKD VMSHSAP 
  1 1 2   1   2    2 
B2_CphA TNYHTDR PAHTPDG GNCILKE IGGHDSP 
B2_Sfh-1 TNYHTDR EAHTKDG GNCILKE IAGHDTP 
      2    2    2 
B3_L1 SHAHADH AGHTPGS ADSLSAP LTPHPGA 
B3_FEZ-1 SHAHFDH PGHTRGC IGSIGVN LGSHAGM 
B3_BJP-1 THAHLDH PGHSPGC FCSGTVA LGPHPEV 
B3_SMB-1 THSHEDH PGHTEGG ADSLTAV IAAHPEV 
B3_AIM-1 SHEHFDH PGHTPGG ADSLTAI VTPHPSA 
  1 1 22   1     2 
B4_SPR-1 SHARLDQ PGHLPGA ADSLATP IVNKGTR 
B4_SLI-1 SHARLDQ PGHLPGA ADSLATP IANKGTR 
B4_SMA-1 SHARLDQ PGHLPGA ADSLATP IANKGTR 
B4_ENTR-1 SHARLDQ PGHLPGS ADSLATP VANKGER 
B4_CDA-1 SHARLDQ PGHLPGS ADSLFTP IANKGDR 
B4_CSA-1 SHARLDQ PGHLPGA ADSLATP LANKGER 
B4_SSV-1 SHARLDQ PGHLPGS ADSLFTP IANKGDR 
B4_AGE-1 SHARLDQ PGHLPGS ADSLFTG LANKADR 
B4_AGE-2 SHARLDQ PGHLPGA ADSLFTG LANKADR 
B4_AGE-3 SHARLDQ PGHLPGA ADSLFTG LANKADR 
  1 1   1   
MPH THMHPDH HGHTPGH LGDLILV AASHLSF 
GLYOXALASE II THHHWDH PCHTSGH TGDTLFV YCGHEYT 
  1 1 22   1   *    2 
 
Table 3.4. Sequence alignment of SPR-1 and other MBL superfamily members 
Conserved ligands are coloured and shown in universal numbers. Number 1 and 2 
underneath the residues mark the ligands for Zn-1 and Zn-2 respectively; green 
ligands are histidines, red ligands are asparagines, purple ligands are cysteines and 
blue ligands proposed for B4 enzymes are arginines. The asterisk mark indicates the 
bridging ligands for MPH and Glyoxalase II. 
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Figure 3.8. Active site ligands of B1, B2, B3 and B4 (SPR-1) MBLs 
Structure of SPR-1 are simulated according to a B3 MBL, L1. 
 
3.5.1 Phylogenetic Analysis 
 
Evolutionary origin of SPR-1 was shown as a maximum-likelihood tree, based on the 
alignment of MBL superfamily members with 1000 bootstrap replicates, made by 
PhyML (Figure 3.10). An expected tree indicates MPH and Glyoxalase II are the most 
diverged members that they have overall MBL folding but different biological 
function from the MBLs. Particularly, the similar structural fold of Glyoxalase II to 
MBLs might reflect the evolution convergence rather than sequence divergence from 
a common ancestor. It is evident that B1 and B2 MBLs are different from B3 MBLs 
with a bootstrap value of 96% that indicates the statistical reliability of the sequence 
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cluster in the branch. Furthermore, the two B2 MBLs have 91% bootstrap score differ 
from the B1 MBLs. Although the unusual MBLs of SPR-1 and CSA-1 are clustered 
within the B3 MBLs, the high divergence of this branch shows only a fair bootstrap 
reliability of 61% to the B1 and B2 subgroups. In fact, the separation of SPR-1 and 
CSA-1 from the B3 MBLs with 90% bootstrap reliability is similar to the B2 MBLs 
from the B1 subgroup. And it should be noted that the distance between SPR-1, CSA-
1 and the B3 MBLs is similar to the distance of the B2 and B3 MBLs.  These analyses 
indicate that SPR-1 and CSA-1 are likely to have same origin ancestral sequences 
with those well characterised B1, B2 and B3 enzymes. However, according to the 
overall sequence homology and the active site residues, SPR-1 and CSA-1 are a 
separate subgroup from the B3 MBLs. In conclusion, B4 MBL subclass is proposed to 
encompass MBLs such as SPR-1 and CSA-1. 
 
 
 
Figure 3.9. Maximum-likelihood tree of MBL superfamily 
This phylogenetic tree, which is generated by PhyML with 1000 bootstrap replicates 
and visualised by PHYLIP version 3.6 (153-155), includes representatives from each 
of the MBL subgroups and an out-group of MPH and Glyoxalase. The bar below the 
tree indicates the genetic distance based on the multiple alignments calculated by 
ClustalW2.1. To keep the tree simple, the rest of eight B4 uncharacterised/ putative 
proteins were not included. 
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3.6 DISCUSSION 
3.6.1 Characterisation 
 
SPR-1 was expressed without signal peptide using pET26b(+) vector in BL21(DE3) 
cells. Most MBLs are transported into periplasm where they can be function. SPR-1 
initially had a signal peptide that was removed in order to express larger quantity of 
recombinant protein in the cytoplasm. However, nearly all the protein was expressed 
in an insoluble form. Many approaches to expression were trialed with a view to 
improving the yield of soluble protein. However, only the low temperature expression 
was successful and even it produced a considerable amount of the soluble protein. 
Purification of SPR-1 involved two columns: an anion-exchange column and a size-
exclusion column. Finally the protein was purified to better than 95% with only traces 
of impurities in an overloaded SDS-PAGE gel. 
 
SPR-1 was very sensitive to higher temperature and purified SPR-1 tended to 
aggregate, slowly at 4 °C and rapidly at higher temperatures. Purified SPR-1 can be 
concentrated to 11 mg/mL but standard crystallisation screens failed to produce 
crystals, presumably due to the unstable nature of the protein. 
 
3.6.2 Solubility Improvement by TMP Directed Evolution 
 
Limited progress was made in evolving SPR-1 to be more soluble with the DHFR 
fusion system. Large libraries were generated but the improvement of TMP resistance 
only increased from 15 to 40 µg/mL. The final round of the directed evolution 
converged with only the mutant #6-1 surviving. This variant contained L9V, A89T, 
L159Q and V251G changes. Sites 9 and 159 were described in Hashim’s thesis 
previously that they are both catalytic and solubility crucial positions. 
 
Substitution L9V is located at the N-terminus extension of the protein. L9 was 
proposed to make hydrophobic interaction with L17, A22, P24, A62 and A66 on the 
other subunit, assuming that the protein forms a higher oligomeric structure. A89 is 
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located near the active site and only a small area is exposed to the solution. The 
function of replacement A89T is yet to be determined. L159 and V251 are 
hydrophobic surface residues. Replacements L159Q and V251G are likely to reduce 
the hydrophobic interaction to other subunit, proposing that has positive impact on the 
solubility. 
 
Despite positive replacements, the solubility of variant #6-1 shows little difference 
form the native protein as described previously (Figure 3.8). Previous study indicates 
that improving solubility by DHFR fusion protein is suitable for a monomer and 
smaller protein (109, 115). It is proposed that the oligomer structure of SPR-1 
impedes the function of DHFR thus it was difficult to achieve the improvement. 
Secondly but evenly important, the directed evolution occurred in the cytoplasm that 
the result could differently from in the periplasm. Due to time restraints, this proposal 
did not put into practice in this study. 
 
3.6.3 Proposing the New Subgroup B4 MBL 
 
Sequence analysis in this study has revealed that a new subclass B4 of MBLs exists. It 
is evident that SPR-1 and CSA-1 of B4 MBLs is clustered with the B3 MBLs, which 
is similar to the cluster formed by the B1 and B2 subgroups. This indicates that the 
divergence between the B1/B2 and B3/B4 MBLs was the first evolutionary separation 
and then the formation of four separate subclasses. Moreover, the B1 MBLs are 
essentially binuclear enzymes with the exception of the BcII MBL from B. subtilis, 
which is active either with one or two metals in the active site. On the other hand, the 
B2 MBLs are only active in mononuclear form and only use Zn-2 metal for catalysis. 
The B3 MBLs are binuclear enzymes that require two zinc ions for catalytic activates. 
As for the B4 MBLs, it is proposed that they have only one Zn-1 metal in the active 
site when in their resting states and they lack of the conserved structure for binding 
the second metal ion. Therefore, SPR-1 and CSA-1 are proposed to be the new B4 
subclass MBLs in this study. 
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3.7 FURTHER STUDIES OF SPR-1 LIKE PROTEINS 
 
Future work should focus on other B4 MBLs in particular CSA-1. A sequence-based 
protein solubility evaluator was used to calculate the solubility score - PROSO II 
(161, 162). This program indicated that CSA-1 scored 0.848 was possibly more 
soluble than SPR-1 (which scored only 0.777).  
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CHAPTER 4 - CHARACTERISATION OF AIM-1 BY 
SITE SATURATION MUTAGENESIS 
 
4.1 INTRODUCTION 
 
Little was known about AIM-1 when this study commenced. The sequence and some 
kinetic data had been published indicating that it was a B3 enzyme (126). The initial 
objective of the present study was to express and characterise the enzyme and then to 
use structural methods and site saturation mutagenesis to gain insights into how it 
functioned. Work preceded along these lines, but unfortunately the structure and some 
preliminary mutagenesis data was published shortly after the structure was solved in 
our laboratory. In this chapter the independent structure determination is recorded 
along with a structure function study that is much more detailed than that previously 
published.  
 
The author is responsible for all the work reported herein with the exception of the 
following. The gene for AIM-1 was synthesised by DNA2.0 with a nucleotide 
sequence specified by Associate Gary Schenk (University of Queensland). Dr. Paul 
Carr (RSC, ANU) was responsible for X-ray diffraction data collection and structure 
determination. The author received some assistance with the mutagenesis experiments 
as described in the following text.  
 
4.2 CHARACTERISATION OF AIM-1 
4.2.1 Expression and Purification 
 
The gene for AIM-1 was obtained in the pJexpress411. This vector was used to 
express the native protein using BL21 cell as shown in the SDS gel given in Figure 
4.1. The variant proteins were expressed using a similar vector, pET26b(+). The 
vectors and the methods used for expression and the protein solubility determination 
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are given in Chapter 2.8.7. AIM-1 exhibited a high level of expression and 
approximately 30 % solubility as evident in Figure 4.1. 
 
 
 
Figure 4.1. Expression of AIM-1 
Lane M, low molecular weight ladder in Dalton. (a) Crude lysate pellet part of 
pJexpress411-AIM-1 expressed in BL21. (b) Supernatant part of the crude lysate.  
 
The methods used to purify the native and variant proteins are given Chapter 2.8. In 
short, ion exchange chromatography was used to obtained protein that was about 90% 
pure as judged by a visual inspection of the gel shown in Figure 4.2. The protein was 
purified using a size exclusion column again described in Chapter 2.8.4.2 As a result 
the protein was better than 95% pure with two minor bands co-purifying with the 
target protein.  
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Figure 4.2. SDS-PAGE gel from the large-scale AIM-1 expression 
Protein molecular weight standards are indicated on the extreme left (Lane M) in 
Dalton, with the expressed protein appearing as a band around 31,000 Da. (a) 
Supernatant part of crude cell lysate that expressing AIM-1. (b) AIM-1 sample after 5 
mL Q Sepharose Fast flow column. (c) Purified AIM-1 after Sephadex G75 size-
exclusion column. 
 
The mass spectrum measured molecular weight of AIM-1 was 29,591.3 Da (data not 
shown) while the approximate molecular weight obtained using the size exclusion 
was 44.5±6.95 kDa (see Chapter 2.8 for details). These experiments suggest that the 
protein could be a dimer. However, AIM-1 was later confirmed as a monomer of the 
result of x-ray crystallography.  
 
4.2.2 Structure Determination  
4.2.2.1 Crystallisation 
 
The protein was dialysed against buffer A (Appendix A) and concentrated to 18 
mg/mL. The Hampton Research screen HT yielded a number of crystal forms with the 
best crystals obtained with the D9 solution.  It was felt that the D9 crystal form was 
sufficiently promising that further effort would be concentrated on it. A systematic 
variation of precipitant concentration (PEG 8000) as well pH (5.0 to 6.0) and zinc 
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concentration (0.05 to 0.5 M) gave crystals suitable for diffraction studies. The final 
conditions were 0.2 M zinc acetate, 0.1 M sodium cacodylate, 18 % (w/v) PEG 8000, 
pH 5.0. 
 
 (a) 
 
 (b) 
 
 
Figure 4.3. Crystals of AIM-1 and the variant S221E 
(a) Optimised crystallography conditions of AIM-1 consisted of 0.2 M zinc acetate, 
0.1 M sodium cacodylate, 18 % (w/v) PEG 8000, pH 5.0. The dimensions of these 
crystals were approximately 0.18 x 0.18 x 0.23 mm. (b) S221E crystals were grown 
under these optimised conditions and observed after 2 weeks. These four conditions 
consist with pH 5.0 18% w/v PEG 8000. A: 0.4 M zinc acetate, 0.3 M sodium 
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cacodylate. B: 0.4 M zinc acetate, 0.2 M sodium cacodylate. C: 0.3 M zinc acetate, 
0.05 M sodium cacodylate. D: 0.4 M zinc acetate, 0.5 M sodium cacodylate. 
Most of the variant proteins were obtained under similar conditions to those used for 
the wild-type protein. The morphology and diffraction of these crystals were similar 
to those of the native protein. A photograph of the native crystals is given in Figure 
4.3. This figure also shows crystals of a variant protein (S221E) that had a 
morphology different form that of the native protein. 
 
4.2.2.2 Data Collection and Structure Comparisons 
 
As was noted at the start of the chapter, Dr Paul Carr collected diffraction data and 
solved the structure of the AIM-1 protein. The crystals diffracted to better than 2.0 Å 
so that a high-resolution structure could be obtained. The crystal form and structure 
are essentially the same as was reported elsewhere and will not be repeated here in 
great detail. 
 
 
 
Figure 4.4. X-ray diffraction patterns of AIM-1 
X-ray diffraction patterns were collected from a Mar345 detector mounted on a 
GeniX-3D Microbeam Cu X-ray generator via a Mar345dtb cardanic cradle. 180 
frames from contiguous one-degree oscillations were collected at a crystal to detector 
distance of 175.0 mm, corresponding to a maximum resolution of 2.0 Å. 
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Unit Cell (Å) 76.55, 76.55, 239.58, 90.0, 90.0, 120.0 
Resolution (Å) 19.5 - 2.0 (2.1 - 2.0) 
Number of Observations 532614 
Unique reflections 28114 
Completeness (%) 99.8 (99.6) 
Multiplicity 19.0 
I/s (I) 42.0 (14.7) 
Rmeas 0.0064 (0.233) 
 
Table 4.1. Data collection statistics subsequent to processing with the program 
XDS (163) 
The crystal formed in point group P622 and inspection of the h0l reciprocal lattice 
zone, using the program HKLVIEW from the CCP4 suite (164) revealed a reflection 
condition of 000l=6n, indicating the space group is either P6122 or P6522. 
 
 
 
Figure 4.5. AIM-1 overall structure 
The α helix structure is shown as red ribbons, and the β sheet structure is shown as 
yellow ribbons. Eight lines of blue colours are the loops that surround the active site. 
Two zinc metals are shown as grey spheres. Three disulfide bonds are shown in 
orange sticks. 
 
The refined structure of AIM-1 consisted of residues A27 to A295. As expected the 
N-terminal sequence directing the protein to the periplasm was not observed. Like 
other MBL proteins, AIM-1 has an α/β/β/α fold with the active site surrounded by 8 
loops that emanate from the central β strands. There are three disulfide bonds that link 
C31 to C56, C208 to C213 and C256 to C290. A schematic diagram of AIM-1, as 
N 
C 
Disulfide bonds 
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visualised with Pymol is shown in Figure 4.5. Two zinc ions were found in the active 
site separated by a distance of 3.6 Å from each other. Zn-1 was coordinated with 
H116, H118 and H196 and Zn-2 was coordinated with D120, H121 and H263. As can 
be seen in Figure 4.6, the two metals are bridged by a water molecule and Zn-2 has a 
second coordinated water molecule that also forms a hydrogen bond with the side-
chain of residue S221.  
 
Figure 4.6. The 
active site of AIM-1 
Zinc metals are 
shown in grey 
spheres. Water 
molecules are shown 
in red spheres. 
Amino acid residues 
are shown in green 
sticks of carbon, blue 
lines of nitrogen and 
red lines of oxygen. 
 
 
 
 
Figure 4.7 Water 
tunnel structure 
observed 
The water tunnel is 
visualised with mesh. 
Red dots are water 
molecules. Cyan 
stick is a super-
imposed antibiotic 
moxalactam fit in the 
active site. And Zinc 
metals are shown as 
grey spheres. 
 
AIM-1 has an extraordinary structure, a water tunnel (Figure 4.7). This structure is 
also found in a B3 enzyme, SMB-1, which is the most similar MBL to AIM-1 to date 
(165-167); but this structure did not mention in the literature. Other well-studied B3 
enzymes i.e. L1, BJP-1, FEZ-1 have no such structure and neither do B1 and B2 
enzymes. It is suspect that the water tunnel involves in water feeding to the active site 
H116 
H118 
H196 
D120 
S221 
H263 
Zn-2 
H121 
Zn-1 
W-1 
W-2 
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during hydrolysis of substrates. However, further research of the water tunnel did not 
carry out in this study. Therefore the real function of the water tunnel will not be 
conducted here. 
 
A diagram showing the residues forming the active site of AIM-1 is given in Figure 
4.8 below. As can be seen in the space filling representation of the active site. AIM-1 
has a long narrow substrate-binding cleft similar to other B3 enzymes, while those of 
IMP-1 and NDM-1 were observed to be more open. The residues thought to be 
important for substrate binding were W37, F119, Q157, S221, T223, I225 and S265.  
 
 
 
Figure 4.8. Surface active site residues of AIM-1 
Residues in sticks form the major shape of active site. Metal ligands are shown in 
lines and H263 is also structural. 
 
Prof. Charles Collyer (University of Sydney) carried out diffraction studies of the 
variant proteins. These crystals were suitable for space group determination, but 
structures were not obtained during the course of these studies. The crystals of the 
S221E variant were not isomorphous with those of the native protein and diffracted to 
only 4.0 Å. Studies to improve the various crystals of the AIM-1 variants were carried 
out as this thesis was being prepared. High-resolution data sets have been collected 
with two variant crystal forms. 
 
W37 Q157 
F119 
I225 
T223 
S221 
H263 
S265 
T87 
W37 
Q157 
F119 
I225 
T223 
S221 H263 
S265 
T87 
  
 
97 
4.2.3 Kinetics 
 
Most B3 enzymes were known to degrade all the classes of β-lactam antibiotics. 
Kinetics parameters for AIM-1 were determined for a total of 13 substrates plus an 
inhibitor for β-lactamase class A enzymes, clavulanic acid. The results of these 
experiments are given in Table 4.2. Generally speaking, AIM-1 has extremely high 
kcat/KM ratio for penicillins, cephalosporins and carbapenems. The values obtained for 
kcat were greater than 1000 s-1 for carbapenem substrates. As for penicillins and 
cephalosporins, kcat values were varied between 40 and 500. KM values were varied 
for cephalosporins and carbapenems. AIM-1 has low KM toward cefuroxime, CENTA 
and cephalothin but high KM for moxalactam and biapenem. There was no activity 
observed for clavulanic acid and no inhibition was detected when assaying 
benzylpenicillin with 100 µM clavulanic acid presented in the buffer (data not 
shown).  
 
Class Compound λ nm 
Extinction 
Co-efficient 
M-1 cm-1 
Enzyme 
Concen
tration 
(nM) 
kcat 
 
(s-1) 
KM 
 
(µM) 
kcat/ KM 
 
(M-1×s-1) 
Penams 
Ampicillin 235 - 820 3.38 410±30.2 110±21.2 3.81±0.48×106 
Benzyl-
penicillin 235 - 775 3.38 323±44.9 106±21.8 3.11±0.28×10
6 
Piperacillin 235 - 820 3.38 44±6.1 108±39.3 4.42±0.98×105 
Cephalos
porins 
Cefmetazole 265 - 7050 3.38 43±0.8 138±5.2 3.1±0.1×105 
Cefotaxime 260 - 7500 3.38 501±16.6 125±13.5 4.05±0.35×106 
Cefoxitin 260 - 7700 3.38 117±8.9 283±36.7 4.16±0.24×105 
Cefuroxime 260 -7600 3.38 251±2.4 68±0.8 3.71±0.01×106 
CENTA 405 6400 3.38 506±37.8 8±3.3 6.75±1.96×107 
Cephalothin 260 -6500 3.38 265±37.5 47±9.9 5.79±0.77×106 
Moxalactam 260 - 4000 3.38 99±29.2 473±196.5 2.28±0.46×105 
Carbapen
ems 
Imipenem 300 - 9000 3.38 1405±242.5 289±65.6 4.96±0.65×106 
Biapenem 293 - 7600 3.38 1984±181.8 644±61.5 3.08±0.08×106 
Meropenem 300 - 6500 3.38 1193±66.2 146±12.3 8.21±0.27×106 
Inhibitors Clavulanic acid 215 - 5120 3.38 N/H N/H N/H 
 
Table 4.2. AIM-1 kinetics of three types of antibiotics  
N/H, no hydrolysis detected. 
 
Generally speaking, AIM-1 was observed to have broad substrate specificity a broad 
spectrum and to exhibit high activity towards most β-lactams. It was found to have 
  
 
98 
very high activity towards imipenem and cefotaxime when compares to other MBLs 
as shown on Table 4.3 below.  
 
Enzymes 
 
Substrates 
B1 B2 B3 
BlaB Bc-II CcrA GIM-1 IMP-1 VIM-1 VIM-2 SPM-1 CphA ImiS L1 AIM-1 
Ampicillin N/D N/D N/D 0.16 4.8 0.04 N/D 1.6 N/D N/D N/D 3.81 
Penicillin G 8.75 0.45 4.80 N/D N/D N/D N/D N/D 0.0074 0.0021 22.0 3.11 
Cefotaxime 0.22 0.67 3.60 0.24 0.35 0.68 0.86 1.9 0.0027 N/H 2.60 4.05 
Cefoxitin 0.25 9×10-5 0.09 0.04 2 0.2 0.12 4 Inact. N/H 0.55 0.416 
Imipenem 0.95 0.12 0.74 0.09 1.2 1.3 0.99 1 2.10 0.91 0.73 4.96 
 
Table 4.3. Kinetics of Class B MBLs 
Comparison of the kcat/KM values (µM−1: s−1) of AIM-1 with those of other class B 
MBLs. N/D, no data. N/H, no hydrolysis detected. Inact., inactivation (168-176). 
  
A previous publication (132) included kinetics results of AIM-1. Most of the 
substrates used in their study were also studied in this thesis except cefaroxime, 
cefopime and aztreonam. Plus, several substrates such as cefmetazole, CENTA, 
moxalactam and biapenem were not assayed previously. There were small differences 
in the kinetic parameters determined of the substrates, presumably due to differences 
in the assay controls and buffer pH. 
 
4.3 PROTEIN ENGINEERING - AIMS AND OUTLINE OF EXPERIMENTS 
 
There were two aims of the engineering experiments. The first was to probe the role 
of active site residues in determining substrate specificity and the second was to see if 
altering active site residues would result in enhanced activity and/ or a change of 
substrate specificity. The approach to answering these questions was to use site-
saturation mutagenesis (SSM) as described in Chapter 2.6 to generate variant proteins 
and to then screen mutants for enhance activity or altered substrate specificity. The 
steps to be taken were:  
 
1) Selection of substrates to be used in screens,  
2) Selection of active site residues to be altered,  
3) Production of mutant libraries and  
4) Screening mutant libraries.  
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Most of these steps are straightforward, but the screening process may require some 
explanation. The number of possible mutants that can be made is quite large and it 
was not feasible to screen all the mutants. The approach that was taken was to use a 
disc diffusion assay to do an initial screen; this could be done with hundreds of 
mutants and with a number of substrates. It was felt that this screen would give 
identify inactive mutants or mutations that gave altered substrate specificity. The 
MICs could be determined for tens of mutants to gain a more informative indication 
of the activity of the mutant; it is a useful secondary screen. Finally, the kinetic 
parameters of the variant proteins could be determined for a small number of mutants. 
  
4.3.1 Choice of Substrates 
 
Kinetic data for the native protein was reported already. Disc diffusion assays were 
carried out for the native protein with representatives of the three classes of β-lactams. 
In addition, the MIC values for the same substrates were determined. The details of 
how these experiments were carried out were given in Chapter 2.10 and the results 
that were obtained are shown in Figure 4.11 provided below. Although imipenem 
gives a significantly higher kcat values than those measured with ampicillin or the 
cefoxitin, the corresponding MIC values can only be described as modest suggesting 
that the MIC values are dependent upon the KM values. 
 
The available penicillins were ampicillin and benzylpenicillin. These compounds 
gave rise to similar kinetic constants, but ampicillin was more stable and was chosen 
for that reason.  There were a number of cephalosporins available as listed in Table 
4.2. Of these cefoxitin was chosen as it had the lowest kcat/ KM so that variants with 
enhanced activity could be most easily detected. The carbapenems gave rise to similar 
kinetic parameters and Imipenem was chosen because it was the most widely used 
and cheapest.  
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4.3.2 Choice of Residues to Mutate 
4.3.2.1 Structural Considerations  
 
Active site residues were chosen for further consideration provided they were not 
involved in metal binding. These residues are listed in the caption of Figure 4.10. 
 
4.3.2.2 Sequence and Structural Comparisons 
 
Sequences similar to that of AIM-1 were found using the ConSurf program. Most of 
the sequences found were labeled as putative MBLs; there was no experimental 
indication that these were indeed MBLs. Other B3 enzymes appeared in the list of 
similar enzymes, but they were not the most similar. The active site residues were 
highly conserved as indicated in the ConSurf output given in Appendix B.3. However, 
these active site residues were, one exception, not absolutely conserved; alternate 
residues could be found in other sequences. The exception was S221 that was 
conserved in the 29 most similar sequences that were found by ConSurf. None the 
sequences used by ConSurf were of B1 or B2 enzymes; these enzymes have a metal 
binding ligand at position 221. Table 3.2 shows the alignment of metal binding 
ligands in the different classes of MBLs as well as two other proteins that have β-
lactamase folds. Structural alignment of AIM-1 with other proteins indicated that 
S221 was indeed close to the metal binding ligand in other proteins, methyl parathion 
hydroxylase (MPH) (Figure 4.9).  
 
All the active site residues that were not involved in metal binding were the subject 
SSM experiments. These residues are listed in the caption of Figure 4.8. In addition 
T87 was also subjected to SSM; this is close to the active site but does not form part 
of the active site surface. However, T87 made contact with active site residues and it 
was thought that replacements at this position might affect substrate binding.  
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Figure 4.9. Active site of superimposed AIM-1 and MPH 
D221 of MPH is shown as a pink stick and S221 of AIM-1 is shown as a green stick. 
 
4.4 PROTEIN ENGINEERING RESULTS 
 
SSM was carried out as described in Chapter 2.6. The mutating oligonucleotides were 
of the form NNK at the codon for the amino acid to be altered so that all possible 
amino acids should be present in the variant proteins. However, particular mutations 
were generated and 80 mutants selected at random were required to be sequenced in 
order to get a 0.95 probability of getting all possible amino acids (158).  
Unfortunately, the sequencing did not work for all the randomly selected mutants and 
the results for successful sequencing are given in Figure 4.10. It was felt that the 
mutants obtained were sufficient in number and type to proceed.    
 
4.4.1 Disc Diffusion and MIC Assays 
 
The results for the disc diffusion and MIC assays are shown in Appendix C.2. With 
the exception of S221, the results obtained with Ampicillin were very similar to that 
of the native. More will be said about S221 variants later. It seems unlikely that active 
site replacements did not affect the enzyme activity with ampicillin; rather the assays 
were just not sensitive enough to detect the differences. With the other substrates,  
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(a) 
W37X T87X E117X F119X Q157X S221X T223X I225X S265X 
WT26 WT9 WT6 WT11 WT13 WT3 WT2 WT15 WT1 
A3 A3 A3 A2 A5 A1 A1 R1 A2 
I1 L1 L1 L1 I1 L2 I1  L2 
L2 V2 F1 M1 L3 W5 V4  M1 
M1 S3 W1 W4 M3 V3 S1  V1 
F2 Q1 Y1 V1 W1 Q1 G8  T1 
V3 G2 V4 S2 Y1 C1 P1  N1 
S2 R1 T3 Q2 V3 G7 R2  Q1 
T1  C1 G5 S3 R3 K2  C3 
Q3  G2 P1 T2 K1 E2  G1 
C2  R1 R1 C2 D1 STOP1  P1 
G11  D2 H1 G6 E1   R2 
R5   STOP2 P5    H1 
E1    R6    D1 
    H1    E1 
    D2     
    E3     
    STOP1     
 
(b) 
 
 
Figure 4.10. Identified SSM variant proteins 
(a) List of the SSM variant proteins in this study. For example, W37X is the SSM 
code; WT is the native; variants are shown as a single amino acid code; Subscript 
numbers are the times of identification. (b) A statistic view of the SSM variant 
proteins. Take W37X for example, 13/37 means there are 13 unique variants and total 
37 variants were sequenced. The result reflects the high efficiency of T7 terminal tail 
method. 
 
13/37 7/13 
11/20 11/23 16/48 
11/26 9/23 14/19 
26 9 
6 11 13 
3 2 1 
0% 
20% 
40% 
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80% 
100% 
W37X T87X E117X F119X Q157 S221 T223 S265 
AIM-1 SSM Statistics 
Variants Natives 
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differences were noted with both or one of the substrates. In some cases, these 
differences do not appear to be entirely consistent; a drop in the disc diffusion result 
was expected to give an increase in the MIC value. However, the two assays were 
quite different; the substrate concentration gradient generated in the disc diffusion 
assay was relatively shallow (should vary inversely with the scale of the distance from 
the origin) while the gradient in the MIC experiments should result in a very steep 
concentration gradient (increases exponentially). 
 
Figure 4.11 shows the number of replacements that positive, negative or little change 
in the activity with respect to the three types of substrates (detailed data can be found 
in Appendix C.2). As noted above, there were few changes with ampicillin; but 
cefoxitin and cephalothin were both produced mutations that altered activity 
(cephalothin is not shown in Figure 4.11). As for ampicillin, substitutions at position 
221 resulted in substantial loses in activity. Changes to E117 were likely to alter 
position of the backbone peptide that then affected the metal binding resulting in a 
loss of activity. Substitutions to W37 in some cases resulted in a loss of activity with 
ampicillin and replacements that retained activity with ampicillin show no detectable 
loss of activity towards that substrate, but they did show a modest increase in activity 
towards cefoxitin and imipenem, as illustrated in Figure 4.11. Similar comments 
apply to replacements of F119, in some cases there was a loss of activity with 
ampicillin and replacements that retained activity with ampicillin show no detectable 
loss of activity towards that substrate, but they did show a modest increase in activity 
towards cefoxitin and imipenem. Substitutions of Q157, with two exceptions gave the 
native activity with ampicillin, but gave a significant loss of activity with cefoxitin 
and imipenem. Similar comments apply to S221. With a few exceptions the 
substitutions of T223 and T265 gave no detectable loss of activity towards ampicillin 
and with two exceptions there were only small changes to the activity towards 
cefoxitin and imipenem. Only one variant was obtained with I225 and it showed no 
detectable decrease in activity towards ampicillin and a modest increase in activity 
towards cefoxitin and imipenem. T87 is on the periphery of the active site and 
substitutions resulted in minor changes in activity. 
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Figure 4.11. Overviews of disc diffusion and MIC results 
These figures can be viewed as the amino acid replacements tolerance of SSM. 
Numbers of distinct mutants are shown in the bars and the colours represent either the 
mutants are positive, neutral or negative activities toward a specific substrate. More 
negatives indicate poor replacements tolerance of a specific site, for example Q157 
and S221 have poor tolerances of replacements.  
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 Ampicillin 
 kcat KM kcat / KM MICs 
 (s-1) (µM) (s-1/M) (µg/mL) 
AIM-1 410±30.2 110±21.2 3.81±0.48x10
6
 >1024 
W37C 131±11 92±21.3 1.50±0.22x10
6
 >1024 
F119M 2327±753.6 388±162.9 6.21±0.53x10
6
 >1024 
S221A 251±62.1 434±190 6.28±0.11x10
5
 >1024 
S221E 0.37±0.16 >50000 6.51±0.26 2 
 
 
 Cefoxitin 
 kcat KM kcat / KM MICs 
 (s-1) (µM) (s-1/M) (µg/mL) 
AIM-1 117±8.9 283±36.7 4.16±0.24x10
5
 128 
W37C 13±1.6 12±3.2 1.19±0.2x10
6
 512 
F119M 122±18.8 30±11.4 4.33±0.83x10
6
 >1024 
S221A 54±3.2 19±2.4 2.93±0.21x10
6
 512 
S221E 0.0075±0.0001 1018±58.1 7.38±0.39 1 
 
 
 Imipenem 
 kcat KM kcat / KM MICs 
 (s-1) (µM) (s-1/M) (µg/mL) 
AIM-1 1405±242 289±65.6 4.96±0.65x10
6
 512 
W37C 254±41.2 157±30.5 1.63±0.53x10
6
 1024 
F119M 1240±394 279±102 4.52±1.94x10
6
 >1024 
S221A 23±3.8 70±12.1 3.35±0.15x10
5
 1 
S221E N/H N/H N/H 1 
 
Table 4.4. Enzyme kinetics of SSM variant proteins 
N/H, no hydrolysis detected. 
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4.4.2 Kinetics of Variant proteins 
 
Kinetic parameters were measured for a number of variant proteins using methods 
described in chapter 2.13 and are given in table 4.4. With one exception, the mutants 
were selected because they exhibited activity as given by the disc diffusion assay and 
the MICs. The exception was S221E; it was thought that this replacement changed the 
coordination of the active site metals and it was thought low levels of activity might 
be some interest. The parameters obtained for this variant indicate that it has 
negligible activity with β-lactams. Comments below pertain to the remaining three 
variants. 
 
The kinetic parameters obtained with ampicillin varied considerably from those of the 
native protein. KM and kcat were reduced in two cases while in the remaining cases the 
KM and kcat were both increased so that the KM/kcat values remain high for the three 
variants. Similar comments apply to the kinetic parameters obtained with cefoxitin 
and imipenem. 
 
4.4.2.1 Activities of AIM-1 and S221E to Organophosphates 
 
Several organophosphates substrates were tested for preliminary activity assays of 
AIM-1 and variant S221E: para-nitrophenylphosphate, para-nitrophenlyacetate, bis-
para-nitrophenylphosphate, methy-paraoxon, ethyl-parathion, methyl-parathion and 
coumaphos-o-analogue. After 24 hours, only the hydrolysis of bis-para-
nitrophenylphosphate was detected (data not shown). This assay indicates that both 
AIM-1 and mutant S221 have little ability to hydrolyse bis-para-
nitrophenylphosphate. These organophosphate substrates were further assayed on a 
96-well plate spectroscopy over 5 hours. However, there were no difference of the 
activity between the wild type and variant S221E toward these organophosphate 
substrates. 
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4.4.3 Gene Shuffling 
 
The genes (W37X, F119X, Q157X and S265X) for the site saturation mutagenesis 
were shuffled and mutants plated out on agar plates containing 75 µg/mL cefoxitin. 
Most cells expressing the native protein survived up to 40 µg/mL with a few 
surviving in 50 µg/mL cefoxitin. The 75 µg/mL cefoxitin was a modest increase over 
the level on which the native cell could survive and it was thought that a few of the 
mutants produced through recombination would survive. In liquid culture a number of 
mutants produced changes that enabled them to survive on significantly higher level 
of cefoxitin. However, no cells were recovered. This approach to finding mutants with 
enhanced activity was abandoned. 
  
4.5 DISCUSSION 
4.5.1 Characterisation 
 
The gene for AIM-1 was expressed using the pET26b(+) vector in BL21(DE3) cells. 
Most of the protein was in the insoluble fractions, but the level of expression was 
extremely high and AIM-1 was the most abundant protein in the soluble fraction. The 
protein purified to better than 95% with only traces of two other bands appearing in 
an overloaded SDS gel. Purification involved the use of an ion-exchange column 
followed by size exclusion column; the latter had been calibrated and the elution 
volume gave an estimate of molecular weight that was closes to that of a dimer, but 
latter the x-ray diffraction results suggest it is more likely to be a monomer. An 
estimate of the subunit molecular weight was made with mass spectroscopy; the mass 
was consistent with the calculated mass of the structural gene minus the signal 
sequence that directed the protein to the periplasm. 
 
The protein was crystallised using standard screens; the conditions obtained were 
refined with grid screens that involved optimizing the concentration Zn2+ and other 
variables. In fact, adding Zn2+ to the crystallisation medium suggested that the metal 
binding sites were not fully occupied. It is possibly because there was insufficient 
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Zn2+ in the cell to saturate all the protein produced as a result of the very high level of 
expression. Several crystal forms were observed in the crystal screens suggesting that 
the protein was stable. The crystal form optimised for X-ray work diffracted to high 
resolution and enable the structure to be determined to 2.0 Å resolution. The crystal 
form and structure obtained in this laboratory were essentially the same as reported by 
Fred et al. (2012) and will not be commented upon here, other than to say that the 
structure was very similar to other β-lactamases as described in the introduction. 
 
The structure as obtained in our laboratory was used to identify active site residues for 
mutagenesis. As was evident in Figure 4.8, access to the active site was possible by a 
long narrow cleft, of similar dimensions to the known substrates of the protein. Most 
hydrolytic enzymes have a relatively rigid structure that dose not undergo drastic 
change during catalysis; they fit the “lock and key” description first proposed by 
Fischer to describe substrate recognition by enzymes. The program SWISS-DOCK 
was used to obtain a model of the enzymes substrate complex. Three AIM-1 models 
were used that gave quite different results, but these models implicated the same 
residues in substrate recognition: see Figure 4.13, 4.17 and 4.19. 
 
4.5.2 Disc Diffusion Results and MIC Screens and Kinetic Assay 
 
Active site residues were subjected to site-saturation mutagenesis and the resulting 
about 80 variant proteins were tested for their ability to degrade three substrates that 
were representative of the three classes of β-lactams. Disc diffusion and MIC assays 
were used in the initial screen; very few replacements abolished activity completely 
although a number resulted in a significant reduction in activity. A small number of 
replacements gave rise to what appeared to be enhanced activity. Kinetic parameters 
were determined for a small selection of mutants that appeared to have enhanced 
activity towards some substrates in the disc diffusion and MIC assays. The results 
were interesting; substantial changes in KM and kcat values were obtained. The initial 
screens were functional in nature and functional outcomes could be achieved by either 
increasing kcat or decreasing KM. Variant proteins with increased kcat and decreased 
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KM were not observed perhaps because the protein was already operating close to the 
diffusion limit. 
 
4.5.3 Mutant MICs and Structural Consideration 
4.5.3.1 W37X 
 
W37 is one of the residues forming the active site that was subjected to SSM. W37C 
replacement gave the best performance against cefoxitin and imipenem. This is a 
surprising result given that cysteine has a relatively small polar side-chain and 
tryptophan has a large hydrophobic side chain. W37L and W37Q give the same MIC 
values as W37C has better performance on the agar surface (See Appendix C.2). It is 
also intriguing that this position has a good tolerance of residue replacements that no 
dramatic activities drop of the mutants. The B3 enzymes, L1 and BJP-1 also have a 
tryptophan at the corresponding position while in FEZ-1 it is a tyrosine. It is also 
noticeable that none of the SSM variants were crystalised for detailed structure 
determination; therefore limited conduction could be made. 
 
 
 
Figure 4.12. MICs assay of W37X mutants 
MICs results are shown in details in the figure: three substrates for each sample are 
shown with three different bars and MICs are indicated as vertical values. Same 
settings are shown in the following MICs assay figures. 
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Figure 4.13. Cefoxitin docking simulation for W37C  
Cefoxitin is shown as cyan stick. The mutated residue is shown as white stick. The 3D 
structure of W37C is visualised by simulation. (Figures of variant active site pocket 
are meant to give a geographic view of the replaced residue.) 
 
4.5.3.2 T87X 
 
Only a few interested variants of T87X were assayed; they all performed better or the 
same as the wild type. The MIC of T87A for Cefoxitin was doubled at 512 µg/mL 
and the MIC of T87G for imipenem was doubled at 1024 µg/mL (as shown in Figure 
4.14). T87S shows the same MICs profiles of the wild type while it performed better 
on the disc diffusion assay. Figure 4.15 indicates that the residue T87 sites in the edge 
of the active site and indirectly affects the active site pocket, perhaps through a 
change in the dynamical properties of the protein. None of the T87X variants were 
purified in this study thus limited information can be given. In L1 and Bjp-1 this 
position is a methionine and in FEZ-1 it is a leucine geometrically. 
 
 
Figure 4.14. MICs of T87X 
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Figure 4.15. Models of T87 
Cefoxitin is shown as cyan stick. 
 
4.5.3.3 E117X 
 
This 117 position is the first non-conserved “x” of SHxHxDH motif. It is an alanine 
for most MBLs and a phenylalanine for IMP-1 and VIM-4, but a glutamate for AIM-1 
is unique among MBL superfamily. According to the MICs experiments E117A 
shows improved performance to cefoxitin and imipenem, but E117F shows 
diminished performance toward imipenem. The evidence indicates that this position is 
flexible for AIM-1 that it can be replaced to almost all side chains without decreasing 
the resistance to cefoxitin. Moreover, the performance of resistance increased mostly 
when substituted to alanine, leucine or asparagine. 
 
SSM variant proteins of E117X show unaffected results on ampicillin in this scale. 
Replacements E117A, L, W, G, R, D show improved performance for cefoxitin while 
the others are the same as the wild type. Most the mutants show improved 
performance against imipenem while only E117F shows decreased result and E117Y 
shows the same profiles as the wild type.  
 
T87 T87 
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Figure 4.16. MICs of E117X 
 
 
 
Figure 4.17. Models of E117 
Cefoxitin is shown as cyan stick. The protein surface is shown as mesh of the figure 
on the right. 
 
4.5.3.4 F119X 
 
MICs profiles of F119X mutants are varied but the overall profiles of F119M were 
stronger than the wild type and the other mutants. The MIC of F119L decreased to 
128 µg/mL while the other mutants were still more than 1024 µg/mL. F119A shows 
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an increased performance against cefoxitin and a same level for imipenem as the wild 
type. MICs of F119L were down to 32 µg/mL for cefoxitin and 4 µg/mL for 
imipenem. As the author mentioned above, F119M shows an extremely high 
performance against these three antibiotics at more than 1024 µg/mL of MICs. 
F119W shows the same profiles as the wild type and F119S has a low performance 
against imipenem. The performances of F119Q were increased double for cefoxitin 
and imipenem. 
 
F119 was a hydrophobic large side chain beside to W37 geometrically and this 
position is the second non-conserved “x” of SHxHxDH motif. SSM variant proteins 
of F119X show various profiles of MICs to substrates that were given previously. 
F119M is the best mutant that found in this study for MICs. Detailed kinetics data of 
F119M indicates that the activity of this mutant toward ampicillin is increased 
dramatically and the KM to cefoxitin is considerably decreased. These evidences show 
that F119 is an important residue of substrate docking into the active site and the 
replacements on F119X will change the specificity toward different substrates. The 
same position in L1 is an alanine and in BJP-1 is a leucine. The other possible 
residues are serine and threonine for MBLs. 
 
 
 
Figure 4.18. MICs of F119X 
0 
200 
400 
600 
800 
1000 
AIM-1 
wt 
Neg. 
control 
F119A F119L F119M F119W F119S F119Q 
F119X  MICs 
Ampicillin Cefoxitin Imipenem 
  
 
114 
 
 
 
Figure 4.19. Cefoxitin docking simulation for variant F119M 
The 3D structure of F119M is visualised by simulation. Cefoxitin is shown as cyan 
stick.   
 
4.5.3.5 Q157X 
 
Total 15 distinct variants of Q157X were assayed by MICs. Ampicillin MICs of 
Q157Y, Q157T and Q157R were 128, 256 and 32 µg/mL respectively; and the other 
Q157X mutants were over 1024 µg/mL. Cefoxitin MICs of Q157M, Y, T and R were 
lower than 16 µg/mL; Q157L, V, G, P and H were between 16 and 64 µg/mL; Q157A, 
W, S, D and E were at the same MIC level as the wild type; Q157I was at 256 µg/mL 
cefoxitin which was doubled than the wild type. As for imipenem MICs, Q157Y, T, P 
and R were 4 µg/mL or less; Q157I, L, M, V, G and D were between 32 and 64 
µg/mL of imipenem; Q157H, Q157W, Q157E, Q157A and Q157S MICs were 256, 
512, 512, 1024 and 1024 µg/mL of imipenem respectively. 
 
Q157 is a moderate conserved residue that interacts with substrates and forms the 
active site pocket. Nearly all of the Q157X SSM variant proteins in this study were 
detrimental to the performance of the enzyme. Only Q157A, W, S and E have slightly 
higher or remain the same MICs levels as the wild type. In the same geometric 
position of 157, it is a phenylalanine in L1 and a tyrosine in BJP-1 and FEZ-1 which 
all are large hydrophobic side chains. For AIM-1 this position can be replaced by 
tryptophan without causing diminished effects to the performances for three types of 
F119M F119M 
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substrates, but it is detrimental when substituted by tyrosine. None of Q157X variants 
were purified therefore detailed kinetics data is not available in this study. 
 
 
 
Figure 4.20. MICs of Q157X 
 
 
 
Figure 4.21. Models of Q157 
Cefoxitin is shown as cyan stick. 
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4.5.3.6 S221X 
 
Most S221X SSM variant proteins have negative impacts against three types of 
substrates and it as can be seen in Figure 4.22. Overall MICs for ampicillin, cefoxitin 
and imipenem of S221L, R, K, D and E were below 8 µg/mL. MICs of S221A were 
more than 1024 µg/mL for ampicillin, doubled for cefoxitin at 256 µg/mL and 
diminished dramatically to 1 µg/mL for imipenem. S221W shows the same profiles as 
the wild type on three substrates; while S221G also keeps the same profiles for 
ampicillin and cefoxitin but its MIC has only 2 µg/mL for imipenem. MICs of S221V 
and S221Q were both at 512 µg/mL for ampicillin and 1 µg/mL for imipenem, but 
they were at 2 and 128 µg/mL respectively for cefoxitin. S221C still have a MIC of 
256 µg/mL for ampicillin, but the MICs were down to 4 and 2 µg/mL for cefoxitin 
and imipenem respectively. 
 
 
 
Figure 4.22. MICs of S221X 
 
S221A and S221E were studied in detailed with kinetics, and S221E were crystallised 
for structure determination. S221 was proposed previously in this study that the 
hydroxyl group of Serine stabilises the Water-2 molecule by forming a hydrogen 
bond. And the Water-2 is part of the hydrolysis mechanism was proposed that it acts 
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as a general base of nucleophile attack to β-lactam ring. Therefore what if the 
hydroxyl group was removed from S221? The kinetics data of S221A was shown 
previously in Section 4.4.2 and indicated that without stabilizing the Water-2 
molecule the enzyme is still able to hydrolysis β-lactams but it losses the activity 
dramatically to Imipenem. When charged side chains for example arginine, lysine, 
aspartate and glutamate substitute S221, activities were diminished to nearly 
minimum. This position in B3 MBLs is a conserved Serine, while in B1 and B2 
MBLs this position is the metal ligand, C221. 
 
(a) 
 
 
(b) 
 
 
Figure 4.23. Models of S221A and S221E 
(a) Docking simulation of Cefoxitin in simulated S221A active site. (b) Visualised 
simulation of variant S221E. 
 
Simulation of S221E indicates that the long side chain might interacts with the metals 
just like MPH has an extra aspartate ligand that coordinate with the di-zincs. As 
S221A 
S221E 
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described in section 4.4.2.1, S221E does not have more organophosphate activity than 
the wild type. The reason could be numbers for instance, the glutamate might not 
coordinates to the metals with a correct angle for organophosphate substrates, or the 
active site formation is not suitable for docking organophosphate substrates in a right 
angle. Further experiment can be done from this point that S221E or S221D can be 
applied directed evolution to screen higher activity mutants for organophosphate 
substrates. Also, it is interesting to discover the metal binding constant and the ratio 
of metals per enzyme for this construct. 
 
4.5.3.7 T223X 
 
T223X SSM variant proteins in this assay were predominantly at a MIC level of more 
than 1024 µg/mL for ampicillin and 128 to 256 µg/mL for cefoxitin, which is not far 
from the wild type. However, the T223X SSM variant proteins MICs of imipenem 
varied. MIC of T223A for imipenem was only 64 µg/mL, then T223R and T223K 
were halved of the wild type that at the level of 256 µg/mL. T223I, G, P and E were at 
the same MIC level of the wild type and only T223S was doubled to 1024 µg/mL.  
 
 
 
Figure 4.24. MICs of T223X 
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Figure 4.25. Models of T223 
Cefoxitin is shown as cyan stick. 
 
According to MICs results T223 is not a conserved position that it can be replaced 
with most residues without interferes the activity to three substrates. The performance 
even better on the agar surface that only T223A has diminished activity toward 
imipenem. For other B3 MBLs, it is a serine in L1 and a glycine in FEZ-1.  
 
4.5.3.8 S265X 
 
The MICs of S265X mutants have a limited variation to the wild type. Three 
substrates MICs Profiles of S265C, G, R and D were the same as the wild type. None 
of the S265X mutants' MICs were lower than 1024 µg/mL of ampicillin. cefoxitin 
MICs results were doubled for S265A, M, N and Q at 256 µg/mL, and quadrupled for 
S265T at 512 µg/mL. MICs of S265A and S265M were at 1024 µg/mL for imipenem, 
while the other S265X mutants were at the same level of the wild type. Position of 
265 might has more interaction with a large R-group substrates. MICs and disc 
diffusion results indicates that most S265X mutants are neutral replacements and only 
few mutants like S265L and S265H has negative effect toward Imipenem. This 
position is a glycine in L1 and FEZ-1, and a glutamate in BJP-1. 
 
T223 
T223 
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Figure 4.26. MICs of S265X 
 
 
 
Figure 4.27. Models of S265 
Cefoxitin is shown as cyan stick. 
 
4.6 CONCLUDING REMARKS 
4.6.1 AIM-1 is A Unique Metallo Enzyme 
 
This newly discovered metallo-β-lactamase has limited similarity to other MBLs in 
many aspects. First, AIM-1 has low sequence identities (less than 50%) to all the 
other identified MBLs. It has a bent N terminal and three disulfide bonds that 
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enhanced the stability of this enzyme. And it has a conserved SHxHxDH MBL motif 
and sandwiched with distinctive glutamate and phenylalanine residues. Two zinc 
metals were incorporated with six ligands in the AIM-1 active site and the distance 
between the metals is 3.6 Å. AIM-1 has high solubility in buffer and it can be 
effortlessly re-natured from inclusion body form. Finally, AIM-1 has broad-spectrum 
activities to all the known β-lactams and the activity can be modified swiftly in a 
single position. 
 
4.6.2 Site Saturation Mutagenesis is A Useful Approach to Study AIM-1 
 
Based on the flexibility of AIM-1 structure, SSM can target on several non- or semi-
conserved residues. In this study, the new SSM approach was successfully picked 
average 74.4% of mutant constructs that is higher than the method of Stratagene and 
overlap extension PCR. Every SSM site picked in this study has both positive and 
negative replacements toward three substrates. One best variant F119M and several 
better variants were found in this study. Some interested variants with specific side 
chain were purified and analysed by kinetics and substrate docking simulation. These 
results gave more details of how AIM-1 works. 
 
4.6.3 Variants with Lower KM Have Increased Tolerance to β-lactams  
 
According to kinetics results of interested SSM variant proteins, higher resistance to 
β-lactam antibiotics is related to a lower KM of the enzyme. For example, W37C, 
F119M and S221A have distinguished lower KM than the wild type with a certain 
level of kcat that keep the bacteria survive at high concentration of cefoxitin. The 
concentration of the substrate in the bacteria must be way lower than in the solution. 
Therefore the function of the enzyme that can keep the cell alive turned to have higher 
velocity when the substrate at low concentration. Therefore, mutants screened at 
higher MICs were prone to have lower KM toward the substrate. Different screening 
approach is needed if variants proteins with higher kcat and lower KM are desired. 
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CHAPTER 5 - DIRECTED EVOLUTION OF AIM-1 - 
BASED ON CEFOXITIN SELECTION 
 
5.1 INTRODUCTION 
 
In this chapter, a different approach of generating AIM-1 variants with the desired 
activity was addressed. The experiments described in Chapter 4 were aimed at finding 
replacements that produced enhanced activity for one substrate or which 
discriminated between the different types of substrates. The final results were modest 
increase in the activity of AIM-1 towards cefoxitin and imipenem with respect to disc 
diffusion assays and MICs. However, no survivors were found when mutants were 
shuffled (all SSM substitutions were mixed and amplified by StEP PCR) and plated 
out on agar plate containing relatively low levels of cefoxitin. It appears that the 
replacements form the active site residues result in substantial changes in the active 
site geometry and that such changes are not an ideal starting point for producing 
proteins with enhanced activity. It was felt that a more subtle approach was needed. 
 
The approach taken in this chapter was to mutate the entire gene rather than targeting 
the sequence corresponding to active site residues. Desired activities were then 
selected and screened using a specific β-lactam antibiotic. The rationale for this 
approach was to find variants (not necessarily active site replacements) that perturbed 
the active site that affecting cells survival on agar plates with levels of β-lactam 
antibiotic. Error-prone PCR was used in the first four rounds of directed evolution and 
started with the wild type blaAIM-1 gene. 
 
Cefoxitin was chosen as the substrate for the work described in this chapter. It had a 
high kcat value and a high KM that meant it had a relatively poor ability to process 
substrate at low concentrations. Of the three classes of β-lactam tested in Chapter 4, it 
conferred the lowest level of resistance. 
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5.2 PREPARATION OF THE MUTANT LIBRARY 
 
Error-prone PCR was used to generate mutant libraries as described in Chapter 2.7.1. 
The average mutation rate of these libraries was 2 replacements per the 300 amino 
acids in AIM-1. This was determined by sequencing 10 randomly chosen genes that 
were selected on the basis of the plasmid to confer resistance only to kanamycin, the 
plasmid marker. The average number of base pair changes was 2.7 with a standard 
deviation of 1.1. The randomly mutated genes were cloned into pET26b(+). It was 
known that BL21(DE3) transformed poorly so that a different strain of BL21 was 
used, BL21 StarTM(DE3), which the transformation efficiency is over 108. The first 
round library was generated from the wild type blaAIM-1 full-length gene using ePCR. 
The 2nd to the 4th round libraries was generated based on the each previous round 
using ePCR as well, for example the 2nd was generated from the 1st round variants. 
Besides, the library used in the final round of evolution was obtained by eStEP PCR 
(Chapter 2.7.3) from variants obtained from the 1st to 4th round experiments. 
 
5.3 SELECTION AND SCREENING THE MUTANT LIBRARY 
 
There were 5 rounds of evolution; the details are summarised in Table 5.1. The 1st 
round library construct was transformed into BL21 StarTM(DE3) competent cells and 
plated on MH agar plates contained 50 µg/mL cefoxitin and 50 µM IPTG. To ensure 
a low expression levels, a final concentration of 50 µM IPTG was used in all selection 
media. The 1st round library was estimated to consist of a total of 4,000 colonies and 
approximately 100 of these survived after overnight incubation at 37 °C. A secondary 
selection was then carried out by growing the colonies in 96 well plates with LB 
medium that contained 100 µg/mL cefoxitin and 50 µM IPTG. The best 10 colonies 
according to OD595 were sequenced to determine the mutations; only one of them was 
a false positive, for example the wild type. The best 10 first round variants’ genes 
were then mixed and were the starting point for the 2nd round library. Subsequent 
rounds were carried out in the same manner. 
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The 2nd round library size was 16,000 colonies with the primary and secondary 
selections using 60 µg/mL and 120 µg/mL of cefoxitin, respectively. The best 10 
mutants were selected form a size of 100 to propagate the 3rd round library. Of these 
10, one was a mutant already appeared in the first round with the addition of 3 silent 
mutations. The 3rd round library consisted of approximately 33,000 colonies with 
primary and secondary selections using 75 µg/mL on agar plates and 150 µg/mL in 
the liquid media of cefoxitin, respectively. A total of 9 new mutants appeared with 
another 10 mutants carried over from the 1st and the 2nd rounds from the secondary 
selection of 200 colonies. Two replacements, F114L and F230Y, appeared in most of 
the genes selected to propagate the 4th round. Library size of the 4th round was only 
10,000 for the primary and 200 for the secondary. Selection media were 100 µg/mL 
and 200 µg/mL cefoxitin for the primary and the secondary selection, respectively. 
 
Evolution 
Rounds Methods 
Cefoxitin 
(Agar/Liquid) 
Repeated 
Samples 
Library Size 
(Primary/Secondary) 
Round 1 ePCR only 50/100 µg/mL 
10 % Wild 
Type 4,000/100 
Round 2 ePCR only 60/120 µg/mL 10 % Round 1 16,000/100 
Round 3 ePCR only 75/150 µg/mL 
47.4 % Round 
1~2 33,000/200 
Round 4 ePCR only 100/200µg/mL 
26.7 % Round 
3 10,000/200 
Round 5 eStEP 125/250 µg/mL 
26.3 % Round 
3~4 242,000/300 
 
Table 5.1. Directed evolution status of AIM-1 by cefoxitin selection 
 
In the last round the mutant library was generated with eStEP as described in Chapter 
2.7.3. Genes from the 1st to the 4th rounds were used to generate a library consisting of 
242,000 with the cefoxitin concentrations set at 125 µg/mL and 250 µg/mL for the 
primary and secondary selections. A total of 300 mutants from primary screen were 
selected for the secondary selection and of these 19 were considered good enough for 
further characterisation. Of these 19 mutants 5 had already appeared in the 3rd round 
and the 4th round; #3-16, #4-15 and three #3-11. The 6th round of evolution was 
carried out with the 1st to the 5th rounds mutants used to generate a library of 10,000 
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colonies. But none of which survived a primary selection of 400 µg/mL cefoxitin; the 
evolution was stopped at this point. All the 5th round mutants were analysed by MICs 
assay and #5-1, #5-2, #5-3 and #5-19 were further purified for kinetic characterisation 
and crystallisation. 
 
5.4 SEQUENCES OBTAINED DURING EVOLUTION 
 
The sequences of variant proteins are given in Table 5.2 with the frequency of 
particular changes given in Figure 5.1. From these results it is apparent that two 
replacements were predominant: F114L and F230Y. Both replacements appeared in 
the 1st round, but did not become common till the 3rd round. F114I, F114S and F114T 
were found in the early rounds but could not be found amongst the variants in the last 
round. Variant #5-2 had only the F114L replacement and could survive on an agar 
plate with over 125 µg/mL cefoxitin. The F230Y change was the second frequent 
replacements in this study and was first identified in variant #1-5 together with M53T 
and P141L replacements. The F230Y replacement was found in better variants of 
every round library and it is one of the replacements present in the best mutant, #5-1. 
R99H is the third frequent replacements in this directed evolution and it can be found 
from round 1st to round 4th but not in the last round. This suggested that the 
replacement R99H did not enable cells to survive on the agar plates with more than 
100 µg/mL cefoxitin. Other important replacements such as S23G, M53T, L55Q, 
A138V, T154A, P166Q, N247S and S267G appeared more than once during the 
course of directed evolution and survived to the last round. 
 
 
 
Figure 5.1. Statistics of replacements over 5 rounds  
Only replacements appeared more than once were shown. 
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Table 5.2. AIM-1 directed evolution variants over 5 rounds  
Only unique variants were shown. 
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5.5 MICS OF THE 5TH ROUND MUTANTS 
 
The MICs values obtained for selected mutants from the 3rd, 4th and 5th rounds. The 
mutants from the 5th round were chosen because of their activities while those in the 
3rd and 4th rounds were chosen because they had two replacements, one of which was 
the most common, F114L. These latter mutants were chosen to gain some idea of how 
a second replacement would add to the effect of the F114L replacement. The MICs 
data are given in Table 5.3. 
 
Several mutants such as #3-11, #5-16, #5-18 and #5-19 had modest MIC values of 
256 µg/mL with cefoxitin while the #5-12 and #5-17 gave resistance at the level of 
512 µg/mL. The mutants #3-16, #4-15, #5-1, #5-2, #5-3 and #5-20 gave MICs values 
of 1024 µg/mL with cefoxitin. 
 
In addition to cefoxitin, MICs values were determined with ampicillin and imipenem. 
The replacements had little effect on the MICs values obtained with ampicillin; they 
could all survive on more than 1024 µg/mL ampicillin, as was the case for the wild 
type. On the other hand, the MICs obtained with imipenem differ significantly. Half 
of the 5th round mutants have higher MICs than the wild type, but #5-16, #5-18 and 
#5-19 have diminished activities toward imipenem. 
 
F114L is the most important replacement for improving MIC of cefoxitin. Mutant #5-
2 had only F114L replacement but it had the same MICs profile as mutants #3-16, #4-
15, #5-3 and #5-20. Mutant #5-1 had the best overall activity with all three substrates 
and it had three changes: L55Q, F114L and F230Y. By way of contrast, mutant #5-19 
had very little activity towards imipenem and had S23G instead of L55Q that is found 
in #5-1. Variant #5-3 had one extra replacement (N247S) in comparison with #5-19 
and the mutant had MICs toward cefoxitin and imipenem at the high level as #5-2. 
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Figure 5.2. MICs of selected mutants 
#3-11 and #3-16 are the 3rd mutants. #4-15 is the 4th round mutant. #5 indicates the 5th 
round mutants. 
 
 
#3-11   F114L 
 
 
 F230Y  
 
#3-16   F114T 
 T154A    
 
#4-15  L55Q F114L   
 
  
 
#5-1  L55Q F114L   
 F230Y  
 
#5-2   F114L 
 
 
 
  
 
#5-3 S23G  F114L   
 F230Y N247S  
#5-12   F114L A138V  
 
  
 
#5-16   F114L I143T  
 F230Y  
S267G 
#5-17 S23G  F114L   
P166Q 
 N247S 
 
#5-18   F114L  T154A    
 
#5-19 S23G  F114L   
 F230Y  
 
#5-20   F114L 
 
 
S207I 
  
 
 
Table 5.3. Replacements of selected variants 
Specific amino acid replacements of the variants are shown in the right column. 
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5.6 CHOICE OF THE 5TH ROUND VARIANTS FOR PURIFICATION 
 
Four of the 5th round variant proteins were selected for purification then kinetic 
characterisation. Variant #5-1 was chosen as it differed form the native protein at one 
location; it had the dominant F114L replacement and the mutant had high MICs with 
all three substrates. Mutants #5-1 and #5-3 both have high MICs with ampicillin and 
imipenem, but slightly lower MICs with cefoxitin. The variants both have the F114L 
change as well as the F230Y change that is the second most commonly observed 
change. The variant #5-1 has a third change at position 55 while Variant #5-3 has two 
additional changes at positions 23 and 247, as indicated in Table 5.3. The fourth 
variant chosen for characterisation had a different substrate specificity to the other 
three; its mutant had a high MIC with ampicillin, a modest MIC with cefoxitin and 
very low MIC with imipenem.  
 
The genes for the native and variant proteins were cloned into the pET26b(+) vector 
and the original signal peptide was used so they were directed to the periplasm. The 
proteins were expressed in BL21 cells as described in Chapter 2.8. Fortunately, the 
calculated isoelectric points of the variant proteins were the same as the native protein 
so that the same purification protocol developed for the native protein was employed 
on the variant proteins as described in Chapter 2.8. Figure 5.3 shows a gel on which 
the purified proteins have been run. Three of the four variants were obtained with 
better than 95% purity while variant #5-3 could undergo proteolytic degradation; two 
lower molecular weight bands were evident in the gel. This degradation would reduce 
the concentration of the variant protein and this could introduce an error into the 
MICs and kcat determinations. The expression of variant #5-19 appears to be lower 
than the other three and this could result in lower MICs values for this mutant 
compared with variants #5-1 and #5-3, but this should not affect the kinetic 
parameters.  
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Figure 5.3. Purified variants #5-1, #5-2, #5-3 and #5-19 
M, low molecular weight marker in Dalton. (a) Purified #5-1. (b) Purified #5-2 (c) 
Purified #5-3. (d) Purified #5-19, from a different gel. 
 
5.7 KINETIC CHARACTERISATION OF THE CHOSEN 5TH ROUND VARIANTS 
 
The kinetic parameters were determined as described in Chapter 2.13 and the results 
are given in Figures 5.4 to 5.6 (detailed original data can be found in Appendix C.4). 
From the plots shown in Figures 5.4 and 5.5 it is clear that the initial velocity values 
obtained for the variant #5-19 have not reached saturation, hence the corresponding 
errors in KM are high. However, the comments made concerning variant #5-19 were 
not invalidated by this high error. The variants were produced as a result of selection 
with cefoxitin and one would expect that this substrate would give kinetic parameters 
for variants that would differ the most form those of the native protein.   
 
For first three (#5-1, #5-2, and #5-3) of the four variants, the kinetic parameters 
obtained with ampicillin were essentially the same as those obtained with the native 
protein. The fourth variant, #5-19, exhibited a greater than five-fold increase in kcat 
and approximately 10 folds increase in KM. The MIC obtained with the fourth mutant 
was indistinguishable from the native protein despite the significant change in 
catalytic parameters.  
97,400 
66,200 
45,000 
 
31,000 
 
21,500 
 
14,400 
     M    (a)    (b)    (c)        (d) 
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As with ampicillin, the kinetic parameters obtained with cefoxitin are very similar 
with the first three variants and quite different to those obtained with the last variant. 
However, with respect to cefoxitin there is a significant drop in the KM values for the 
first three variants while the KM values obtained with the fourth variant are essentially 
the same as the native protein. The kcat values for the first three variants show a 
modest decrease compared with the native protein while the fourth variant shows an 
approximate three fold increase. The MICs values obtained with the first three 
mutants have reached the top of the detectable limit while the fourth mutant shows a 
modest increase.  
 
With imipenem, all four variants show significant drops in both kcat and KM values; 
the drops observed with the fourth mutant being larger than those observed with the 
other variants. As a result to the replacements, the first three mutants have MICs 
values that are better than double that of the wild type; while that of the fourth 
mutants was reduced to the point it was barely survived to 2 µg/mL imipenem.  
 
It is worth mentioning that although variants #5-1 and #5-19 have nearly the same KM 
and similar kcat for imipenem, but their MICs are significantly different. Analysing 
from the kinetics parameters, #5-19 has only half kcat than the #5-1 might be the major 
reason caused the drop of the mutant’s MICs result. Secondly, according to the 
protein purification result, variant #5-19 is likely expressed less protein in the cell 
than the native and other purified variants. Further studies need to be done to give a 
better understanding of this phenomenon for example utilising isothermal titration 
calorimetry for determining the interaction between the proteins and the substrates. 
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 Ampicillin 
 kcat KM kcat/KM MICs 
 (s-1) (µM) (s-1/M) (µg/mL) 
AIM-1 410±30.2 110±21.2 3.81±0.48x10
6
 >1024 
#5-1 382±2.7 92±7.1 4.17±0.29x10
6
 >1024 
#5-2 481±34.5 206±48.9 2.42±0.37x10
6
 >1024 
#5-3 440±16.7 140±12.3 3.17±0.34x10
6
 >1024 
#5-19 2335±361 1065±216 2.22±0.14x10
6
 >1024 
 
 
 
Figure 5.4. Kinetics of the 4 fifth round variants with ampicillin as the substrate 
Vo, Initial velocity. [S], substrate concentration, here is ampicillin. 
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 Cefoxitin 
 kcat KM kcat/KM MICs 
 (s-1) (µM) (s-1/M) (µg/mL) 
AIM-1 117±8.9 283±36.7 4.16±0.24x10
5
 128 
#5-1 60±2.0 17.6±2.1 3.46±0.27x10
6
 >1024 
#5-2 79±7.3 28±1.4 2.84±0.37x10
6
 1024 
#5-3 93±4.5 36±4.9 2.64±0.27x10
6
 1024 
#5-19 352±43.8 237±44.4 1.51±0.12x10
6
 256 
 
 
 
Figure 5.5. Kinetics of the 4 fifth round variants with cefoxitin as the substrate 
Vo, Initial velocity. [S], substrate concentration, here is cefoxitin. 
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 Imipenem 
 kcat KM kcat/KM MICs 
 (s-1) (µM) (s-1/M) (µg/mL) 
AIM-1 1405±242 289±65.6 4.96±0.65x10
6
 512 
#5-1 82.9±7.3 11±1.4 7.59±0.37x10
6
 >1024 
#5-2 141±20.4 40±5.3 3.51±0.06x10
6
 >1024 
#5-3 196±49.1 87±34.2 2.36±0.30x10
6
 >1024 
#5-19 40±3.4 13±2.2 3.09±0.28x10
6
 2 
(a) 
 
(b) 
 
 
Figure 5.6. Kinetics of the 4 fifth round variants with imipenem as the substrate 
Vo, Initial velocity. [S], substrate concentration, here is imipenem. (a) [S] range from 
0 to 250 µM. (b) [S] range from 0 to 10 µM.   
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5.8 CRYSTALLISATION OF VARIANT #5-1 
 
The methods used to produce crystals were described in Chapter 2.12. Two crystal 
forms were found for variant #5-1. Bi-pyramidal crystals, similar in appearance to 
those obtained with the native protein, were obtained with 0.2 M zinc acetate, 0.1 M 
sodium cacodylate pH 5.0 and 5% to 11% w/v PEG 8000. Rods like crystals were 
found with 0.3 M zinc acetate, 0.2 M sodium cacodylate pH 5.0, 15% to 18% w/v 
PEG 8000. These crystals are similar in appearance to those obtained with the S221E 
variant as described in the last chapter. Crystals of other variants were also obtained. 
 
The X-Ray diffraction with the crystals of variant #5-1 was not suitable for structure 
determination, data could only be measured to 3.5 Å and the frames could not be 
scaled together. However, later attempts at the synchrotron by Professor Charles 
Collyer (University of Sydney) produced a good high-resolution data set (to 1.89 Å). 
Structure determination was finished during the thesis was examined.  
 
(a)            (b) 
 
 
Figure 5.7. Crystals of AIM-1 variant #5-1 
The condition of the picture (a) is 0.2 M zinc acetate, 0.1 M sodium cacodylate pH 
5.0, 11% w/v PEG 8000 and the picture (b) is 0.3 M zinc acetate, 0.2 M sodium 
cacodylate pH 5.0, 15% w/v PEG 8000. 
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5.9 DATA COLLECTION, PHASING AND REFINEMENT STATISTICS 
 
X-ray crystallography of variant #5-1 was carried out using Australian Synchrotron 
MX2 (Melbourne, Australia). Diffraction radiation protocol was single wavelength at 
0.8856 angstroms. Monochromatic/ Laue type was M and scattering type was single 
crystal. The diffraction detector was ADSC Quantum 315r. Native AIM-1 produced 
in our lab was used as a search model. Iterative manual adjustment using REFMAC5 
(CCP4) (177, 178) and Coot (179) refinement made the models converge to the final 
Rwork and Rfree values of 17.5 and 20.0 % respectively for mutant #5-1 (Table 5.4). 
The stereochemistry of the structures was checked with Sfcheck (CCP4) (180). The 
main-chain torsion angles of the models for #5-1 was 97.4% with 0 outliers.  
 
Statistic #5-1 
Data collection  
Space group P6122 
Cell dimensions  
a, b, c (Å) 76.45, 76.45, 240.27 
Resolution (Å) 66.21-1.89 
Reflections (n) 34233 
Rsym or Rmerge 99.7 (98.1) 
I/σI 25 (6.9) 
Completeness (%) 99.7 (98.1) 
Redundancy 12.7 (7.2) 
Refinement  
Resolution (Å) 1.89 
No. reflections 32,428 
Rwork/ Rfree 0.175/0.200 
Residues (n)  
Protein 271 
Zinc ion 2 
Water 214 
R.m.s deviations  
Bond lengths (Å) 0.018 
Bond angles (deg) 1.812 
pH 5.0 
PDB ID 4P62 
 
Table 5.4 Data collection, phasing and refinement statistics of variant #5-1  
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5.10 DISCUSSION 
 
Protocols were developed to generate mutant libraries and screen them for increased 
ability to confer resistance to cefoxitin. The mutation rates for the libraries were kept 
at a modest level of 2 replacements per protein gene and the concentration of 
cefoxitin in the early screen was kept close to the level tolerated by the native protein. 
The cefoxitin concentration was raised through the course of evolution to a level well 
beyond that tolerated by the native protein and the resulting variant proteins gave had 
a spread of resistance levels with a few exhibiting a significantly increased ability to 
confer resistance to cefoxitin. The evolution was stopped when resistance levels 
reached 1024 µg/mL in the secondary screen; this is close to the solubility limit of 
cefoxitin.  
 
Amino acid replacements had little effect on the observed resistance to ampicillin, but 
they did have a dramatic effect on their ability to confer resistance to imipenem. It 
appeared that mutants that gave rise to significantly increased resistance to cefoxitin 
also had good resistance to imipenem. The #5-19 mutant showed a marked ability to 
discriminate between the three different β-lactams.  It had gave rise to high levels of 
resistance to ampicillin and showed a modest increase in its ability to increase 
resistance to cefoxitin, but its ability to confer resistance to imipenem was practically 
zero, below that of the wild type.   
 
Surprisingly only one of the SSM (#1-3, T87A) was observed in random mutagenesis. 
It was observed in the first round and was not observed in later rounds. The best 
mutant in the SSM study, F119M did not appeared in the directed evolution library. 
One possible reason for this observation is that the phenylalanine to methionine 
change requires that two of the three bases of the coding triplet need modification, as 
shown in Figure 5.8 below. Given that the mutation rate is low, two changes to a 
single triplet were unlikely.  
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Figure 5.8. Scheme of random mutation to F119M 
DNA codons are indicated in capital letters and corresponding amino acids are shown 
as three letters format i.e., DNA code of phenylalanine is TTC. 
 
Interestingly, the SSM experiments produced some mutants that exhibited greatly 
increased MICs with imipenem, but these same mutants had only modest increases in 
the MICs obtained with cefoxitin.  It would appear that replacements remove from the 
active site, such as F114L, can cause changes in the active site that enhanced activity 
with cefoxitin. More will be said about the location of replacements later in this 
discussion.  
 
Kinetic analysis revealed that the effect of changes conferred increased levels of 
resistance by two mechanisms that resulted in increased catalysis at low substrate 
concentrations. Increased resistance to cefoxitin or imipenem was achieved by a drop 
in the KM of the enzyme as found in variants #5-1, #5-2 and #5-3. Variant #5-19 
illustrated an alternative approach. In this case, a significant increase in the KM as 
determined with ampicillin was compensated for by a dramatic increase in the kcat. 
From these results it would appear that the concentration of β-lactams in the 
periplasm is considerably lower than the concentration of the reagent in the medium 
and that it is easier to decrease KM rather than increasing kcat.  
 
So, how did the replacements cause a change in the kinetic properties of AIM-1? One 
approach of answering this question is to examine the environment of the altered 
residues in the native structure.  
 
F119 = TTC (Wild Type) 
 
TTC (Phe) -> TTG (Lue) -> ATG (Met) 
                       ATC (ILe) 
Activity decreased dramatically 
Activity increased 
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 (a) 
 
(b) 
 
 
Figure 5.9. Scheme of the replacements in the variant #5-1 
Replacements in mutant #5-1 compared with the native protein. (a) Mutations of 
L55Q, F114L and F230Y. (b) An inner view of AIM-1. Native protein is shown as 
green sticks and the variant #5-1 is shown as cyan sticks. The native and the variant 
zinc metals are shown in gray and yellow respectively. The replacement of F114L 
modifies the backbone of the active site; slightly alters the coordination of the metals. 
Structure shifts are also observed to remote replacements L55Q and F230Y.  
 
Three replacements were found in variant #5-1; this was the best variant in the sense 
that it had good activity with all three substrates. Figure 5.9 shows the locations of 
replacements in this mutant. F114L was the most common replacement and appears to 
be the major factor in increasing resistance to cefoxitin. It is the only change that was 
observed in variant #5-2, so that the lowering of KM and kcat parameters as well as the 
F230Y F114L L55Q 
H263 
H121 
D120 
Zn-2 
Zn-1 
H118 
H196 
H116 
F114L 
  
 
140 
mutant had an increase in MICs values were attributed to this change.  The change 
from a phenylalanine to a leucine is generally regarded as a conservative change since 
the side-chain volumes of the two residues are similar. However, one aromatic while 
the other is an aliphatic residue would be expected to cause a change in the local 
environment of the proteins. This residue is found between two histidines that are 
responsible for metal coordination; subtle changes in the conformation of the peptide 
could affect metal coordination that could then affect catalysis. 
 
This residue is on a loop that is removed from the active site and is not likely to have 
a direct effect on activity. However, the change from a phenylalanine to a tyrosine 
could result in a hydrogen bond being formed between it and H238; such an 
interaction could stabilise the protein and this may increase the activity in the cell and 
an increase in MIC. A small change in the local environment may also affect the 
conformation of T232 and Y241 and this might also have structural/ stability 
consequences.  
 
L55 lies at the start of a strand near the N-terminus of the proteins; it is remote form 
the active site and the replacement is not likely to affect catalysis directly. The side-
chain is in mainly hydrophobic environment, but it is close to the N-terminus and a 
change from a leucine to a glutamine may result in a stabilizing interaction.   
 
5.10.1 Surface and N-terminal Replacements 
 
There were several replacements that survived into the last round of evolution that 
were not common and were found on the surface of the protein. These replacements 
were: S23G, M53T, I143T, T154A, P166Q, N247S and S267G. These replacements 
are remote from the active site and are located as can be seen in Figure 5.10. The 
variant proteins found in the last round usually have one or two of these surface 
replacements along with the more common replacements of F114L and F230Y. These 
replacements may stabilise the structure, but at this stage a more definite statement 
cannot be made. The N-terminal mutation S23G is the first residue of the matured 
AIM-1 that is likely to do with the half-life of the protein (181). 
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Figure 5.10. Surface replacements arose in the directed evolution 
N-terminal is indicated as a bold capital “N” but replacement S23G is not refined in 
the structure. C-terminal is indicated as a bold capital “C”. 
 
5.10.2 Replacements A138V and S207I 
 
Residues A138 and S207 are found in the interior of AIM-1. Variants #5-12 had the 
A138V replacement while variant #5-20 had the S207I replacement. These 
replacements had little effect of the MICs values of the #5-12 and #5-20 mutants as 
shown in Figure 5.2. Both replacements are remote to the active site, but their 
locations suggest that these changes may have structural consequences. A138V is 
likely to fill up the space between residues I170 and I143, the later residues being 
subject to change in early rounds of evolution. Replacement S207 was found in a 
M53T 
P166Q I143T 
N247S 
S267G 
T154A 
N
C
C
    MICs µg/mL AMP Cefoxitin Imipenem 
Wild Type      >1024 128 512 
#5-14 M53T   F230Y  >1024 256 4 
#5-16  F114L I143T F230Y S267G >1024 256 4 
#5-17 S23G F114L P166Q  N247S >1024 512 512 
#5-18  F114L T154A   >1024 256 128 
#5-13  F114T T154A   >1024 1024 >1024  
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hydrophobic pocket and its conversion to an isoleucine may stabilise its local 
environment.  
 
(a)      (b) 
 
 
Figure 5.11. Replacements A138V and S207I 
(a) A138V surrounded by I143 and I170. (b) S207I surrounded by Y58, G59, N60, 
T61 and W205. 
 
It should be apparent from the above discussion that predicting the effects of 
replacements based upon the structure of the native protein is very speculative and 
that alternative interpretations are possible. Clearly, structure determination using X-
ray diffraction is the more accurate methods for assessing the effects of replacements. 
To this end crystal of variant #5-1 have been obtained and diffraction data collected; 
as well as the structure was solved.  
 
5.11 CONCLUDING REMARKS 
 
A method to evolve AIM-1 has been developed and applied to finding amino acid 
replacements that required enhancing the activity of the enzyme towards a particular 
substrate, Cefoxitin. The selection screen required that the variant proteins confer 
enhanced resistance towards cefoxitin. A number of variant proteins were found and 
characterised with respect to ability to act on cefoxitin as well as ampicillin and 
imipenem. A number of mutants were identified that gave considerably higher MICs 
values with cefoxitin. These mutants had little effect on the MICs observed with 
ampicillin, although changes of the variant proteins in kinetic parameters were 
I143 
A138V I170 
W205 
S207I 
T61 
N60 
G59 Y58 
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observed. These same variants differed considerably in their ability to degrade 
imipenem. The kinetic parameters of the variant proteins were measured and 
suggested that there were two approaches to enhancing the ability of AIM-1 to confer 
resistance against β-lactams: simply lowering the KM of the enzyme was the most 
common approach although in some instances an elevated kcat was observed. The 
structural changes required to bring about the changes in the kinetic parameters were 
not obvious from an inspection of the native and the variant #5-1 structures. This 
suggests that relatively modest changes in the structure could have a significant 
impact on catalysis. It is expected that further diffraction and even isothermal titration 
calorimetry studies will yield an accurate picture of the protein that may shed light on 
the means by which replacements enhance catalysis. 
 
5.12 FUTURE DIRECTIONS 
 
Since crystal structure of AIM-1 has been identified and many improved variants 
were characterised, there are still several directions can be studied. First, the metal 
binding to ligand residues can be studied in details. In a trial of metals removal from 
AIM-1 shows that this protein is stable without metals in the active site. Therefore 
AIM-1 is suitable for metals replacement and it should have a certain level of activity 
when using metals other than zinc. Measuring activity in different metal 
concentrations can also determine the metal binding constant. It is essential to know 
how this enzyme utilises the metals in the active site. Secondly, AIM-1 variants can 
be crystalised for the completion of the studies in this thesis. And the metal bindings 
profiles of the variants can also be carried out for uncovering the mechanism of the 
altered amino acids. Hence further works can be done of understanding the function 
of this protein. 
 
Moreover, AIM-1 can be directed evolved for other substrates. It is important to 
disclose the flexibility of AIM-1 that how large the library size needs to be evolved to 
adapt a none-specific substrate. AIM-1 could be directed evolved to several known β-
lactam substrates that is harder for AIM-1 to hydrolyse for example, piperacillin and 
moxalactam. Moreover, AIM-1 has very slightly activity toward an organophosphate 
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bis-p-nitrophenyl phosphate. Therefore it will be a breakthrough if this MBL can be 
engineered into an organophosphatase.  
 
Finally, AIM-1 and its variants can be assayed on new inhibitors. It is noticeable that 
pyrrole compounds are good inhibitors against IMP-1 (182, 183), but unaffected to 
AIM-1 in a preliminary study by Mr. Daniel Tan (University of Queensland). Another 
broad-spectrum MBL inhibitor, D-Captopril, has inhibition to BcII, IMP-1, NDM-1, 
CphA and L1 (184-187), but it seems less affected to AIM-1. All these AIM-1 
features prompt an urgency of developing useful inhibitors in the war of combating 
pathogens. 
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CHAPTER 6 CONCLUSIONS AND FUTURE 
DIRECTIONS 
 
The work carried out for this thesis was concerned with MBLs, proteins that are 
responsible for conferring resistance in bacteria to β-lactam antibiotics. This is a very 
intensely studied field with a great deal of detailed information about a number of 
common MBLs. However, despite considerable effort, there are no clinical inhibitors 
to these enzymes and new variants continue to appear in the clinic. The broad 
objective of this thesis was initially study a putative MBL, one that had been 
classified as an MBL on the basis of its sequence, but which showed considerable 
sequence differences to common variants.  
 
Much work had already been done on the SPR-1 MBL. Its ability to degrade β-
lactams had been established and a variant with enhanced activity had been produced. 
But work on this project was limited by the poor solubility and stability of the 
enzyme. The initial aims of this project were to improve the properties of a putative 
MBL so that sufficient quantities of stable protein were available to enable its 
catalytic properties to be studied by a variety of physical and chemical methods. This 
work was described in chapter 3.  
 
The results of the work with SPR-1 were largely negative. Despite considerable 
effort, variants with improved solubility could not be identified. Furthermore, efforts 
to refold the denatured enzyme did not produce significantly more soluble protein.  
 
Given the results of the work with SPR-1, a search of databases led to the 
identification of proteins that had similar sequences to SPR-1 and that might express 
in a soluble form. During the course of this search, a similar protein was identified 
and a comparison of its sequence with that of SPR-1 suggested that their metal 
binding ligands were the same and different to those found in the other classes of 
MBLs. These comparisons led to the idea that these proteins might represent a new 
class of MBLs (188); one that could appear in the clinic at some future date. 
Computational methods suggested that the new protein CSA-1 might be more stable 
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and soluble that SPR-1; its gene is currently being synthesised so that the soluble 
protein might be expressed for characterisation.  
 
During the course of the work with SPR-1, our attention was drawn to a B3 enzyme 
that had recently been identified in an Adelaide hospital. The blaAIM-1 gene was made 
and the protein expressed in Schenk laboratory so that it could undertake the 
biochemical characterisation. The protein was purified and crystallised by the author 
and the structure determined by Dr. Carr as noted in Chapter 4. This structure 
provided a good starting point for a detailed mechanistic study. The objective of this 
study was to identify active site residues that were important for substrate specificity 
and which could be altered to give enhanced activity with substrates that were turned 
over slowly by the native protein. It was felt that this object would aid in the design of 
MBL inhibitors and give a better understanding of MBL structure and function.  
 
There were two approaches taken to the identification of residues that had an effect on 
substrate specificity. This work is described in Chapters 4 and 5 and was carried out 
at the same time. In one approach active site residues were subjected to site saturation 
mutagenesis as described in Chapter 4. In a second approach, directed evolution was 
used to select for mutants that had enhanced activity towards cefoxitin, described in 
Chapter 5. The results of the two sets of experiments gave similar results in the sense 
that mutants with enhanced activities could be identified. However, the means by 
which enhanced activities were achieved were quite different in the two sets of 
experiments. The directed evolution experiments did not identify any of the active site 
replacements that were found in the SSM experiments. That is, the directed evolution 
experiments produced replacements that were removed from the active site, but which 
probably caused structural changes that affected the active site. Structural studies 
have been initiated to determine the nature of the structural changes. In both the 
directed evolution and the SSM experiments, it appeared that the easiest way to 
generate enhanced activity (enhanced resistance to antibiotics) is by reducing the KM 
of the enzyme towards the β-lactam. In few cases, variant proteins with increased kcat 
values were obtained, but in these enzymes there was also a significant increase in the 
KM so that the kcat/KM of the enzymes remained at a similar level to the native protein. 
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These results suggest that the concentration of the antibiotic in the cell is much lower 
than the concentration in the solution and that it is the ability of the enzyme to 
degrade the substrate at these low levels that enable the enzyme to confer resistance to 
the antibiotic. In no case were variant proteins with increased kcat and decreased KM 
observed. This is consistent with the idea that the enzyme is already operating at close 
to the diffusion limit.  
 
Considerable effort was made to combine the mutant/variant activity data for the 
different substrates with the knowledge of the structures of AIM-1 and the β-lactams.   
Models were calculated using a number of software packages, however these models 
varied considerably depending upon the software package and the substrate being 
used. None of these models appeared to be consistent with the MIC and kinetics data 
obtained with the variant proteins. For this reason, this work has not been included in 
the thesis. As we point out in Chapter 5, it is possible that crystal structures of the 
variant proteins may be a better staring point for analysis of the biochemical data.    
 
The work presented in this thesis should be viewed as part of a longer-term project. 
The initial aim was to gain a better understanding of a putative MBL. To try and 
anticipate its effect in the clinic and try to gain a better understanding of how it and 
other MBLs might function. However, the physical properties of SPR-1 were not 
tamed in this work and the author set about looking for a similar and more tractable 
form of the enzyme. This becomes a problem for future studies.  
 
The work with AIM-1 has shown that the protein can be easily altered to better 
accommodate poor substrates; this may have some clinical significance. It was hoped 
that the biochemical data gained with the variants would yield a good understanding 
of how the protein interacted with substrates. In fact, this question is probably better 
addressed by structure analysis of inhibitor bound enzyme, for example using 
isothermal titration calorimetry. However, the structure analysis of the variants 
produced as part of this work may well gives considerable insight into the mechanism 
of catalysis, again work for other researchers. Furthermore, variant structures may 
also be useful in the design of inhibitors that could be used as anti-bacterial agents. 
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APPENDIX A. CHEMICALS, EQUIPMENT AND 
SOLUTIONS 
 
A.1 BUFFERS AND SOLUTIONS 
A.1.1 Assay Buffer for MBL 
20 mM HEPES, 50 µM ZnCl2, pH 7.6 
A.1.2 5x Big Dye Buffer 
400 mM Tris, 10mM MgCl2, pH 9.0 
A.1.3 Buffer A for FPLC 
A1.3.1 Buffer A for AIM-1 and SPR-1 
20 mM Tris, 150 µM ZnCl2, 10% glycerol, pH 7.6 
A1.3.2 Buffer A for AIM-1 variant S221E  
20 mM HEPES, 150 µM ZnCl2, 10% glycerol, pH 6.5 
A1.3.3 Buffer A for Ni2+ column 
20 mM sodium phosphate buffer, 0.5 M NaCl, pH 8 
A.1.4 Buffer B for FPLC 
A.1.4.1 Buffer B for AIM-1 and SPR-1 
20 mM Tris, 150 µM ZnCl2, 1M NaCl, 10% glycerol, pH 7.6 
A1.4.2 Buffer B for AIM-1 variant S221E 
20 mM HEPES, 150 µM ZnCl2, 1M NaCl, 10% glycerol, pH 6.5 
A.1.4.3 Buffer B for Ni2+ column 
20 mM sodium phosphate buffer, 0.5 M NaCl, 0.5 M imidazole, pH 8 
A.1.5 Cracking Buffer 
Prepared by combining 120 µl of 0.1% bromophenol blue, 1.12 mL of 80% glycerol, 
800 µL of 2 M Tris buffer pH 6.8, 2 mL of 10% SDS and 0.31 g of dithiotheritol 
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(DTT). MilliQ water is added to a final volume of 10 mL. Immediately prior to use, 
10 µl of BME is added to 190 µl of the mix. 
A.1.6 EB Buffer  
10 mM Tris, pH 8.0 
A.1.7 Loading Buffer / DNA Loading Dye 
BPB loading dye was used in the electrophoresis of DNA on agarose gels. This 
loading buffer was prepared by combining 10 mM Tris pH 8.0, 10% w/v of 
bromophenol blue (BPB) and 40% v/v glycerol. 
A.1.8 Luria-Bertani (LB) Medium 
LB medium is prepared by 5 g of yeast extract, 10 g of tryptone and 10 g of NaCl 
dissolved in 0.9 L of MilliQ water. pH is adjusted to 7.5 and MilliQ water is added to 
1 L. The medium is sterilised by autoclaving. When the medium is cooled to about 50 
°C, appropriate antibiotic is added. When solid medium is desired, 15 g of agar is 
added into 1 L of medium prior to autoclaving. Ampicillin and kanamycin are added 
to a final concentration of 50 µg/mL and chloramphenicol of 33 µg/mL 
A.1.9 Minimal A Medium 
10.5 g/L K2HPO4, 4.5 g/L KH2PO4, 1 g/L (NH4)2SO4, 0.5 g/L NaCitrate-2H2o and 4 
g/L glucose with 1 mL/L 20% MgSO4-7H2O, 0.5 mL/L 0.5% Vitamin B1, 20 mL/L 
BME amino acids plus desired antibiotics were added MilliQ water to 1 L. Sterilising 
by filtration. 
A.1.10 Mueller Hinton Agar/Broth 
32 g or 21 g of respective powder is added into 1 L of MilliQ water and autoclaved. 
A.1.11 Running Buffer 
A 10X stock is made by dissolving 144 g glycine, 30 g Tris base and 10 g SDS in 1 L 
of MilliQ water. 
A.1.12 SB Buffer 
A 20X stock is made by dissolving 8 g of NaOH in 0.9 L of MilliQ water. pH is 
adjusted to 8.0 with boric acid (requiring approximately 48 g). The volume is made 
up to 1 L of MilliQ water. 
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A.1.13 YENB Broth 
7.5 g of yeast extract and 8 g of nutrient broth (Difco) are dissolved in 1 L of MilliQ 
water. The media are sterilised by Autoclaving. 
 
A.2 OLIGONUCLEOTIDES 
 
Oligos Names Description Sequences 
pCY76 F Sequencing of genes in 
pJWL1030 and 
pJWL1030folA 
F: 5’- GCC GGC GAT ATC GGA TCC 
G - 3’ 
1030folA R Sequencing of genes in 
pJWL1030folA 
R: 5’- TCG GCA GGC AGG TTC CAC 
GGC - 3’ 
T7 sequencing Sequencing of genes in 
pET26b(+) 
F: 5’- TAA TAC GAC TCA CTA TAG 
GG - 3’ 
T7 terminator Sequencing of genes in 
pET26b(+) 
R: 5’- CTA GTT ATT GCT CAG CGG 
TG - 3’ 
spMBL-NdeI 
F 
Primer for SPR-1 with NdeI 
restriction site 
F: 5’- GGA GAT ATA CAT ATG CAG 
CTG AAT CCG GCG CAG CCG - 3’ 
spMBL-EcoRI 
R 
Primer for SPR-1 with EcoRI 
restriction site 
F: 5’- TTA GGC CC GAATTC CAT 
TTT GCT CTG CTG CTG TTT CAG - 
3’ 
SP∆Q274 SPR-1 deletion after Q 274 
with HindIII restriction site 
R: 5’- CTG GAA TTC AAG CTT CTG 
CTG TTT CAG CTG CG - 3’ 
spMBL-
pHUE-SacII F 
Primer for SPR-1 with SacII 
restriction site 
F: 5’- CCT CCG CGG TGG ACA GCT 
GAA TCC GGC GCA - 3’ 
SP L159P SPR-1 SDM L159P 5’ and 3’ F: 5’- AAA CTG ACC GCG CCG ATG 
ACG CCG GGT CAT - 3’ 
R: 5’- ATG ACC CGG CGT CAT CGG 
CGC GGT CAG TTT - 3’ 
SP M160K 
 
SPR-1 SDM M160K 5’ and 
3’ 
F: 5’- AAA CTG ACC GCG CTG 
AAA ACG CCG GGT CAT - 3’ 
R: 5’- ATG ACC CGG CGT TTT CAG 
CGC GGT CAG TTT - 3’ 
SP 
L159P+M160
K 
SPR-1 SDM L159P and 
M160K 5’ and 3’ 
F: 5’- AAA CTG ACC GCG CCG 
AAA ACG CCG GGT CAT - 3’ 
R: 5’- ATG ACC CGG CGT TTT CGG 
CGC GGT CAG TTT - 3’ 
SPMBL-
L197Q 
SPR-1 SDM L197Q 5’ and 3’ F: 5’- CCG GAT TAT TAT CAG ATC 
GAT AAC AAA AAC - 3’ 
R: 5’- GTT TTT GTT ATC GAT CTG 
ATA ATA ATC CGG - 3’ 
spMBL-
L9Dfrag F 
SPR-1 SDM L9D 5’ F: 5’- GGA GAT ATA CAT ATG CAG 
CTG AAT CCG GCG CAG CCG GAT 
TCT AGC GCA CCG CCG - 3’ 
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AIM-1-NdeI-F Primer for AIM-1 with NdeI 
restriction site 
F: 5’- GGA GAT ATA CAT ATG 
AAA CGT CGC TTC ACC - 3’ 
AIM-1-EcoRI-
R 
Primer for AIM-1 with EcoRI 
restriction site 
F: 5’- AAG CTT GAA TTC TTA CGG 
GCG AGC ACC GCT - 3’ 
AIM-1-
W37X-SSM F 
SSM primer for AIM-1 W37 F: 5’- GCG GAT GAC GCA GGT 
NNK AAT GAT CCG GCT ATG - 3’ 
AIM-1-
F119X-SSM F 
SSM primer for AIM-1 F119 F: 5’- TTT TCG CAC GAG CAC NNK 
GAC CAC GCA GGT AGC - 3’ 
AIM-1-
Q157X-SSM 
F 
SSM primer for AIM-1 Q157 F: 5’- GAC CGC ACT GAT CCG NNK 
TTC GAA GTT GCG GAG - 3’ 
AIM-1-
S221X-SSM F 
SSM primer for AIM-1 S221 F: 5’- ATG GTG TAT GCG GAT NNK 
CTG ACC GCG ATT TCT - 3’ 
AIM-1-
S252X-SSM F 
SSM primer for AIM-1 S252 F: 5’- GTT ACC CCG CAT CCG NNK 
GCG AGC GGT CTG TGG - 3’ 
AIM-1 T87X 
SSM F 
SSM primer for AIM-1 T87 F: 5’ - CTG GTT GAT GCG GCG 
NNK CCG CAA GCT GGC CCG - 3’ 
AIM-1 E117X 
SSM F 
SSM primer for AIM-1 E117 F: 5’ - ATT GTG TTT TCG CAC NNK 
CAC TTC GAC CAC GCA - 3’ 
AIM-1 T223X 
SSM F 
SSM primer for AIM-1 T223 F: 5’ - TAT GCG GAT AGC CTG 
NNK GCG ATT TCT GAT GAC - 3’ 
AIM-1 I225X 
SSM F 
SSM primer for AIM-1 I225 F: 5’ - GAT AGC CTG ACC GCG 
NNK TCT GAT GAC GTG TTC - 3’ 
AIM-1 Y227X 
SSM F 
SSM primer for AIM-1 Y227 F: 5’ - ACC GCG TGC CGC CGT 
NNK GCG CAG GGT GCA CGT - 3’ 
T7term-tail T7 terminal primer plus 
designed tail 
R: 5’- ATC GGG TAA TAC AGT TCG 
TCT TTC GTT ATG CTA GTT ATT 
GCT CAG CGG - 3’ 
Tail Tail primer for SSM R: 5’- ATC GGG TAA TAC AGT TCG 
TCT TTC - 3’ 
AIM-1 wo 
signal NdeI F 
AIM-1 5’ primer without the 
signal peptide 
F: 5’- GAT ATA CAT ATG AGC GAC 
GCT CCG GCA TCT - 3’ 
 
A.3 EQUIPMENT SUPPLIERS 
 
EQUIPMENTS MANUFACTURERS AND 
SUPPLIERS 
30 ° C and 37 ° C temperature control 
units 
Qualtex Solidstat 
AKTA FPLC system GE Healthcare 
All glassware Duran, E-Mil England, Hirschmann 
Germany, LMS Germany, Pyrex 
All plastic ware Geiner Bio-one, Sarstedt 
Autoclave model ASB270BT Astell Scientific 
Autoclave vortex mixer Chiltern 
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Cell density meter WPA Biowave 
Centrifuge 5415, 5804 Eppendorf 
Centrifuge 3K18 Sigma Laboratory Supplies 
Centrifuge RC5C, RC6+ Thermo Electron Corporation 
Centrifuge tubes Nalgene 
Centrifuge filter devices Amicon, Millipore 
Class II Biological safety cabinet Flow Laboratories 
Combination pH electrode Orion Pacific Pty Ltd 
DEAE SepharoseTM fast flow column GE Healthcare 
Dri-Bath Type 17600 Thermolyne 
Electricity power supply Bio-Rad, Pharmacia LKB 
French® pressure cell press SLM Aminco 
Fume cabinet Dynaflow 
GeneAmp PCR system 9700 P.E. Applied Biosystems 
Hot plate IKA laboratory Equipment 
iCycler® Bio-Rad 
Labsystem Multiskan Ascent plate 
reader 
Pathtech Pty Ltd 
Light scattering detector Wyatt 
Micropipettes Gilson 
MicroPulserTM Bio-Rad 
Microscope Olympus 
Mighty small gel tank Hoefer 
MFTM 045 µm membrane filter Millipore 
Millex® -GV 0.22 µm filter unit Millipore 
Milli-Q reagent water system Millipore 
Minisart® 0.20 µm filter unit Sartorius 
NanoDrop®ND-1000 spectrophotometer NanoDrop 
Orbital mixer and incubator New Brunswick Scientific, Ratek 
Instruments 
Orbital shaker Bio-Line 
Orbital shaking water bath Paton Scientific 
Peristaltic pump Gilson 
Phenyl SepharoseTM fast flow column GE Healthcare 
Q SepharoseTM fast flow column GE Healthcare 
Quik Spin microcentrifuge United Biosciences 
Robotic dispensing system Cartesian 
Rotors 11133 Sigma Laboratory Supplies 
Rotors SA-600, SLA-3000, SS-34 Sorvall 
SephadexTM G-75 column GE Healthcare 
Sonicator Soniclean Pty Ltd 
SpectraMax® M2/M2e multi-detection 
microplate reader 
Molecular Devices 
SuperdexTM 200 column GE Healthcare 
Syringe Terumo 
UV transilluminator 312 nm with 
attached UVItec camera for photo 
Hanimax Statesman, UVP Inc. 
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acquisition UV transilluminator 365 nm 
Varian Cary UV/V is spectrophotometer Varian 
Water bath with temperature control Polystat, Thermomix 
Weighing scales Sartorius 
 
A.4 CHEMICAL SUPPLIERS 
 
KITS MANUFACTURERS AND 
SUPPLIERS 
QIAprep® Spin Miniprep Kit Qiagen 
QIAprep® PCR Purification Kit Qiagen 
QIAprep® Gel Extraction Kita Qiagen 
QuikChangeTM Multi-Site Kit Stratagene 
Wizard® SV Gel and PCR Clean-Up 
System 
Promega 
CHEMICALS AND REAGENTS  
1 kb DNA marker New England Biolabs 
10X BugBuster Merck 
10X PCR Buffer Roche 
10X PCR Buffer without MgCl2 Roche 
2% (w/v) N,N’ –methylene-
bisacrylamide 
Merck 
40% (w/v) acrylamide solution Bio-Rad 
Acetic acid, anhydrous Ajax Finechem 
Agar technical Bacto Laboratories 
Agarose, for routine use Sigma-Aldrich 
Alkaline phosphatase, calf intestinal New England Biolabs 
Ammonium chloride BDH Chemicals 
Ammonium sulfate, for molecular 
biology 
Sigma-Aldrich 
Ampicilin Amresco 
β-mercaptoethanol Sigma-Aldrich 
Benzylpenicillin Sigma-Aldrich 
Biapenem Sigma-Aldrich 
BigDye terminator v3.1 BRF, JCSMR, ANU 
Bis-Tris Sigma-Aldrich 
Boric acid BDH Chemicals 
Bovine serum albumin Sigma-Aldrich 
Dihydrofolate Sigma-Aldrich 
Bug Buster Merck 
Bromophenol blue Chem Supply 
Buffer 2 New England Biolabs 
Buffer 4 New England Biolabs 
Calcium chloride Ajax Finechem 
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Captopril Sigma-Aldrich 
Cefmetazole Sigma-Aldrich 
Cefotaxime Sigma-Aldrich 
Cefoxitin Sigma-Aldrich 
Cefuroxime Sigma-Aldrich 
Cephalothin Sigma-Aldrich 
Clavulanic acid Sigma-Aldrich 
Crystallisation screens Hampton Research, JENA Bioscience 
D-(+)- Glucose, anhydrous Sigma-Aldrich 
dNTP mix Roche 
DpnI New England Biolabs 
EcoRI New England Biolabs 
Ethanol, absolute Ajax Finechem 
Ethidium bromide Sigma-Aldrich 
Ethylenediaminetetraacetic acid 
disodium 
Ajax Finechem 
Gelcode® blue stain reagent Pierce/BioRad 
Glycerol Ajax Finechem 
Glycine, for electrophoresis Sigma-Aldrich 
Guanidine hydrochloride Sigma-Aldrich 
Hydrochloric acid 37% Scharlau 
Imipenem Ningbo Samreal Chemical 
Low range molecular weight standard Bio-Rad 
Magnesium chloride hexahydrate BDH Chemicals 
Manganese (II) chloride Sigma-Aldrich 
Meropenem Sigma-Aldrich 
N,N,N’,N’,-tetramethylethylenediamine Sigma-Aldrich 
Native Pfu DNA polymerase Stratagene 
NdeI New England Biolabs 
Nutrient broth Bacto Laboratories 
Petroleum jelly Shell 
Piperacillin Sigma-Aldrich 
Potassium chloride Ajax Finechem 
Potassium sulfate Sigma-Aldrich 
Kanamycin Amresco 
Mualler Hinton Agar/Broth Bacto Laboratories 
NiSO4 Sigma-Aldrich 
PstI New England Biolabs 
Trimetophrim Sigma-Aldrich 
Sodium chloride Chem Supply 
Sodium phosphate dibasic Sigma-Aldrich 
T4 DNA ligase and buffer New England Biolabs 
Taq DNA polymerase Bio-Line, Roche 
Tris Amresco 
Tryptone Bacto Laboratories 
Yeast extract Bacto Laboratories 
Zinc chloride BDH Chemicals 
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APPENDIX B. PROTEINS SEQUENCES 
 
B.1 SERRATIA PROTEAMACULANS METALLO-Β-LACTAMASE (SPR-1)  
 
MQLNPAQPLS SAPPYSLFEQ WAQPVAPFQM FPHVYYVGTR NLSSVLLSTP  
EGLILIDAAL DASAPAIRAH IEALGFNIKD LRYILNSHAR LDQAGGIARL  
QVWSGAKVVA SAANAQQLAL GGKQDFALGD ALSFPPVKVD IIVGEGDSIT  
LGDLKLTALM TPGHLPGATS WLTTLHQGGQ SYRLVYADSL ATPDYYLIDN  
KNYPSLVQDI RGSFARLAQQ QADIFIVNKG TRFDLDNKMQ RLQAGDLDAF  
VDRQGLQQYV QQSQQTFEAQ LKQQQSKM* 
 
B.2 PSEUDOMONAS AERUGINOSA METALLO-Β-LACTAMASE (ADELAIDE 
IMIPENEMASE-1/ AIM-1) 
 
MKRRFTLLGS VVALALSSTA LASDAPASRG CADDAGWNDP AMPLKVYGNT  
WYVGTCGISA LLVTSDAGHI LVDAATPQAG PQILANIRAL GFRPEDVRAI  
VFSHEHFDHA GSLAELQKAT GAPVYARAPA IDTLKRGLPD RTDPQFEVAE  
PVAPVANIVT LADDGVVSVG PLALTAVASP GHTPGGTSWT WRSCEGDDCR  
QMVYADSLTA ISDDVFRYSD DAAHPGYLAA FRNTLARVAA LDCDILVTPH  
PSASGLWNRI GPRAAAPLMD TTACRRYAQG ARQRLEKRLA EEAATSPSSG 
ARP* 
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B.3 CONSURF RESULTS OF AIM-1 
 
  
ConSurf Results
1
S
e
D
e
A
e
P
e
A
e
S
e
R
e
G
e
C
b
A
e
11
D
e
D
e
A
e
G
e
W
e
f
N
e
D
e
P
e
A
e
M
e
21
P
e
f
L
b
K
e
V
b
Y
b
G
e
f
N
b
T
b
W
b
Y
b
31
V
b
s
G
b
s
T
b
s
C
e
G
e
I
b
S
b
A
b
L
b
L
b
s
41
V
b
T
e
S
b
D
e
A
e
G
b
s
H
b
I
b
L
b
s
V
b
51
D
b
s
A
b
A
b
T
b
P
e
Q
e
A
b
G
b
P
e
Q
b
61
I
b
L
b
A
e
N
b
s
I
b
s
R
e
A
e
L
e
G
e
f
F
b
71
R
e
P
e
E
e
D
e
f
V
b
R
e
A
b
I
b
V
b
F
b
81
S
b
s
H
b
s
E
e
f
H
b
s
F
b
D
b
s
H
e
f
A
b
G
e
f
S
b
91
L
b
A
b
s
E
e
L
b
Q
e
K
e
A
e
T
e
f
G
e
f
A
b
s
101
P
e
V
b
Y
b
A
b
R
e
A
b
P
e
A
b
I
b
D
e
111
T
b
L
b
K
e
R
e
G
b
s
L
e
P
e
D
e
R
e
T
e
121
D
e
f
P
e
Q
e
f
F
e
E
e
V
e
A
e
E
e
P
e
V
b
131
A
e
P
e
V
b
A
e
N
e
I
e
V
e
T
b
L
b
A
e
141
D
e
D
e
G
e
V
e
V
b
S
e
V
b
G
b
s
P
e
L
b
151
A
e
L
b
T
b
s
A
b
V
b
A
b
S
b
P
b
G
e
f
H
e
f
161
T
e
f
P
e
G
e
f
G
e
T
e
S
e
f
W
b
T
e
W
b
R
e
171
S
e
C
e
E
e
G
e
D
e
D
e
C
b
R
e
Q
e
M
b
181
V
b
Y
b
A
b
D
b
S
b
s
L
b
T
e
A
e
I
e
S
e
191
D
e
D
e
V
e
F
b
R
e
Y
b
S
e
D
e
D
e
A
e
201
A
e
H
e
P
e
G
e
Y
b
L
b
A
e
A
e
F
b
R
e
211
N
e
T
b
L
b
A
e
R
e
V
b
A
e
A
e
L
b
D
e
221
C
b
D
e
f
I
b
L
b
V
b
T
b
P
e
H
b
s
P
e
f
S
e
231
A
b
S
e
f
G
e
L
b
W
e
N
e
R
e
I
e
G
e
P
e
241
R
e
A
e
A
e
A
e
P
e
L
e
M
e
D
e
T
e
T
e
251
A
b
C
b
R
e
R
e
Y
b
A
b
Q
e
G
e
A
b
R
e
261
Q
e
R
e
L
b
E
e
K
e
R
e
f
L
b
A
e
f
E
e
E
e
f
271
A
e
A
e
f
T
e
S
e
P
e
S
e
S
e
G
e
A
e
R
e
281
P
e
The conservation scale:
1 2 3 4 5 6 7 8 9
Variable Average Conserved
e  - An exposed residue according to the neural-network algorithm.
b  - A buried residue according to the neural-network algorithm.
f  - A predicted functional residue (highly conserved and exposed).
s  - A predicted structural residue (highly conserved and buried).
X  - Insufficient data - the calculation for this site was
     performed on less than 10% of the sequences.
23           33            54           64           74!
84           94            104          115           125!
35          145          155           165          175!
87          197           207          217           227!
37          247           56          266           76!
86          296           306!
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APPENDIX C. FULL LIST OF MUTANTS 
C.1 TMP SELECTED VARIANTS OF SPR-1 
 
Mutants        
TMP 
(µg/ml) 
Library 
size 
#4-4 L9V A89T  L159Q    25  
#6-1 L9V A89T  L159Q  V251G  25 310,000 
#7-3 L9V A89T  L159Q  V251G L256P 
30 280,000 
#7-4 L9V A89T  L159Q Q208R V251G  
#7-6 L9V A89T Q117R L159Q  V251G  
#7-8 L9V A89T  L159Q T174I V251G  
#7-10 L9V A89T G105V L159Q  V251G  
#7-13 L9V A89T D130G L159Q  V251G  
#7-14 L9V A89T  L159Q D248G V251G  
#8-1 
(#6-1) L9V A89T  L159Q  V251G  40 100,000 
 
C.2 SITE-SATURATION MUTAGENESIS OF AIM-1 - DISC DIFFUSION AND 
MINIMUM INHIBITION CONCENTRATIONS 
 
Disc Diffusion values are in millimeters and MICs are in µg/mL. 
 
  AMP Cephalothin Cefoxitin Imipenem  
  D.D. MICs  D.D. MICs D.D. MICs Picked 
AIM-1 wt  0 >1024 7 7 128 0 512 26 
Neg. control  15 1 15 15 1 15 1  
W37 A 0 >1024 8 7 256 0 1024 3 
W37 I 0  7 6  0  1 
W37 L 0 >1024 7 7 512 0 1024 2 
W37 M 0  8 8  2  1 
W37 F 0 >1024 7 7 256 0 1024 2 
W37 V 0 >1024 7 7 256 0 1024 3 
W37 S 0  9 8  2  2 
W37 T 0 >1024 7 7 128 0 512 1 
W37 Q 0 >1024 7 7 512 0 1024 3 
W37 C 0 >1024 5 5 512 0 1024 2 
W37 G 0  10 8  0  11 
W37 R 0 >1024 7 7 128 2 512 5 
W37 E 0  10 8  7  1 
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W37 STOP        0 
W37       Total  63 
 
  AMP Cephalothin Cefoxitin Imipenem  
 
 D.D. MICs  D.D. MICs D.D. MICs Picked 
AIM-1 wt  0 >1024 7 7 128 0 512 9 
Neg. control  15 1 15 15 1 15 1 
 T87 A 0 >1024 2 2 512 0 512 3 
T87 L 0  2 3  0  1 
T87 V 0  2 2  0  2 
T87 S 0 >1024 2 2 128 0 512 3 
T87 Q 0  2 3  0  1 
T87 G 0 >1024 2 2 128 0 1024 2 
T87 R 0  2 4  0  1 
T87 STOP 
 
 
  
 
 
 0 
T87 
  
 
  
 Total  22 
 
  AMP Cephalothin Cefoxitin Imipenem  
 
 D.D. MICs  D.D. MICs D.D. MICs Picked 
AIM-1 wt  0 >1024 7 7 128 0 512 6 
Neg. control  15 1 15 15 1 15 1 
 E117 A 0 >1024 5 5 512 0 1024 3 
E117 L 0 >1024 7 5 512 0 1024 1 
E117 F 5 >1024 10 10 128 3 256 1 
E117 W 1 >1024 9 9 512 2 1024 1 
E117 Y 1 >1024 8 9 128 3 512 1 
E117 V 1 >1024 9 9 128 2 1024 4 
E117 T 0 >1024 7 7 128 1 1024 3 
E117 C 0 >1024 7 8 128 2 1024 1 
E117 G 0 >1024 7 6 256 0 1024 2 
E117 R 0 >1024 7 6 256 0 1024 1 
E117 D 0 >1024 5 5 512 0 1024 2 
E117 STOP 
 
 
  
 
 
 
 E117 
  
 
  
 Total  26 
 
  AMP Cephalothin Cefoxitin Imipenem  
 
 D.D. MICs  D.D. MICs D.D. MICs Picked 
AIM-1 wt  0 >1024 7 7 128 0 512 11 
Neg. control  15 1 15 15 1 15 1 
 F119 A 0 >1024 7 7  0  2 
F119 L 0 128 10 10 32 7 4 1 
F119 M 0 >1024 4 3 >1024 0 >1024 1 
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F119 W 0 >1024 8 11 128 0 512 4 
F119 V 0  7 8  0  1 
F119 S 0 >1024 7 9 128 0 32 2 
F119 Q 0 >1024 3 2 256 0 1024 2 
F119 G 0  5 6  0  5 
F119 P 0  4 6  0  1 
F119 R 0  10 10  3  1 
F119 H 0  7 7  4  1 
F119 STOP 
 
 
  
 
 
 2 
F119    Total  34 
 
  AMP Cephalothin Cefoxitin Imipenem  
 
 D.D. MICs  D.D. MICs D.D. MICs Picked 
AIM-1 wt  0 >1024 7 7 128 0 512 13 
Neg. control  15 1 15 15 1 15 1 
 Q157 A 0 >1024 7 10 128 0 1024 5 
Q157 I 0 >1024 7 7 256 0 32 1 
Q157 L 7 >1024 8 11 32 4 64 3 
Q157 M 0 >1024 7 12 8 0 64 3 
Q157 W 0 >1024 2 4 128 0 512 1 
Q157 Y 0 128 9 11 8 7 4 1 
Q157 V 0 >1024 8 11 16 13 64 3 
Q157 S 0 >1024 7 11 128 6 1024 3 
Q157 T 0 256 8 11 2 11 1 2 
Q157 C 0  7 12  10  2 
Q157 G 0 >1024 8 13 64 5 32 6 
Q157 P 0 >1024 7 12 16 15 2 5 
Q157 R 1 32 13 15 2 4 2 6 
Q157 H 0 >1024 5 10 32 1 256 1 
Q157 D 0 >1024 10 9 128 3 64 2 
Q157 E 0 >1024 7 10 128 4 512 3 
Q157 STOP 
 
 
  
 
 
 1 
Q157 
  
 
  
 Total  61 
 
  AMP Cephalothin Cefoxitin Imipenem  
 
 D.D. MICs  D.D. MICs D.D. MICs Picked 
AIM-1 wt  0 >1024 7 7 128 0 512 3 
Neg. control  15 1 15 15 1 15 1 
 S221 A 0 >1024 7 7 256 15 1 1 
S221 L 8 4 12 14 2 13 1 2 
S221 W 0 >1024 6 7 128 0 512 5 
S221 V 4 512 10 14 2 13 1 3 
S221 Q 4 512 9 8 128 15 1 1 
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S221 C 6 256 11 15 4 13 2 1 
S221 G 0 >1024 7 9 128 12 2 7 
S221 R 8 8 12 16 1 15 1 3 
S221 K 15 1 11 15 4 14 1 1 
S221 D 15 2 13 15 1 15 1 1 
S221 E 15 2 15 15 1 13 1 1 
S221 
STO
P 
 
 
  
 
 
 
0 
S221 
  
 
  
 Total  29 
 
  AMP Cephalothin Cefoxitin Imipenem  
 
 D.D. MICs  D.D. MICs D.D. MICs Picked 
AIM-1 wt  0 >1024 7 7 128 0 512 2 
Neg. control  15 1 15 15 1 15 1 
 T223 A 0 >1024 7 7 128 10 64 1 
T223 I 0 >1024 3 4 256 0 512 1 
T223 V 0  5 2  0  4 
T223 S 0 >1024 3 2 256 0 1024 1 
T223 G 0 >1024 3 0 128 0 512 8 
T223 P 0 >1024 5 3 256 0 512 1 
T223 R 0 >1024 2 2 256 0 256 2 
T223 K 0 >1024 3 5 128 0 256 2 
T223 E 0 >1024 4 4 128 0 512 2 
T223 
STO
P 
 
 
  
 
 
 
1 
T223 
  
 
  
 Total  25 
 
  AMP Cephalothin Cefoxitin Imipenem  
 
 D.D. MICs  D.D. MICs D.D. MICs Picked 
AIM-1 wt  0 >1024 7 7 128 0 512 15 
Neg. control  15 1 15 15 1 15 1 
 I225 R 0 >1024 2 4 512 0 1024 1 
I225       Total  16 
 
  AMP Cephalothin Cefoxitin Imipenem  
 
 D.D. MICs  D.D. MICs D.D. MICs Picked 
AIM-1 wt  0 >1024 7 7 128 0 512 1 
Neg. control  15 1 15 15 1 15 1 
 S252 A 0 >1024 2 5 256 0 1024 2 
S252 L 0  8 8  13  2 
S252 M 0 >1024 6 4 256 0 1024 1 
S252 V 0  7 8  7  1 
S252 T 0 >1024 2 2 512 0 1024 1 
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S252 N 0 >1024 8 8 256 0 512 1 
S252 Q 0 >1024 8 10 256 14 512 1 
S252 C 10 >1024 9 9 128 4 512 3 
S252 G 0 >1024 7 7 128 0 512 1 
S252 P 1  7 7  7  1 
S252 R 0 >1024 9 10 128 0 512 2 
S252 H 1  10 10  12  1 
S252 D 0 >1024 9 10 128 0 512 1 
S252 E 0  7 8  0  1 
S252 
STO
P 
 
 
  
 
 
 
0 
S252 
  
 
  
 Total  20 
 
C.3 CEFOXITIN SELECTED VARIANTS OF AIM-1 
C.3.1 Full List of Cefoxitin Selected Variants of AIM-1 
 
Round 1  
ePCR 
only 
50 
µg/mL Cefoxitin 
10% picked 
WT 
Library size: 
4,000 
#1-1  R99H F114L    
#1-2   F114S Q129R   
#1-3  Y63H T87A    
#1-4  R295H     
#1-5  M53T P141L F230Y   
#1-6  P166Q     
#1-7  D235V     
#1-8  D33E P51Q I273V   
#1-9  V183I     
Round 2  
ePCR 
only 
60 
µg/mL Cefoxitin 
0% picked 
WT 
Library size: 
16,000 
#2-1  G36D D176G R295H   
#2-2  D33E I273V    
#2-3  L101S P166Q    
#2-4  S23G F230Y S267G   
#2-5  R297H     
#2-6   F114S P141L   
#2-7 3 silent mutations     
#2-8  T154A     
#2-9  R99H F114L F230Y   
#2-10 #1-1 R99H F114L    
Round 3  
ePCR 
only 
75 
µg/mL Cefoxitin 
0% picked 
WT 
Library size: 
33,000 
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#3-1  F230Y A237S    
#3-2   T172A F230Y   
#3-3   F114I D175V V183I  
#3-4 #1-1 R99H F114L    
#3-5 #1-6 P166Q     
#3-6 #2-1 D176G     
#3-7  R99H F114L A138V   
#3-8  A224P F230Y    
#3-9 #2-9 R99H F114L F230Y   
#3-10 #1-5 M53T P141L F230Y   
#3-11   F114L F230Y   
#3-12 #2-9 R99H F114L F230Y   
#3-13  L55Q F114L N247S   
#3-14 #2-6  F114S P141L   
#3-15 #1-4 R295H     
#3-16   F114T T154A   
#3-17 #2-1 G36D D176G R295H   
#3-19  R99H F114L K300E   
#3-20 #1-1 R99H F114L    
Round 4  
ePCR 
only 
100 
µg/mL Cefoxitin 
0% picked 
WT 
Library size: 
10,000 
#4-1   F114T T154A A307V  
#4-2   F114L N247G   
#4-3 #3-16  F114T T154A   
#4-4 #3-13 L55Q F114L N247S   
#4-5  M53T R99H F114L F230Y  
#4-7  L55Q F114L T154A F230Y  
#4-8  R99H F114L L242Q   
#4-9     F230Y S267G 
#4-10   F114L A138V N247S  
#4-11 #3-13 L55Q F114L N247S   
#4-12  S18P F114L Y216F T248A  
#4-15  L55Q F114L    
#4-16   F114L Q292R K300E  
#4-17 #3-13 L55Q F119L N247S   
#4-19   F114I N169D   
Round 5  eStEP 
125 
µg/mL Cefoxitin 
0% picked 
WT 
Library size: 
242,000 
#5-1  L55Q F114L F230Y   
#5-2   F114L    
#5-3  S23G F114L F230Y N247S  
#5-4 #5-2  F114L    
#5-5 #3-11  F114L F230Y   
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#5-6 #5-2  F114L    
#5-7 #4-15 L55Q F114L    
#5-8 #3-11  F114L F230Y   
#5-9 #3-11  F114L F230Y   
#5-10 #5-2  F114L    
#5-11 #5-2  F114L    
#5-12   F114L A138V   
#5-13 #3-16  F114T T154A   
#5-14  M53T  F230Y   
#5-16   F114L I143T F230Y S267G 
#5-17  S23G F114L P166Q N247S  
#5-18   F114L T154A   
#5-19  S23G F114L F230Y   
#5-20   F114L S207I   
 
C.3.2 Minimum Inhibition Concentrations of the 5th Round Mutants 
 
  Concentration (µg/mL) 
  AMP Cefoxitin Imipenem 
AIM-1 wt  >1024 128 512 
Neg. control  1 1 1 
#5-1  >1024 >1024 >1024 
#5-2  >1024 1024 >1024 
#5-3  >1024 1024 >1024 
#5-5 #3-11 >1024 256 512 
#5-7 #4-15 >1024 1024 >1024 
#5-12  >1024 512 1024 
#5-13 #3-16 >1024 1024 >1024 
#5-14  >1024 256 4 
#5-16  >1024 256 4 
#5-17  >1024 512 512 
#5-18  >1024 256 128 
#5-19  >1024 256 2 
#5-20  >1024 1024 >1024 
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C.4 KINETICS OF AIM-1 VARIANTS 
 
 
  
AIM-1 Wild type F119M
kcat Km kcat/Km MIC kcat Km kcat/Km MIC
Compound (s-1) (µM) (s-1/M) (µg/mL) (s-1) (µM) (s-1/M) (µg/mL)
Ampicillin 410±30.2 110±21.2 3.81E+06 >1024 2327±754 388±163 6.21E+06 >1024
Cefoxitin 117±8.9 283±36.7 4.16E+05 128 122±18.8 30±11.4 4.33E+06 >1024
Imipenem 1405±242 289±65.6 4.96E+06 512 1240±394 279±102 4.59E+06 >1024
W37C
kcat Km kcat/Km MIC
Compound (s-1) (µM) (s-1/M) (µg/mL)
Ampicillin 131±11 92±21.3 1.50E+06 >1024
Cefoxitin 13±1.6 12±3.2 1.19E+06 512
Imipenem 254±41.2 157±30.5 1.63E+06 >1024
S221E S221A
kcat Km kcat/Km MIC kcat Km kcat/Km MIC
Compound (s-1) (µM) (s-1/M) (µg/mL) (s-1) (µM) (s-1/M) (µg/mL)
Ampicillin 0.3679±0.158 56788±25001 6.51E+00 2 251±62 434±190 6.28E+05 >1024
Cefoxitin 0.0075±0.0001 1018±58.1 7.38E+00 1 54±3.2 19±2.4 2.93E+06 256
Imipenem ND ND ND 1 23±3.8 70±12.1 3.35E+05 1
#5-1 L55Q F114L F230Y #5-3 S23G F114L F230Y N247S
kcat Km kcat/Km MIC kcat Km kcat/Km MIC
Compound (s-1) (µM) (s-1/M) (µg/mL) (s-1) (µM) (s-1/M) (µg/mL)
Ampicillin 382±2.7 92±7.1 4.17E+06 >1024 440±16.7 140±12.3 3.17E+06 >1024
Cefoxitin 60±2.0 17.6±2.1 3.46E+06 >1024 93±4.5 36±4.9 2.64E+06 1024
Imipenem 82.9±7.3 11±1.4 7.59E+06 >1024 196±49.1 87±34.2 2.36E+06 >1024
#5-2 F114L #5-19 S23G F114L F230Y
kcat Km kcat/Km MIC kcat Km kcat/Km MIC
Compound (s-1) (µM) (s-1/M) (µg/mL) (s-1) (µM) (s-1/M) (µg/mL)
Ampicillin 481±34.5 206±48.9 2.42E+06 >1024 2335±361 1065±216 2.22E+06 >1024
Cefoxitin 79±7.3 28±1.4 2.84E+06 1024 352±43.8 237±44.4 1.51E+06 256
Imipenem 141±20.4 40±5.3 3.51E+06 >1024 40±3.4 13±2.2 3.09E+06 2
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